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7. Abstract
Compelling evidence indicates that long-term aspirin or related non-steroidal anti-inflammatory drugs
(NSAIDs) ingestion can protect against colorectal cancer (CRC). The predominant mechanism of
action ofNSAIDs is the induction of apoptosis and it has been shown that NSAIDs stimulate the NF-
kB pathway as a key component of this pro-apoptotic effect. Here, I demonstrate that aspirin activates
the c-Src tyrosine kinase pathway in CRC cells. This activation occured in a time- and dose-dependent
manner, preceding aspirin-mediated degradation of IkBcx, nuclear/nucleolar translocation of NF-
KB/ReIA and the induction of apoptosis. Furthermore, inhibition of c-Src activity, by chemical
inhibition or expression of a kinase-dead form of the protein, abrogated aspirin-mediated degradation
of IkBcx, nuclear translocation of RelA and apoptosis, suggesting a causal link. Expression of
constitutively active c-Src mimics aspirin-induced stimulation of the NF-kB pathway. These data
established the role of c-Src activation in the NF-kB and apoptotic response to aspirin in CRC cells in
vitro.
However, difficulty exists in the translational relevance of experimental findings derived from cancer
cell lines, therefore I developed and optimised an in-vitro organ culture (IVOC) of human ex-vivo
colonic mucosa. This provides an experimental platform that recapitulates the complex molecular,
cellular and architectural environment of the in-vivo human colonic mucosa. I demonstrated that
following a period of degeneration, the tissue regained its original architecture and was repopulated
with a cell population that was representative of the original tissue. Furthermore, I identified putative
colonic stem cell (CSC) populations within the tissue and demonstrated that colonic tissue growth and
differentiation can be modulated by Wnt signalling agonists and Notch signalling antagonists. Finally,
I show aspirin-mediated c-Src activation, NF-kB signalling and apoptosis in this setting. These data
provide compelling evidence that c-Src is an upstream mediator of aspirin effects on NF-kB signaling
and apoptosis in CRC cells and have relevance to the development of future chemotherapeutic /
chemopreventative agents. Furthermore, these data describe a model system providing a relevant and
translational experimental platform of much utility to the future study of aspirin-induced effects, CSC
regulation and dynamics in the human colonic mucosa, including further confirmation of the role of
Wnt and Notch signalling pathways in cell proliferation and differentiation.
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1.1 Colorectal cancer (CRC): incidence, treatment and detection
1.1.1 CRC: incidence and mortality
Colorectal Cancer (CRC) is a disease characterised by abnormal growth and development of a
malignant neoplasm arising from the lining of the large intestine (colon or rectum) (Cooper et al
2010). In the developed world, CRC is the third most common cancer in men after lung and prostate
cancer and the second most common in women after breast cancer (Parkin 2001).
Worldwide, there are 1.2 million new cases per year and over 600,000 disease-related deaths (Ferlay
et al 2010), accounting for greater than 10% of the total worldwide cancer related deaths (Greenlee et
al 2001). In 2008, there were 40,000 new cases of CRC in the UK and 16,000 disease-related deaths,
comprising around 13% of the total cancer burden. The lifetime risk is approximately 1 in 19 in
females and 1 in 14 in males (Heavey et al 2004). All age groups have demonstrated an increased
incidence of CRC since 1975 but it is those in the over 60s age group that have shown the greatest
increase (20%) (83% of CRCs occur within this group). Gender distribution is roughly equal, however
male risk is 1.5 fold that of females (http://info.cancerresearchuk.org/cancerstats) (Heavey et al 2004).
Hence, CRC is a major public health issue and whilst the detection and various treatment options have
led to improved outcomes, the overall 5-year survival rate continues to remain around 50% (Cooper et
al 2010, Gondos et al 2009).
Metastatic disease
Approximately 20-25% of patients already have metastases at the time of diagnosis and 40-50% of
patients develop metastases after resection of the primary tumour (Goldberg et al 2005, Scheele et al
1990). The liver is often the first site of metastatic disease and may be the only site of spread in as
many as 30^40% of patients with advanced disease. Given that tumour dissemination in this case is
putatively via the portal system, surgical resection of isolated hepatic metastases from CRC may be
curative in a number of cases (reviewed in Garden) (Garden et al 2006). For patients with extra-
hepatic metastases or non-resectable liver metastases, systemic treatment to reduce the size and
number of metastases can be undertaken. For most patients with metastatic CRC (mCRC), treatment
is palliative with the aim of prolonging survival and maintaining quality of life (Folprecht 2008).
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Pathologicalfactors that influence prognosis
The prognosis of patients with CRC is highly correlated with the extent of tumour penetration through
the bowel wall, the presence or absence of nodal involvement and the presence or absence of distant
metastases. These characteristics form the basis for all staging systems developed for this disease.
Staging of the tumour is the strongest predictor of survival for patients with CRC. Some of these
staging systems are described in table 1.1. The associated stage-specific 5-year survival rates are
outlined in table 1.2 (Compton 2003).
The different histological types of CRC are outlined in table 1.3. More than 90% of CRC cases are
adenocarcinomas, derived from the colonic mucosal epithelium (Kerr and Midgley 2010). Other
histological types include, mucinous (colloid) carcinomas, which display large areas of mucus
external to the cell, and signet-ring cell carcinomas, which have large amounts of mucus within the
cell, pushing the nucleus to the periphery. Mucinous, signet-ring cell and small-cell carcinomas are
prognostically unfavorable (Compton et al 2000, Compton 2003). Medullary carcinoma is a distinct
type of non-gland-forming carcinoma, which has a favourable prognosis and a strong association with
microsatellite instability (MSI), DNA mismatch repair gene (MMR) dysfunction, and the hereditary
non-polyposis colon cancer (HNPCC) syndrome (Ponz de Leon and Di Gregorio 2001). Other rarer
forms of colonic tumour include lymphoma or squamous cell cancers, but as these are clinically and
pathologically distinct, we will not focus on these sub-types within this thesis.
Tumour grading depends on cell differentiation within the tumour and relates to the degree of
glandular architecture, cellular pleomorphism, and mucosecretion of the predominant cell pattern
within CRC tumours. Whilst this has been described by a variety of different grading systems,
generally low grade tumours are those containing cells that are well or moderately differentiated and
high grade tumours those containing cells that are poorly differentiated or undifferentiated (Compton
2003). High-grade tumours provide a poor stage-independent prognostic factor (Compton et al 2000).
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Table 1.1 CRC staging systems
UICC/TNM Modified Dukes'
Stage 0 Carcinoma in situ A
Stage I No nodal involvement, no distant metastasis
Tumour invades submucosa (Tl, NO, MO)
Tumour invades muscularis propria (T2, NO, MO)
Stage II No nodal involvement, no distant metastasis B
Tumour invades into subserosa (T3, NO, MO)
Tumour invades into other organs (T4, NO, MO)
Stage III Nodal involvement, no distant metastasis C
1 to 3 regional lymph nodes involved (any T, Nl, MO)
4 or more regional lymph nodes involved (Any T, N2, MO)
Stage IV Distant metastasis (any T, any N, M1) D
From Colorectal Cancer Pathology
(C. C. Compton)
Table 1.2 Stage-specific 5-year survival rates and incidence

















Table 1.3 Histological types ofCRC
World Health Organization Classification ofColorectal Carcinoma
Adenocarcinoma
Medullary carcinoma
Mucinous (colloid) adenocarcinoma (<50% mucinous)
Signet-ring cell carcinoma (>50% signet-ring cells)
Squamous cell (epidermoid) carcinoma
Adenosquamous carcinoma
Small-cell (oat cell) carcinoma
Undifferentiated carcinoma
Other (e.g., papillary carcinoma)
From Compton CC 2002
Figure 1.1 (obtained from CRUK CancerStats) displays the anatomical distribution of CRC. Differing
anatomical locations are associated with reported variations in survival, one of the most investigated
variations is that which exists between rectal and colonic cancer (table 1.4). Right-sided CRC tumours
(ascending colon and caecum) tend to have a worse prognosis compared to left sided tumours, as
patients tend to present at a more advanced stage and their occurrence is proportionally greater in
elderly patients (Meguid et al 2008, Suttie et al 2011). Right-sided tumours also tend to be exophytic
and present with anaemia, whereas left-sided tumours tend to be more annular and can present with
obstruction. Other anatomical and biochemical differences also exist between the right and left colon,
as they have a different arterial supply, differing mucin production (Caldero et al 1989) and luminal
content (Macfarlane et al 1989). Further molecular, microbiological and signalling differences within
right and left colonic mucosa are described in chapter 4.
Patientfactors that influence prognosis
Patient factors associated with poor prognosis from CRC are increasing age, BM1, smoking, patients
with co-morbidities, or those requiring operative urgency. Specifically, patients presenting with bowel
obstruction/bowel perforation have a particularly poor prognosis (Morris et al 2011, Tan et al 2007).
Studies have also found that survival rates in the UK are significantly associated with levels of
deprivation, with the most deprived in the population having the poorest outcomes (Coleman et al
2001). Racial differences in outcome have also been observed, particularly in the US. African
American males experience higher CRC incidence rates and almost a 50% greater disease-related
mortality, compared to white males (Edwards et al 2010). It is likely that these differences are
multifactorial and reflect variations in tumor biology (increased right-sided (proximal) tumors among
African Americans, genetics by race (Polite et al 2006)) or relate to other factors such as
socioeconomic factors, obesity, screening rates and health care utilization (Loconte et al 2011).
Molecular factors associated with prognosis
Tumours can be distinguished by the mutational status of the distinct molecular pathways responsible
for their development or continuing survival. Some of the mutations in these pathways are
prognostically relevant, such as those responsible for MMR function. MMR deficiency accounts for
24
Figure 1.1 Distribution ofCRC, Great Britain, 2006-2008
Figure modified from CRUK Cancerstats









about 15 - 20% of sporadic CRC and also includes those patients with Lynch Syndrome (See chapter
1.2). Mutations in MMR genes cause instability of nucleotide repeats (microsatellites (MSI)). If >
30% of the microsatellite markers are altered, the tumour is defined as microsatellite-high (MSI-H).
MSI-H tumours are found predominantly on the right side of the colon and have a better prognosis
(Samowitz et al 2001) but are associated with a resistance to fluorouracil (FU)-based adjuvant
chemotherapy (French et al 2008, Sargent et al 2010). KRAS activating mutations also engender
resistance to some chemotherapeutic agents (see 1.1.2 Chemotherapy).
The gene, Deleted in Colon Cancer (DCC/18q), plays a role in cellular differentiation and
epitheliakstromal interaction. 18q loss of heterozygosity (LOF1), which is detected by PCR
amplification of polymorphic MSI markers at or near 18q21, has been associated with shorter disease-
free and overall survival (Wang et al 2010). However the evidence is conflicting (Carethers et al
1998).
Components of the systemic inflammatory response, C-reactive protein, albumin, white cell,
neutrophil, lymphocyte and platelet counts have been studied over many years to assess their
prognostic value in predicting outcome following cancer diagnosis. These have been combined to
form inflammation-based prognostic scores (such as the modified Glasgow Prognostic Score (mGPS),
Neutrophil Lymphocyte Ratio (NLR), Platelet Lymphocyte Ratio (PLR), Prognostic Index (PI) and
Prognostic Nutritional Index (PNI)). Generally, higher inflammatory scores are associated with a
reduced cancer survival (Proctor et al 2010). However, to date, many of these markers continue to
remain research tools only and are excluded from treatment/diagnostic algorithms (Kerr and Midgley
2010).
1.1.2. Treatment options and outcomes
Surgery
Mortality rates from CRC are progressively decreasing over time and the majority of this
improvement is due to improvements in detection, surgical technique and peri-operative management
(Morris et al 2010). An estimated 92% of colon cancer patients and 84% of rectal cancer patients
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undergo surgical resection as the primary mode of treatment (Compton 2003). For the majority of
these patients, surgery is performed with curative intent and approximately 40% will remain disease-
free in the long term. In 20-30% of cases, the disease is too far advanced at initial presentation for
curative intervention to be possible and many of these patients die within a few months (reviewed in
the National Institute for Health and Clinical Excellence (NICE). Guidance on cancer services:
improving outcomes in colorectal cancers London: NICE; 2004).
The majority of UK patients with CRC currently undergo resection by open approach but
developments in surgical techniques such as laparoscopic colorectal surgery are increasingly being
employed (ACPGBI National bowel cancer audit 2010). Whilst, there are no differences in the rates
of overall survival, lymph node harvest, disease-free survival and tumour recurrence between these
two approaches, patients undergoing laparoscopic resections have improved recovery times (hospital
stay is 20% shorter (Abraham et al 2004) and decreased post-operative morbidity, less post-operative
pain and need for analgesia (Schwenk et al 2005). Wound infection rates, incisional herniation, small
bowel obstruction, blood loss and blood transfusion requirements (Schwenk et al 2005) are all
reportedly reduced with laparoscopic surgery but key surgical quality indicators, such as anastomotic
leakage and mortality rates, are similar to those for open procedures (Duepree et al 2003). The
addition of enhanced recovery after surgery (ERAS) programmes following laparoscopic CRC
surgery may further improve short-term recovery and reduce hospital stay.
Chemotherapy
Adjuvant chemotherapy can help reduce the chance of recurrence of disease and significantly improve
overall survival in patients with early stages of CRC undergoing surgery (Chau and Cunningham
2002). 5-fluorouracil (5-FU) has been utilized as a treatment for patients with mCRC over the past 40
years (Kohne and Folprecht 2004) but its use is associated with a significant degree of side effects
(Xiong and Ajani 2004). Moreover, resistance to the drug can occur and certain molecular subtypes of
tumour are prognostically relevant (MSI-H/18q LOH)) (Banerjee et al 2002). Thymidylate synthase
(TS) is needed for DNA synthesis in the S-phase of the cell cycle and is reported to be a target enzyme
of 5-fluorouracil. Higher levels of TS putatively correlate with resistance to 5-fluorouracil, however
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studies have been conflicting (Allegra et al 2003, Lenz et al 1998). Clinical studies have also reported
that high TS protein expression is strongly associated with tumour recurrence (Leichman et al 1995).
Furthermore, several clinical studies have reported that CRC patients with wild-type TP53 derive a
survival benefit from fluorouracil (FU)-based chemotherapy but those with mutant TP53 do not
(Iacopetta 2003).
Other chemotherapeutic agents have been developed and used to treat CRC including: capacitabine
(thymidylate synthase inhibitor) and oxaliplatin (diaminocyclohexane platinum, a DNA cross-linker)
(Napier and Ledermann 2000). Other drugs like CPT11 (irinotecan, a DNA topoisomerase I inhibitor)
are available but like 5-FU, associated with a significant degree of toxicity. Different combinations of
these drugs, such as the FOLFOX regimen (leucovorin, 5-FU and oxaliplatin), the FOLFIR1 regimen
(leucovorin, 5-FU and irinotecan) and the XELOX regimen (oxaliplatin and capecitabine) with or
without a monoclonal antibody agent, have been shown to improve outcomes for patients with
metastatic disease [Reviewed in Edwards] (Edwards et al 2012).
Bevacizumab (which targets vascular endothelial growth factor (VEGF)) was the first approved
monoclonal antibody for CRC treatment in 2004 and is indicated for the first- and second-line
treatment of mCRC in combination with fluoropyrimidine-based chemotherapy. Cetuximab and
panitumumab, which target the epidermal growth factor receptor (EGFR), are also now in use.
Activating mutations of the KRAS oncogene occur in 30-50% of CRC tumours and are of key
relevance to treatment, as KRAS activating mutations give rise to tumours that are resistant to anti-
EGFR antibody therapy (Kerr and Midgley 2010, Walther et al 2009). Cetuximab and panitumumab
are therefore only indicated for wild-type KRAS mCRC as monotherapy, and cetuximab in
combination with chemotherapy, in Europe and in combination with irinotecan in irinotecan-
refractory wild-type KRAS mCRC in the US, however, despite this, 40-60% of patients with wild-type
KRAS will still not respond to these agents (Amado et al 2008, Karapetis et al 2008, Wilson et al
2010). Mutated BRAF is present in 5-10% of CRC tumours and affects the tumour response to these
agents, especially in those with wild-type KRAS i.e. wild-type KRAS tumours have a survival benefit
with these agents, BRAF mutation is a marker of poor prognosis and response (Bokemeyer et al 2012).
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Rectal Cancer
Treatment of rectal cancer is stage specific. Surgery alone is usually undertaken for those with Tl/2
disease. The role of short course preoperative radiotherapy (SCPRT) for rectal cancer has been
examined in a number of large RCTs. These have found that there is little benefit in treating Tl/ T2
NO tumours and no statistically significant difference in the local recurrence rate for tumours lying
from 0 to 5 cm from the anal verge. Short-course pre-operative radiotherapy (SCPRT) is therefore
reserved for T3 Tumours >5 cms from anal verge (evidence is conflicting below 5cms), anterior
tumours in men in which the mesorectal fascia is not breached and Tl/2 tumours with grossly
involved perirectal lymph nodes within fascia. Downstaging or long course chemoradiotherapy (CRT)
is usually reserved for fixed, inoperable tumours or those with a high risk of breaching mesorectum
and not achieving clearance through resection [reviewed in Gollins S] (Gollins 2010).
The development of local recurrence has a major influence on long-term survival after rectal cancer
resection and is highly dependent on pathological clearance of the tumour at the time of resection
(avoidance of a "positive resection margin") (Nagtegaal and Quirke 2008). Significant variation in
local recurrence rates of 0 to 21% among surgeons operating on rectal cancers was previously
detected (McArdle et al 1990). However, the development of standardised total mesorectal excision
(TME) surgery by Cecil and others (Cecil et al 2004, Moore et al 2005, Taylor et al 2011) as the
surgical standard of care, was one of the most important factors in reducing local recurrence. Together
with a >lmm clear resection margin, this is still the mainstay of treatment for operable tumours with
no metastases and in those fit for surgery.
Perforation of the tumour during resection (Patel et al 1977, Zirngibl et al 1990) and anastomotic
leakage are associated with worse survival (up to a five-fold increase in 30-day mortality) and a
significant increase in the local recurrence rate (McArdle et al 2005). Therefore, surgical technique is
an important factor in patient outcome after rectal resection. Recent developments such as an extra-
sphincteric (prone) resection excludes the formation of a TME waist and putatively results in further
reduction of recurrence rates but is associated with increased surgical morbidity (de Campos-Lobato
et al 2011).
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1.1.3 Detection and screening
The goal of screening is to reduce cancer mortality by early detection of the disease. Preventative
screening is distinctly different from early detection screening, as this aims to target the disease before
it becomes malignant by detecting and removing precursor lesions. CRC screening provides both
detection and prevention as more than 90% of bowel cancer cases are adenocarcinomas and the
majority of these are thought to arise from pre-existing adenomatous polyps (adenomas) and develop
over time.
Adenomatous polyps/adenomas are growths arising from the lining of the intestine, which may or may
not develop into colorectal cancer. There are three histological types of adenomas: tubular,
tubulovillous and villous. Tubular adenomas are the most common and have a tube-like structure.
Villous adenomas are the least common and have a 'frilly' or cauliflower-like structure. Tubulovillous
adenomas are a mix between the two. Villous adenomas are the most likely to become cancerous,
followed by tubulovillous adenomas (Cooper et al 2010).
Polyps are present in about a third of the European and USA populations. Indeed, approximately 5%
of people have polyps by age 50, increasing to 50% for people over 70 years old (Kinzler and
Vogelstein 1996). 1 in 10 of these will progress to malignancy. Flat adenomas account for about 10%
of all lesions and have a greater propensity to malignant change. Adenomas that are either greater than
or equal to 1 cm in diameter or have villous or tubulovillous features or severe dysplasia are called
high-risk or advanced adenomas. Low-risk adenomas are less than 1 cm in diameter and are non-
villous/tubulovillous without severe dysplasia (Cooper et al 2010).
The various screening options that are currently available for CRC are Faecal Occult Blood Testing
(FOBT), endoscopy (Sigmoidoscopy and colonoscopy) and molecular faecal and blood markers. The
rationale behind FOBT is based on the observation that traces of blood (occult blood) are released into
the bowel lumen by CRC/larger polyps. The FOBT analyses stool samples for the presence of this
occult blood either by guaiac-based tests (gFOBTs) (which detects the presence of any blood in the
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stool, including that from raw meat), or immunochemical tests (iFOBTs), which are more specific for
human blood (Bretthauer 2011).
The Scottish Bowel Screening Program biannually screens all men and women between 50 and 74
years of age. FOBTs are performed on three different bowel movements and the test is returned to a
processing centre. Depending on the number of positive tests, the patient will either be retested with
iFOBTs, or invited for a colonoscopy. Randomised studies have demonstrated a reduction in cancer-
related mortality of around 15-33% in those undergoing routine FOBT screening (Mandel et al 1999)
(Flardcastle et al 1996, Hewitson et al 2007).
However, the sensitivity of screening tests is more impressive in those undergoing more invasive
screening methodologies, such as sigmoidoscopy and colonoscopy (Segnan et al 2005), with
additional reductions in cancer-related mortality. A number of RCTs have reported the beneficial
effect on incidence and mortality associated with distal CRC after screening with flexible
sigmoidoscopy (Atkin et al 2010, Hoff et al 2009, Segnan et al 2002, Weissfeld et al 2005). In the
recent large multicentre UK RCT of over 150,000 people aged 55-64 years of age, incidence of CRC
in people attending for flexible sigmoidoscopy was reduced by 33% and mortality by 43%. The
incidence of rectal and sigmoid cancer was reduced by 50%. In this trial, patients had all polyps under
lcm removed, and were referred for follow-up colonoscopy if there were >3 adenomas or pathology
revealed >25% of the polyps were villous or had high grade dysplasia (Atkin et al 2010).
Colonoscopy has a high sensitivity for both adenomas and cancer and several countries such as Poland
and Germany have introduced screening programmes. Colonoscopy is the most commonly used
method for CRC screening in the USA (Hoff 2010). However, no RCT has yet reported on the effects
of colonoscopy on reduction of CRC incidence or mortality.
It must also be considered that both positive results and false positives following FOBT lead to
colonoscopy with associated potential for morbidity (Hewitson et al 2007). The rate of serious
complications, such as bleeding and bowel perforation, due to colonoscopy is between 0.2% and 0.8%
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(Hanley 2005). There is also significant psychological morbidity associated with positive test results
in any screening modality, some ofwhich can be ameliorated by better counselling and information.
Compliance with almost all CRC screening methodologies, including FOBT screening, remains
consistently poor (Vernon et al 1995). Only 75% of suitable patients are likely to be compliant
towards screening endoscopy, with obese patients and patients with lower educational attainment least
likely to comply (Anderson et al 2011a). In a recent review of the Scottish screening programme,
gFOBT uptake decreased with increasing deprivation and was higher in women than men.
Furthermore, increasing deprivation was negatively associated with uptake of follow-up colonoscopy
in men with a positive gFOBT. These findings may contribute to the observation that increased
deprivation is associated with decreased CRC survival (Steele et al 2010).
New methods of screening in CRC are currently being developed and evaluated, including
investigations of patient stool for colonocyte DNA mutations, epigenetic changes or microRNA
expression and blood tests for plasma DNA mutations, epigenetic changes, heteroplasmic
mitochondrial DNA mutations, plasma microRNA expression or protein and autoantibody expression
[reviewed in Pawa] (Pawa et al 2011). One example, which has previously been evaluated, is
screening for KRAS mutations in DNA within stools (Villa et al 1996). Flowever, this approach is
limited as these mutations occur in less than half of all CRCs and may also occur in pancreatic
hyperplasia and other non-malignant conditions. Research into developing tests for multiple DNA
alterations, including mutant KRAS, may offer greater potential for new non-invasive screening for
CRC with high levels of sensitivity and specificity (Kopreski et al 2000, Villa et al 1996).
Given the poor patient compliance with screening, the risk of false positives, the invasiveness,
unacceptability to the patient and risks associated with advanced screening methodologies; approaches
to prevent the initiation of CRC have obvious attractions to assist a reduction in CRC incidence and
related mortality, on a population basis. In order to develop new methods of early CRC detection and
diagnosis, cancer prevention, and targeted therapies, a better understanding of the causation of CRC is
required as an obvious pre-requisite.
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1.2. Causation
Understanding of the cause and management of cancer has been pursued since ancient times.
Hippocrates (BC 460-375) hypothesized that tumours were caused by an imbalance in the four
humors "blood, phlegm, yellow bile, and black bile", and nominated tumours as "cancer", as the
growths reminded him of moving crabs. Claudius Galen (AD 131-203) agreed with this "humoral"
view and argued that accumulation of black bile in the breast, uterus, lips, and in hemorrhoids caused
cancer. These views essentially persisted until the 18th century, truncating any moves towards
innovation or developing surgical resection of tumours (as this would not resolve a humoral
imbalance). However, new theories in the 18th century developed regarding the local origin of cancer,
supplemented by development of additional tools such as microscopy [reviewed in Soride] (Soreide et
al 2009). During the 1920-50s, tumourigenesis was thought to be a multistep process (Foulds 1958)
and latterly, as observations supported the view that CRC arose from preexisting neoplastic lesions
(polyps), this evolved into the "adenoma-carcinoma- sequence" theory (Fearon and Vogelstein 1990).
The genetic aetiology of cancer became more apparent following the publication of the stepwise
model (Fearon and Vogelstein 1990) and subsequent major discoveries, such as the adenomatous
polyposis coli (APC) mutation, MMR deficiencies and chromosomal alterations (Powell et al 1992),
(Thibodeau et al 1993). However, since then, at the very least, CRC development has demonstrated
itself to be both highly complex and still not completely understood.
1.2.1 Theories of development and genetic risk factors
The "adenoma-carcinoma" stepwise sequence model
The majority (70-80%) of CRCs are sporadic in nature, putatively due to genetic mutations acquired
through the accumulation of genetic "hits" over a lifetime (Knudson 1985). One theory attempting to
explain this is the multi-step carcinogenesis model, which was developed by Fearon and Vogelstein in
1990, amongst others (Fearon and Vogelstein 1990). This states that tumours develop in a stepwise
fashion via an adenoma-carcinoma sequence. A schematic representation is shown figure 1.2 (Janne
and Mayer 2000). Normal epithelium progresses through adenoma to invasive carcinoma due to a
series of accumulated mutations in oncogenes and tumour suppressor genes and histological changes
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Figure 1.2 Progressive multi-step model of Colon Carcinogenesis
















in which the adenomatous polyp is an intermediate step (Jung et al 2006, Kinzler and Vogelstein
1998).
The belief that CRC arises from pre-existing adenomatous polyps is supported by several lines of
evidence; (a) the prevalence of adenomas correlates with that of carcinomas, (b) adenomatous tissue
often accompanies cancerous tissue at resections (adenomas are found in one third of colorectal
resections for cancer), (c) sporadic adenomas are also identical histologically to those from the pre-
malignant adenomas of Familial Adenomatous Polyposis (FAP), (d) large adenomas are more likely
to display cellular atypia and genetic abnormalities than smaller adenomas, and (e) the incidence of
CRC has been shown to fall with the introduction of long term screening and polypectomy (Bond
2005).
The most common mutations in CRCs affect the Wnt signalling pathway, responsible for cell growth
and differentiation. The most common genetic mutation in this pathway is in the APC gene
(chromosome 5q). Mutations in this gene are reported as one of the earliest genetic alterations in the
genesis of CRC and may be required to initiate the adenomatous process, resulting in the clonal
growth of a single cell (Fodde et al 2001b). APC is a multi-functional protein that is involved in
several key cellular processes, such as adhesion, migration, microtubule assembly, chromosome
segregation and signal transduction (Senda et al 2005) (Fearnhead et al 2001, Fodde et al 2001a)
(Polakis 1997). The majority of these functions are mediated through its interaction with p-catenin.
APC complexes with glycogen synthase kinase 3-beta (GSK-3P) and axin which binds P-catenin. This
association allows casein kinase 1 (CK1) firstly then and GSK-3P subsequently, to phosphorylate P-
catenin targeting p-catenin ubiquitinisation and degradation by proteosomes. The vast majority (95%)
ofAPC germ line mutations are nonsense or frame shift mutations, which result in a truncated protein.
This mutant APC is unable to bind P-catenin, causing p-catenin to accumulate in the cell and induce
deregulation of growth and differentiation and subsequently, tumour development (Fearnhead et al
2002, Markowitz 2007).
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Familial adenomatous polyposis (FAP) patients carry a germ line mutation of the APC gene. FAP is a
condition that occurs in 1:7000 to 1:14,000 live births (de la Chapelle 2004, Rowley 2004) and is
responsible for less than 1% of all CRC. It is characterised by the development of thousands of
adenomatous polyps throughout the large bowel (de la Chapelle 2004, Rowley 2005) and presents at a
much younger age in these patients (Rowley 2005). Additionally, 6% of Ashkenazi Jews hold a lysine
to isoleucine amino acid substitution (I1307K or Ilel307Lys) in APC, which is associated with a 20%
increased risk of CRC (Fodde 2002).
According to the "adenoma-carcinoma" stepwise sequence, once this initial mutation has occurred, a
small polyp subsequently develops. When a cell in the polyp has acquired enough mutations and
undergone further clonal expansions, it acquires the ability to invade and metastasise (Hawk and
Levin 2005, Kinzler and Vogelstein 1998). Further such mutations occur in oncogenes such as KRAS,
RAF and PI3-Kinase. Isolated activating KRAS mutations induce cell proliferation, leading of the
development of hyperplastic lesions, but if the mutation in KRAS occurs after a pre-existing APC
mutation has occurred, transformation to carcinoma is reported. As previously discussed, KRAS
activates the EGFR pathway downstream of the EGF receptor and KRAS activating mutations result in
a tumour phenotype that is relatively more resistant to certain anti-tumour agents, such as anti-EGFR
antibodies (Kerr and Midgley 2010, Walther et al 2009).
RAF (proto-oncogene serine/threonine-protein kinase) is encoded by the RAF-1 gene and functions as
part of the MAPK/ERK signalling cascade responsible for accurate control of cell cycle, division,
apoptosis and differentiation. Activating mutations in RAF genes drive dysfunction in these pathways,
leading to transformation. Anti-RAF agents are potential targets for drug development (Sridhar et al
2005) and mutations ofRAF are detected in about 5% ofCRC (Li et al 2006).
Tumour suppressor function is also affected in the adenoma-carcinoma sequence. The p53 protein,
product of the TP53 gene (ch 17p), plays a role in regulation of cell division and inhibits the survival
of cells with Wnt pathway defects. Mutations in the TP53 gene, occurring in 40-50% of CRCs
(Iacopetta 2003), putatively transform an adenoma into an invasive carcinoma. This is also similar to
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the gatekeeper function of BAX, which targets cells for apoptosis, which can also be deactivated in
CRC. Another protein that can be deactivated in CRC is TGF-(3 or members of the downstream
SMAD pathways, which have a deactivating mutation in at least halfof CRC (Markowitz 2007).
However, the multi-step carcinogenesis model has a number of weaknesses. Firstly, it fails to explain
the development of de novo CRC, which can affect between 20-40% of all tumours and where
tumours evolve from the colorectal mucosa de novo and grow invasively into the bowel wall without
passing through the adenoma stage. Secondly, Aberrant Crypt Foci (ACF) are small circumscript
areas in the colorectal mucosa with enlarged crypts, compared to surrounding normal mucosa. It is
thought that accumulation of biochemical and mutational changes within the cells of some ACF can
lead to the transformation of those cells into cancer. Data indicates that some ACF directly bypass the
polyp stage and progress directly to carcinoma (Bedenne 1992, Takayama et al 1998).
Fearon (Fearon and Vogelstein 1990) based some of the rationale for the multi-step carcinogenesis
model on the fact that many colonic tumours (from adenomas to carcinomas) were monoclonal and
putatively developed from clonal expansion of a mutated cell, however, reports state some 75% of
early adenomas are polyclonal and whilst, one explanation postulated is that short-range interaction
between adjacent initiated crypts is responsible for polyclonality (Leedham et al 2005), further
problems with this theory exist. Therefore, an alternative theory is required to explain the complex
heterogeneity of primary colonic tumours and the ability of distant metastases to undergo further
differentiation, when they have accumulated a level of acquired mutations presumed to prevent further
differentiation. Hence the "Cancer Stem Cell Theory" has developed.
The "Cancer Stem Cell Theory"
Stem cells are defined as cells that have the ability to perpetuate themselves through self-renewal and
to generate mature cells of a particular tissue through differentiation. Stem cells share many
characteristics that mimic the behaviour of cancer cells, such as their ability to self-renew and avoid
apoptosis. Stem cells can give rise to phenotypically heterogeneous cells that exhibit various degrees
of differentiation. Hence, polyclonality could be the result of the existence of a subset of cancer cells
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which produce heterogeneous progeny, replicating the behaviour of stem cells. This explains
therapeutic failures achieved with molecular-biological therapeutics utilising target-based therapies
which assume homogeneity of the cancer cell population within a tumour mass.
Many of the pathways utilised by stem cells to potentiate self-renewal, such as the Wnt, Shh and
Notch pathways, are also aberrantly used for survival and proliferation by cancer cells in a variety of
human cancers, including CRC (further description of these pathways can be found in Chapter 4).
Additionally, stem cells, as they live for longer periods than normal cells, may be more prone to
accumulating chance mutations. Furthermore, as stem cells already have an activated self-renewal
pathway, they may require less mutations to occur in order to undergo neoplastic change, in contrast
to non-stem cells which theoretically require more mutations to create an activated de-novo survival
and proliferation signalling pathway to undergo transformation (reviewed in Reya and Clevers 2005).
However, both of these theories are yet more complicated by the observation that cancer cells can
undergo an epithelial-mesenchymal transition (EMT)-like dedifferentiation. This transition involves
several mechanisms and aids in invasion, with re-differentiation observed in some metastases
(Brabletz et al 2005, Heslin et al 2001, Matsuyama et al 2002). The process of carcinomatous
progression is therefore dynamic and genetic alterations are not irreversible. Elements in the extra¬
cellular matrix, immune cells and fibroblasts have all been postulated to play a part in this
phenomenon (Fidler 2003, Heslin et al 2001, Mueller and Fusenig 2004).
Polyclonicity theory
A traditional view exists that tumours originate from a single cells which develop along the traditional
monoclonal model of an established sequence of genetic events, during the multistep process of colon
carcinogenesis. However, this does not explain the finding of unrelated clones in some tumour types,
including CRC (Parsons et al 2008). This is supported by evidence of tumoural polyclonicity from
studies in human adenomas (Thirlwell et al 2010), and rodent models of CRC (Merritt et al 1997). As
such, some authors have felt that the monoclonal tumour theory, as the underlying premise in the field
of oncology, could explain why some attempts at chemotherapy, based on a monoclonal population,
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are ineffective (Parsons et al 2008).
The theory of polyclonicity, proposes a number of tumour developmental stages. Firstly, tumour cells,
derived from a founder cell population, are affected by chromosomal instability and therefore display
an increased mutation rate. This leads to cells within the tumour population possessing different
genetic mutations. These mutations may or may not offer a Darwinian survival advantage against
other cell populations, as the tumour cell number begins to increase. As a number of successful clones
may survive, there exists a heterogenic genotype across the tumour mass. With this altered gene
expression, the tumour may be composed of cells which become phenotypically heterogenous.
Through further processes of clonogenic selection and poly/monoclonal expansion, the tumour may
result in a heterogenous, polyclonal population of cells. Of course, if one clone is a dominant survivor,
the tumour may be monoclonal, as a result of clonal selection, rather than the monocloncal theory of
evolution of all cells in the tumour concurrently from a single founder (Gisselsson, 2001).
It is impossible to detect currently whether the polycolonicity theory is correct based as tumours are
highly variable in themselves and the ability to determine the founder origin of a tumour and measure
precisely the genetic and molecular changes which occur in a step-wise progression within a tumour's
evolution are, as yet, not available (Parsons et al 2008). The situation is even more complex to
determine in-vivo as external factors, such as changes in the tumour microenvironment may work to
influence the outcome of clonal survival pressures, and clones may be dependent on eachother in
tumours forming a symbiotic relationship. Therefore, debate between the polyclonicity and
monoclonicity theories of colorectal carcinogenesis will continue (Parsons et al., 2008).
Genetic Instability
The stability of the genome in cancer cells becomes compromised because several cancer-
predisposing genetic mutations also affects the function of genes that are responsible for maintaining
the integrity and number of chromosomes during cell division. At least three major elements of
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genetic instability are known to play a role; Chromosomal instability (CIN), microsatellite instability
(MSI) and epigenetic silencing [reviewed in Soreide] (Soreide et al 2009).
Chromosomal instability (CIN)
Chromosomal instability leads to gains and losses of large segments of chromosomes (Lengauer et al
1998). Mutations in CIN-associated genes drive imbalance in the number of chromosomes per cell
(aneuploidy) and an enhanced rate of loss of heterozygosity (LOH), as whole or large fractions of
chromosomes are gained or lost during cell division. This chromosomal instability (CIN) phenotype,
describing allelic losses, chromosomal amplifications, and translocations, accounts for 85% of
sporadic CRC cases (Dunican et al 2002).
The CIN phenotype arises through mutations in many different pathways and genes, particularly those
responsible for telomere maintenance, cell division, centrosome duplication and chromosome
segregation (Paulovich et al 1997). Some examples are chromosome 7 amplification, deletion at lp
(MUTYH) and 8p, as well as loss of heterozygosity (LOH) of 17p (P53) and 18q (DCC.BCL2)
Chromosome Ip encodes for MUTYH glycosylase, which is involved in oxidative DNA damage
repair. Mutations in the MUTYH gene affect the ability of cells to correct mistakes made during DNA
replication and cause an autosomal recessive form of colonic polyposis (also called MUTYH-
associated polyposis). Polyps caused by mutated MUTYH do not appear until adulthood and are less
numerous than those found in patients with APC gene mutations. 8p comprises a metastatic
susceptibility locus involved in tumour progression whose disruption increases metastatic potential
involving a large number of genes, such as TNFRSF10B (involved in transcription of DR5 and
TRAILR2) (Macartney-Coxson et al 2008).
Microsatellite instability (MSI)
The microsatellite instability (MSI) phenotype is not as prevalent in sporadic CRC, accounting for
15% of such malignancies, and has been firmly linked to a faulty DNA mismatch repair system
(Markowitz 2000). Nucleotide sequences (i.e. CACACACA; or [CA]4) known as "microsatellites"
contribute to genetic stability and errors generated within these areas may cause frame shift mutations
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leading to protein alterations and carcinogenesis. These tumours often demonstrate characteristic
mutations such as those in Transforming Growth Factor beta Receptor II (TGF/3RII) (ch 3p22), Bcl2-
associated X protein (19ql3.3-ql3.4) and insulin-like growth factor receptor II {IGFRII) (Parsons et al
1995, Souza et al 1996).
Widespread MSI was discovered to be a marker in hereditary non-polyposis CRC (HNPCC), a
condition accounting for approximately 3-5% of all CRC cases (de la Chapelle 2004, Rowley 2004).
MSI is observed in the vast majority (>90%) of HNPCC patients and is also seen in approximately
15% of sporadic CRC (Fearnhead et al 2002). FINPCC is characterised by a 70-80% risk of
developing early onset CRC (Rowley 2005) and is associated with the development of other cancers,
such as endometrial, stomach, ovarian, small bowel, hepatobiliary, and brain (the HNPCC syndrome)
(de la Chapelle 2004, Rowley 2005). HNPCC is caused by germline mutations in DNA mismatch
repair (MMR) genes, such as hMLHl, HMSH2, hMSH6, PMS1 or PMS2, and the condition is inherited
as autosomal dominant (Rowley 2004). Dysfunction of these genes essentially causes widespread
genome instability, which can manifest as different numbers of simple repeated sequences, such as
microsatellites, (referred to as the replication error phenotype, RER+). (Fodde et al 2001a); (Hopper
2005). A study of 48 HNPCC kindreds (Liu et al, 1996) investigated the proportion of mutations in
known mismatch repair genes; 31% had mutations in the MSH2 gene, 33% had mutations in the
MLH1 gene, 2% had mutations in the PMS1 gene, and 4% had mutations in the PMS2 gene. MSH6
mutations account for 10%-20% of HNPCC patients and 0.4% of all CRC (Southey et al 2005).
Base excision repair genes also acts to prevent mutagenesis induced by 8-oxo-7,8-dihydroxy-2'-
deoxyguanosine (8-oxo-dG) (Sieber et al 2003). MUTYH removes adenines mispaired with 8-oxo-dG




Approximately 40% of CRC tumors are characterized by epigenetic changes, such as DNA
methylation (Weisenberger et al 2006). This 'Epigenetic change' affects gene function (without
genetic changes) by aberrant methylation of DNA that 'silences' the gene, causing deficiency in
protein expression.
CpG islands are genomic regions, typically 300-3000 base pairs in size, where there are a significant
number of cytosine and guanine bases adjacent to each other in the backbone of the DNA (linked by
phosphodiester bonds; thus named CpG). Hypermethylation ofCpG islands in the promoter regions of
tumour suppressor genes is associated with transcriptional silencing. For selected genes, epigenetic
changes are tightly related to neoplastic transformation in CRC i.e. loss of the tumour suppressor gene
PTEN located at 10q23 occurs through promoter hypermethylation in CRC with MSI-H (Goel et al
2004). Aberrant DNA methylation may be part of the age-related field defect observed in sporadic
CRC. Excessive aberrant methylation through a hypermethylator phenotype termed CpG Island
Methylator Phenotype (CIMP) contributes CRC formation (Toyota et al 1999). Non-neoplastic but
epigenetically disrupted stem/progenitor cells might be a crucial target for cancer risk assessment and
chemoprevention in the future (Feinberg et al 2006).
1.2.2 Inherited risk factors
Only 5-6% of cancers develop on a truly inherited genetic background (de la Chapelle 2004),
however, a further 10-20% of CRCs have a "familial" clustering of cases without any detectable or
known specific genetic alterations leading to increased risk (a relative risk (RR) increase of 2-3 is
noted in those with a first-degree relative with CRC) (Rowley 2004). In one study, 2.3 for those with 1
first-degree relative affected, 4.3 for those with more than one first-degree relative affected, 3.9 if the
relative is less than 45 years of age and 2.0 if the relative has an adenoma (Johns et al 2001). When 2
or more relatives are affected by CRC the possibility of a genetic syndrome increases substantially.
These include the major genetic syndromes, described in table 1.5 (Slattery and Kerber 1994).
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Hereditary conditions include those mentioned above, such as; Familial Adenomatous Polyposis
(FAP) syndrome and Hereditary Non-Polyposis CRC (HNPCC; the Lynch syndrome) (Lichtenstein
2002). The lifetime gastrointestinal cancer risk associated with HNPCC is reported as around 80% for
CRC (Vasen 1994). In FAP, the development of large bowel cancer is virtually certain without
prophylactic surgery (Bulow 1991).
Genetic factors including high-penetrance mutations and low-penetrance polymorphisms, which
determine a patient's defense and adaption when faced with exposure to carcinogens, effect
susceptibility to CRC development. However, the effect of common low-penetrance risk determinants
is small when in isolation, with increasing susceptibility observed only through the cumulative effect
associated with multiple risk variants (Ostrowski and Wyrwicz 2009). Recently, Genome Wide
Association Studies have identified that part of the heritable componant of the risk of developing CRC
is due to common germline genetic variants, which are of modest effect. These single nucleotide
polymorphisms (SNPs), some which are associated with genes that have a putative role in CRC
development and others which have yet to be characterized, have been validated in unrelated
populations, and are reported to explain about 8% of heritability risk of developing CRC (Dunlop et al
2012, Peters et al 2012). However, whilst these loci are associated with development they are not
associated with CRC survival (Tenesa et al 2010). A recent metanalysis review more than 600 papers
naming genetic polymorphisms associations with CRC found 445 polymorphisms in 110 different
genes. 16 independent variants at 13 loci (MUTYH, MTHFR, SMAD7, and common variants tagging
the loci 8q24, 8q23.3, llq23.1, 14q22.2, lq41, 20pl2.3, 20ql3.33, 3q26.2, 16q22.1, and 19ql3.1)
were found to have to have the highest associations with CRC (Theodoratou et al 2012).
CRC may also develop on a background of colonic inflammation, such as in long-standing ulcerative
colitis, with cumulative probabilities for cancer development of 2% by 10 years, 8% by 20 years, and
18% at 30 years (Ullman and Itzkowitz 2011). It is reported there is a similar step-wise progression of
genetic mutations from inflamed colitic mucosa, through dysplasia to cancer development. For
instance, loss of p53 function is an important step in progression of colitis-associated cancer and
allelic deletion ofp53 is observed in approximately 50%-85% of colitis-associated tumors (Burmer et
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al 1992). If there is a clear family history of CRC i.e. those who have two or more first- or second-
degree relatives (or both) with CRC - then the risk is even higher (Lynch and de la Chapelle 2003).
Other settings with an increased risk include a personal history of CRC or adenomas and a personal
history of ovarian, endometrial, or breast cancer.
Familial Adenomatous
Polyposis (FAP)
1:7000 autosomal dominance, mutations of the APC gene ; 5q21, >100
adenomatous polyps in the colon and rectum, other extra-colonic
features (Gardner syndrome) may include upper gastrointestinal tract
polyps, congenital hypertrophy of retinal pigment epithelium, osteomas
and epidermoid cysts, supernumerary teeth, desmoid formation, and
other malignant changes such as thyroid tumours, small bowel cancer,
hepatoblastoma, and brain tumors, particularly medulloblastoma. 90%
CRC risk by age of 45 years.
Attenuated FAP Missense mutations in APC, Fewer 30-100 polyps, CRC develops later,
similar extra-colonic manifestations, 69% CRC risk by 80 years
Lynch Amsterdam criteria = 3+ cases of CRC over 2+ generations, with at
least 1 diagnosed < 50, and no evidence of FAP. 25% test positive for an
informative MSH2 or MLH1 mutation. MSI-H tumours. Familial
clustering with early age at onset; high risk of second primary tumour;
preferentially right colon; improved clinical outcome; extracolonic sites=
endometrium, ovaries, other G1 tract, uroepithelium, brain, and
sebaceous tumor. 40%-80% CRC risk by 75 years;
MYH-associated
polyposis
Develop fewer adenomas and at a later age compared to FAP.
Adenomas, serrated adenomas, and hyperplastic polyps can be seen in
MAP patients. CRCs tend to be right-sided and synchronous; carry a
better prognosis than sporadic CRC. Extracolonic cancers have been
reported including gastric, small intestinal, endometrial, liver, ovarian,
bladder, and thyroid and skin cancers including melanoma, squamous
epithelial, and basal cell carcinomas. 35-53% CRC lifetime risk,
Peutz-Jeghers Early-onset autosomal dominant; germline mutations in the STK11 gene
at chromosome 19pl3.3 melanocytic macules on the lips, and the
perioral and buccal regions, and multiple gastrointestinal polyps, both
hamartomatous and adenomatousAutosomal recessive 39% CRC risk by
70 years
Juvenille Polyposis Genetically heterogeneous, rare, childhood-onset, autosomal dominant
germline mutations in SMAD4, 18q21 (15-20%) and BMPR1A ; 10q22
(20-40%); presents as hamartomatous polyposis throughout the GI tract
and diarrhea, Gl tract hemorrhage, and protein-losing enteropathy. 17-
68%CRC risk by 60 years
CHEK-2 Rare subset of families with hereditary breast and colon cancer; mutation
in the CPIEK2 gene.
Fig 1. 5 Major Genetic Syndromes
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1.2.3 Environmental risk factors
CRC is also considered to be an environmental disease, as the majority of CRCs are 'sporadic' with
no apparent genetic predisposition. "Environmental" is defined broadly to include a wide range of
often ill-defined cultural, social, and lifestyle factors. As such, modifiable causes may be identified
which would allow a large proportion of cases to theoretically be prevented (Boyle and Langman
2000, Johnson and Lund 2007). Evidence of environmental risk comes from large scale
epidemiological studies, twin cohorts or studies showing that CRC cases increase in migrant
populations that move from a low incidence to a high incidence countries (Johnson and Lund 2007).
The major environmental factor thought to influence CRC risk is diet.
Dietary factors
It has been proposed that changes in food habits could reduce CRC in the western world by up to 70%
(Michaud et al 2005, Willett 2001). However, the dietary constituents that contribute to the
development of CRC have not yet been fully defined, primarily because of methodological and
practical difficulties in undertaking dietary studies. Results from case-control studies often fail to
replicate data from cohort studies and vice versa.
Fish oils, especially rich in polyunsaturated omega-3 fatty acids (03Fas) have also been shown to
reduce the risk of bowel cancer (Cho et al 2011). A multitude of other studies are currently
investigating the effects of Vitamin (especially C and E), nutrient and mineral supplementation in
reducing CRC risk (see below).
A number of factors identified to contribute to CRC risk are listed below:
Fruit and vegetables
The EPIC study recruited 520,000 healthy people from 10 European countries and tracked their diet
and health over the years (Norat et al 2005). The findings from this study demonstrated that for every
two portions of vegetables and fruit consumed per day there was a 2.5 percent lower risk of cancer.
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However, in a metanalysis of seven studies evaluating fruit and vegetables intake and CRC risk there
was a weak but statistically significant reduction in risk (RR=0.99), per 100 g/d taken. However, when
taken individually, there was no significant association between fruit and vegetable intake and colon
cancer risk or rectal cancer risk. Therefore, when viewed against the strong effect of confounding
lifestyle issues, the evidence is not convincing that fruit and vegetable intake is related to reductions in
CRC risk (Norat et al 2010).
Saturatedfats
The dietary factor which has the strongest association with CRC risk is saturated animal fats
[reviewed in Martinez] (Martinez 2005). CRC rates are high in populations with high total fat intake
and low in populations consuming less fat. Furthermore, populations migrating from low fat intake to
high fat intake areas significantly increase their CRC risk (Key et al 2002). Several theories exist as to
the mechanism of this association, including that dietary intake of saturated fats results in increased
bile acid and cholesterol in the colonic lumen, which favours the development of a bacterial flora
capable of degrading bile salts to potentially carcinogenic TV-nitroso compounds (Gill and Rowland
2002, Giovannucci and Willett 1994, Mason 2002).
Redmeat and N-nitroso compounds (NOC)
High meat consumption has also been implicated in the development of CRC (Larsson and Wolk
2006, Santarelli et al 2008, Santarelli et al 2010). A recent meta-analysis of 18 published, prospective
trials, (Larsson and Wolk 2006), found an RR of 1.28 for CRC risk in high meat intake versus low
meat intake populations. This association was stronger for rectal cancer than colon cancer (Larsson
and Wolk 2006). The EPIC study, (Norat et al 2005) the largest ever prospective cohort study to
investigate the association between diet and cancer, involving 520,000 participants in 10 European
countries, also demonstrated a significant association between CRC risk and consumption of red and
processed meats. However, red meat alone (in the absence of processed meat) was not found to be
significantly associated, despite the very large numbers of study subjects. Based on the association
between meat consumption and disease risk, the UK Committee on Medical Aspects of Food and
Nutrition Policy (Truswell 2002) has advised that people who are consuming high levels of red meat
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—more than 14 portions a week (140_g cooked weight per day)—should consider a reduction. The
World Cancer Research Fund recommend individuals "limit intake of red meat to less than 80g daily".
N-nitroso compounds (NOCs), including nitrosamines and nitrosamides, have previously been
implicated in gut carcinogenesis in humans. This is of interest as nitrosamines have been detected in
processed foods with added nitrates or nitrites (such as salt-preserved fish and meat, and in foods
processed by smoking or direct-fire drying), which may explain the association between processed
food consumption and CRC risk. NOCs are produced from nitrogen-containing compounds by the
nitrosation of amines, amides and urea, following the ingestion of high protein/ high red meat diets.
(Bingham et al 1996, Bingham et al 2002, Santarelli et al 2010). Furthermore, NOCs are alkylating
agents with the potential to cause intrinsic DNA damage in the colorectal epithelium. The most
common KRAS mutations found in CRC are characteristic of alkylating agents, namely G-A
transitions at the 3' G of a GG pair at codon 12 or 13. Indeed, there have been reports showing an
excess prevalence of KRAS mutations in CRCs from high dietary meat consumers (Lewin et al 2006,
Santarelli et al 2008)
Other hypotheses to explain why processed meat intake is linked to cancer risk are that cooking meat
at a high temperature forms carcinogenic heterocyclic amines and polycyclic aromatic hydrocarbons
and that the heme iron in red meat can promote carcinogenesis because it is a pro-oxidant (Lund et al
1999), which increases cell proliferation in the mucosa, through lipoperoxidation and/or cytotoxicity
of fecal water [reviewed in Santarelli] (Santarelli et al 2008).
Physical activity
A substantial body of epidemiological evidence supports an association of a sedentary lifestyle with
an increased risk of CRC (Martinez 2005). Friedenreich et al. studied physical activity and risk of
colon and rectal cancers amongst more than 400 000 individuals concluding that 2 hours of moderate
physical activity per day or 1 hour of more vigorous activity was associated with a risk reduction for
colon cancer of 20-25% overall and of around 35% for right-sided colon cancer (Friedenreich et al
2006). This is supported by the findings of earlier studies that have demonstrated a 30%-50%
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reduction in CRC incidence among individuals with the highest levels of physical activity compared
to those with low levels of activity (Ahmed 2004, Giovannucci 2003, Lao and Brenner 2004).
In the dose-response meta-analyses of 3 studies, the AICR/WCRF report found total physical activity
(expressed as increase of 5 METs-hour/day) associated with a significant decreased RR ofCRC (0.97)
and colon cancer (0.92), but not with rectal cancer (1.02). Interestingly, further analysis revealed a
statistically significant RR reduction was observed for proximal colon cancer (0.91) and not for distal
colon cancer (1.01) (Norat et al 2010).
A high body mass index (BMI) as a result of positive energy balance, is also associated with an
increased risk of CRC (BMI>30 = 2 x CRC risk) [reviewed in (Ahmed 2004, Gatof and Ahnen 2002,
Gunter and Leitzmann 2006); (Martinez 2005)]. This effect increases significantly with age and is
stronger for men than for women. A larger waist size was associated with increased risk of CRC in
both sexes, and this effect was independent of BMI (Moore et al 2004). In another larger trial, body
weight and BMI were significantly associated with CRC risk in men but not in women. Risk of colon
cancer was associated with waist circumference and waist: hip ratio in men and in pre-menopausal
women, but not for post-menopausal women using hormone replacement therapy. The association was
not significant for rectal cancer (Pischon et al 2006, Pischon et al 2008). Several studies have found
increased adenoma occurrence in those patients who are obese (Kim et al 2009). In a recent
matanalysis, obesity (BMI>30) or overweight (25 < BMI <29.9) was examined as a risk factor for
colorectal adenoma (CRA). Adenoma occurrence risk in those with BMI > 22 was 1.42, > 25 was 1.81
and > 30 was 1.47 (Omata et al 2013).
Overall, a statistically significant increased RR risk of CRC was found with increasing waist
circumference. The RR per inch increase for colorectal, colon and rectal cancer were 1.03
(95%CI=1.02-1.04), 1.05 (95%CI=1.03-1.06) and 1.03 (95%CI=1.01-1.04), respectively, with the
association between waist circumference and colon cancer stronger in men than women. Even with
adjustment for BMI - the results indicated that abdominal obesity might be a CRC risk factor
independent ofBMI (Norat et al 2010).
48
A recent metanalysis demonstrated that diabetes, a condition increased in obese people, is associated
with both CRC incidence and mortality (Jiang et al 201 lb). High concentrations of circulating insulin,
as occurs in obesity, has a mitogenic effect on colonocytes and induces activation of signalling
pathways such as protein kinase C (PKC) and mitogen activated protein kinase (MAPK) (Campos et
al 2005); (Gunter and Leitzmann 2006). They also increase the proliferative effect and availability of
insulin-like growth factor-1 (IGF-1) (Campos et al 2005, Giovannucci 2003). Another mechanism to
consider is the production of endocrines ('adipokines' such as leptin and adiponectin), and cytokines
(such as tumour necrosis factor alpha (TNF-a) and interleukin 6 (IL-6)) (Rondinone 2005), by adipose
tissue. These factors, released by excessive amounts of adipose tissue, have been shown to induce
increased expression of inducible nitric oxide synthase (iNOS) and COX-2 and activate NF-kB
transcription factor signaling within colonic mucosa (John et al 2006), suppressing apoptosis, which is
a prerequisite for tumourigenesis.
Alcohol
Case-control and prospective studies suggest an association between high alcohol intake and increased
risk of CRC development, but reports have been conflicting (Heavey et al 2004); (Ahmed 2004,
Martinez 2005). In a recent study, in comparison with non-drinkers with no family history, the RR for
colon cancer was 2.8 for individuals who consumed >30 g/d and who had a family history of CRC
(Cho et al 2011). In a pooled analysis of primary data from 8 cohort studies in 5 countries, increased
risk for CRC was limited to persons with an alcohol intake of greater than 30 g/day (approximately 2
drinks/day). Therefore, regular alcohol intake was correlated with a modest relative elevation in CRC
rate, mainly at the highest levels of alcohol intake (Cho et al 2005).
Breakdown products of alcohol are known to inactivate protective elements, such as folate
(Giovannucci and Willett 1994, Giovannucci 2003) (Martinez 2005). As folate is implicated in key
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cellular processes such as DNA synthesis and repair, reduced folate levels, which occurs as a result of
excessive alcohol intake, could underlie the a 2-5 fold elevation in CRC risk among individuals with
high intakes of alcohol and low intakes of folate (Giovannucci 2003). Additionally, reports suggest
alcohol stimulates cell proliferation in the rectum and can induce a MSI phenotype (Heavey et al
2004).
Smoking
Smokers have increased risk of both adenomatous polyps (Giovannucci 2002) and hyperplastic polyps
(Martinez et al 2011), but evidence of the association between smoking and CRC is conflicting
(Ahmed 2004, Martinez et al 2011, Martinez 2005). Some studies have found CRC risk is 2-4 times
higher in smokers (Ahmed 2004, Giovannucci 2002). Compared to non-smokers, female smokers had
an increased risk of advanced adenomas with an exposure of 10 or more pack-years while men had an
increased risk with smoking over 30 pack-years. An increased association with smoking was observed
for proximal advanced adenomas and large hyperplastic polyps in women (Anderson et al 201 lb).
Molecularly, cigarette smoking increases concentrations of carcinogens, such as polycyclic aromatic
hydrocarbons, nitrosamines and aromatic amines (Ahmed 2004).
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1.3 Prevention and chemoprevention
Given that conventional treatment is expensive and associated with significant morbidity and
mortality, and that early detection and prompt surgery in the early stages of colon cancer offers the
best chances of a long-term cure, there has been a great deal of focus on developing primary,
secondary and tertiary prevention strategies to combat the disease. Primary prevention is concerned
with aetiological factors, such as lifestyle and dietary modification, to eliminate potential mutagens
(Krishnan et al 1997). Secondary prevention attempts to reduce incidence by identifying and treating
pre-malignant conditions in subjects at risk (Rigas and Williams 2002). In tertiary prevention or
chemoprevention, the use of natural or laboratory-made substances is employed to prevent a disease
such as cancer (Cooper et al 2010), the aim is either to prevent the initiation of carcinogenesis in
healthy individuals or to prevent recurrence, invasion and metastasis in people diagnosed with
symptomatic disease (Vainio and Miller 2003). Although dietary and lifestyle intervention can have a
considerable impact on reducing the risk of developing CRC, it is very difficult to devise and
impliment such prevention strategies on a large scale due to lack of compliance.
Chemoprevention therefore represents an attractive, alternative approach to reducing the mortality
from CRC and essentially involves the long-term use of chemical agents that can delay, prevent or
reverse the development of adenomas and interfere with the multi-step progression from adenoma to
carcinoma (Arber and Levin 2005, Benamouzig et al 2005). The challenge for those attempting
chemoprevention in CRC is to develop safe and effective drugs which are easy to administer and have
a low cost (Thun et al 2002). Several agents have been postulated as having a chemopreventative
effect on the development of premalignant lesions, polyps or cancers in human studies (Hong and
Sporn 1997). Here I will concentrate on a few of the more extensively studied candidates.
1.3.1 Folate
Folic Acid is important in DNA synthesis and in control of cellular division and differentiation.
Studies of patients who have polymorphisms in the genes which control folate processing i.e.
Methylenetetrahydrofolate reductase (MTHFR), report a reduced relative risk of CRC compared to the
unaffected population (Ma et al 1997, Slattery et al 1999). Evidence for the chemopreventative effect
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of folate is mixed. In a pooled analysis of 13 prospective studies of folate supplementation and CRC
risk, including 725,134 participants, a 2% risk reduction (95% CI 0-3%) was estimated for every 100
pg/day increase in total folate intake, concluding that higher folate intake is modestly associated with
reduced risk of colon cancer (Kim et al 2010). However, in a combined metanalysis of RCTs of folic
acid supplementation (0.5 or 1.0 mg/day) in patients with an adenoma history, after 3.5 years of folic
acid use, there was no clear decrease or increase in the occurrence of new adenomas (Figueiredo et al
2011). Furthermore, there is evidence that excessive folate supplementation can actually transform
normal bowel mucosa. It has been reported that once a malignant lesion has developed, there is a
direct inhibitory effect on its growth by folate deficiency and the reported opposite effect with folate
supplementation (Kim 2007).
1.3.2 Calcium and vitamin D
Calcium binds to bile salts and fatty acids (Janne and Mayer 2000). Vitamin D levels (1,25
dihydroxyvitamin D, l,25(OH)D), are related to solar ray exposure and demonstrated an inverse
relationship with solar radiation and CRC incidence in human populations (Emerson and Weiss 1992).
Both calcium and vitamin D have an antiproliferative effect on colorectal epithelial proliferation,
promoting cellular differentiation and cell death (apoptosis) (Lamprecht and Lipkin 2003). Calcium
putatively also reduces CRC tumour initiation in animal models of intestinal carcinogenesis (Pence
1993).
Epidemiological studies suggest a reduction in adenomas in persons who take calcium
supplementation (1200-2000 mg/day) (18% reduction in the risk of adenoma recurrence after 3-4
years) and a non-significant reduction in the risk of advanced adenomas (RR 0.77) (Baron et al 1999,
Martinez et al 2002). However, a metanalysis of 3 RCTs of calcium with or without another agent
versus placebo in individuals with a history of adenomas showed a reduced RR for adenoma
recurrence (RR = 0.80 [95% CI, 0.69-0.94], P = 0.006) for those receiving calcium 1200 to 2000
mg/d, but no effect was seen in advanced adenoma (RR = 0.77 [95% CI, 0.501.17], P = NS).
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However, evidence from trials is mixed when observing CRC risk (Martinez and Willett 1998).
Studies assessing calcium (1000-1500 mg/day) plus vitamin D (400-1100 IU/day) in populations
with no increased baseline risk of CRC have reported no protective effect on the relative risk of CRC
(Lappe et al 2007, Wactawski-Wende et al 2006). Of note, differences in vitamin D levels (sun
exposure) amongst participants could account for discrepancies found in studies reporting on calcium,
given its confounding effect and relevance in the regulation of calcium metabolism, control and
uptake (Holt et al 2002).
1.3.3 Hormone Replacement therapy (HRT) / Oestrogens
The correlation between HRT and CRC has been widely researched and the majority of case-control
and cohort studies, to date, have demonstrated that women who use HRT postmenopausal ly have an
approximately 20-40% decreased risk of CRC (Hawk et al 2004, La Vecchia et al 2005, Raju and
Cruz-Correa 2006). In the cancer prevention study II, CRC mortality was reduced in those who took
HRT for greater than 10 years (Calle et al 1995). Oestrogens decrease the synthesis of secondary bile
acids, decrease response to Insulin-like growth factor and have direct regulatory effects on epithelial
proliferation (Janne and Mayer 2000), providing a putative mechanism by which HRT may exert its
effect. It is also possible that HRT confers protection through biological mechanisms involving
vitamin D (via UV and other sources) and/or components of the vitamin D signaling pathway
(Gallagher et al 1980).
1.3.4 Fibre
Burkitt first proposed that dietary fibre reduces the risk of CRC in the 1970s whilst observing the low
rates of CRC among rural Africans (Burkitt 1971). A large number of animal and epidemiological
studies examining fibre intake and CRC risk have been performed; the majority show a protective
effect [reviewed in (Ahmed 2004, Howe et al 1992, Martinez 2005, Trock et al 1990). However,
increasing the daily amount of fibre does not seem to increase the dose effect (Alberts et al 2000).
Fibre is a complex carbohydrate and several mechanisms have been postulated to explain the
protective effect, including increased stool bulk and dilution of carcinogens in the colonic lumen
(limiting exposure of colonic epithelium to carcinogens) (Lao and Brenner 2004, Lipkin et al 1999).
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Fibre may also act as a substrate for bacteria in the gut, resulting in an increase in concentration of
short chain fatty acids, such as butyrate (Campos et al 2005). Butyrate has diverse and apparently
paradoxical effects on cellular proliferation, apoptosis and differentiation and may be either be pre¬
neoplastic or anti-neoplastic, depending upon factors such as the level of exposure, availability of
other metabolic substrate and the intracellular milieu (Sengupta et al 2006). However, butyrate has
been shown to be anti-carcinogenic and can induce apoptosis in colon adenoma and colon cell lines
(Key et al 2002). Furthermore, butyrate is an important fuel for regeneration of the colonic epithelium
and may also have protective effects by lowering the pH in the colonic lumen (Heavey et al 2004).
Whole grains are a major source of dietary fibre and contain germ, endosperm, and bran, in contrast
with refined grains that contain only the endosperm. The germ and bran contain numerous nutrients,
which are removed during the refining process. In addition, whole grains are a major source of several
vitamins, minerals, and phytochemicals, which have anticancer properties and could influence the risk
of CRC by several potential mechanisms (Slavin et al 1999).
To clarify the association between dietary fibre and whole grain intake and risk of CRC, Aune et al.
recently carried out a systematic review and meta-analysis of all published prospective studies. The
RR of developing CRC with 10 g daily total dietary fibre (16 studies) was 0.90, for fruit fibre was
0.93, for vegetable fibre was 0.98, for legume fibre was 0.62, and for cereal fibre was 0.90. The
summary RR for an increment of three servings daily ofwhole grains was 0.83 (Aune et al 2011).
In a metanalysis of previous studies within the AICR/WCRF report, the RR per 3x60g of wholegrain
servings /day of intake was 0.79 for CRC, 0.84 for colon cancer (n=3) and 0.72 for rectal cancer




Statins are small-molecule inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA)
reductase, and are used as cholesterol-lowering drugs. In addition to their use in the treatment of lipid
disorders, studies have suggested they may have chemopreventative potential against CRC (Agarwal
et al 1999, Cho et al 2008). However, large-scale epidemiological studies evaluating the preventative
effects of statins against CRC are inconsistent (Coogan et al 2007). This is partially as data relied on
retrospective self-reporting by study participants and there was an element of non-compliance. In
addition, few studies control for confounding variables such as concurrent NSAID/aspirin use,
exercise, vegetable consumption, hypercholesterolaemia, and family history of CRC (Poynter et al
2005). Unfortunately, even in clinical studies specifically set-up to measure the clinical effect of statin
use, CRC case numbers are often small and thus fail to demonstrate any risk reduction with the agents
(Shepherd et al 1995, Strandberg et al 2004).
1.3.6 Other agents
Oxidation of molecules can produce free radicals (molecules with an unpaired electron), which are
highly reactive and cause cellular damage. Antioxidants which prevent oxidation, thereby reducing the
number of free radicals, such as micronutrients (vitamins A, C, D, E, folic acid and B6; selenium; and
carotenoids and flavonoids), have been shown to have a protective effect against CRC (Gatof and
Ahnen 2002, Heavey et al 2004, Lin et al 1998, Martinez 2005). However, the results of clinical trials
with vitamin supplementation have been disappointing (Giovannucci et al 1998). The Physician
Health Study and the a-tocopherol P-carotene cancer prevention study both demonstrated no
encouraging chemopreventative effects and a further RCT with a combination of P-carotene, vitamin
C or E, also demonstrated no difference in colonic carcinogenesis endpoints after one year (Giacosa et
al 1997). Reported side effects of antioxidant have included pruritus (vitamins A, C, E), epistaxis
(vitamin E), risk of haemorrhagic stroke (vitamin E), alopecia and dermatitis (selenium), and
yellowing of the skin and belching (beta-carotene) (Cooper et al 2010). Other reviews have reported a
possible association between P-carotene and vitamin A and an increased risk of upper GI cancer
(Bjelakovic et al 2007). Additional agents such as Ursodiol, a modulator of Bile acid composition
(Earnest et al 1994), e-flornithine, an inhibitor of cellular proliferation by altering polyamine
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metabolism (Meyskens and Gerner 1999) and Oltipraz, an inducer ofmutagen detoxification enzyme,
gluathathione 5-transferase (Helzlsouer and Kensler 1993) have been reported in isolated studies to
reduce the risk of CRC in animal models, but evidence has yet to be verified and therefore the weight
given to such findings requires appropriate mitigation.
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1.3.7 Aspirin and related Non-Steroidal Anti-inflammatory Drugs (NSAIDS)
Aspirin belongs to a family of compounds called the salicylates. Aspirin is absorbed primarily in the
upper GI tract following first order kinetics and has an absorption half-life of 5-16 minutes. It is
mainly unchanged in the lumen of the GI tract but once absorbed is hydrolysed carboxylesterases in
the gut wall and liver, so that only 68% of the dose reaches the systemic circulation as acetylsalicylic
acid. Salicylates are excreted via the kidney and broken down into salicyluric acid, (reviewed in Hare
et al 2003). The serum half-life of Aspirin is 20 mins, Salicylic acid is the principal metabolite of
aspirin which has a serum half-life of 2-30 hours dependant on concentration (Needs et al 1985).
Salicylic acid is also present in dietary fruits and vegetables, with some herbs and spices containing
particularly good sources of dietary salicylates (Venema et al 1996). A normal diet provides 0-6 mg
of salicylates daily, and no measurable aspirin (Janssen et al 1996).
Aspirin and related compounds (of which there are greater than 20) are the most widely studied agents
in the chemoprevention of CRC (Janne and Mayer 2000). They have a major role in the primary and
secondary prevention of myocardial infarction, thromboembolic disease and stroke (Sanmuganathan
et al 2001) and it was through analysis of larger trials of the above conditions that a protective effect
against CRC was first noted. Compelling evidence from a number of experimental, animal, human
and population studies indicates that these agents have a CRC chemopreventative effect (Dube et al
2007, Levy 1997, Thun et al 1991).
Effects on aberrant cryptfoci development
Case control and animal studies demonstrate a reduction in both Aberrant Crypt Foci (ACF) formation
and the incidence of early adenomas (DuBois et al 1996, Reddy et al 1993). In one particular study,
the total number of ACF were significantly reduced in colon carcinoma resections in patients who
received preoperative aspirin for greater than one year (Shpitz et al 2006). The incidence of ACF is
also noted to be decreased in individuals treated with sulindac (Kuno et al 2002).
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Effects on the development ofcolorectal lesions in high-risk patients
Several studies ofNSAIDs in FAP (sulindac, celecoxib or tiracoxib) have demonstrated that NSAIDs
reduce the number and size of polyps in FAP patients (polyp regression) (Guldenschuh et al 2001,
Makela and Laitinen 1994, Rigau et al 1991, Waddell and Loughry 1983, Winde et al 1997). The
metabolite of sulindac, sulindac sulfone (exisulind), has also been shown to have a protective effect
against the development of rectal adenomas in FAP (Stoner et al 1999).
The CAPP1 study (Colorectal Adenoma Prevention Programme 1) studied daily resistant starch or
daily aspirin (600 mg as 2 tablets) in 206 FAP patients. After a median of 17 months, the primary
endpoint of polyp risk, reported that polyp numbers in the rectum and sigmoid colon was not
significantly reduced in either treatment group but there was a trend toward reduced polyp number
and diameter of the largest polyp detected in the aspirin arm. This was later supplemented by evidence
from subgroup analyses of patients who continued on the study for more than one year, which found a
significant reduction in the size of the largest polyp (Burns J et al 2011, Burns et al 2013).
In CAPP2, 1009 Lynch syndrome gene carriers were recruited and after a mean of 29 months, there
was no evidence that aspirin 600mg/d influenced development of colonic neoplasia after 2 years.
However, the design included double blind follow-up for at least 10 years, and after a mean of 55.7
months, 48 recruits developed CRC. The HR for CRC with aspirin was 0.63. The evidence was
sufficient to recommend aspirin to all Lynch syndrome gene carriers (Burn J et al 2011). This was
also the first time that a trial had demonstrated a beneficial effect of aspirin on the incidence of CRC
or death.
Effects on adenoma occurrence in persons of "normal" risk
Epidemiological studies demonstrate persons who regularly take aspirin or related non-aspirin
NSAIDs have a 40-50% lower risk of developing colorectal adenomas and tumours. Some studies
even suggest NSAIDs reduce CRC-related deaths (Asano et al 2004, Giovannucci et al 1998, Janne
and Mayer 2000) [reviewed in (Benamouzig et al 2005, Brown and DuBois 2005, Imperiale 2003)
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(Giovannucci 1999, Shiff and Rigas 1997)]. Flossman et al. (Flossmann and Rothwell 2007)
retrospectively analysed CRC incidence data from two previous prospective British trials involving
aspirin randomisation, the British Doctors Aspirin Trial and the UK-TIA Aspirin Trial, originally
designed to examine association with myocardial infarction and Transient Ischaemic Attacks (TIAs),
respectively. The maximum chemopreventative effect occurred after 5 years, or more, duration of
aspirin intake and at a dosage of greater than 300mg per day (lesser dosages gave more inconsistent
results), with a latency period until the chemopreventative effect became significant of over 10 years.
Figure 1. 3 Previous case control trials examining aspirin and related NSAIDs impact on CRC endpoints (A)
any use of aspirin or NSAID and (B) maximum reported use of aspirin or NSAID (Flossmann and Rothwell).
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Metanalysis of four RCTs of aspirin in the general population, (two low dose (100-325 mg every
other day) and two higher dose (300-1500 mg/day), with a combined follow-up to 10-23 years,
demonstrated no effect on CRC risk over the first 10 years of follow-up (RR 1.01). However, analysis
of the higher dose studies demonstrated a significant reduction in CRC incidence over the full 23-year
follow-up period (RR 0.74). An even greater reduction was observed when analysing years 10-19
only (RR 0.61) (Cook et al 2005, Cooper et al 2010). Only one trial to date has demonstrated an
increased risk of CRC following Aspirin or NSA1D administration (Paganini-Hill et al 1989).
However, this questionnaire study had considerable flaws including compliance weakness, recall bias
and the reliance on analysis of both male and female subpopulations combined, to present a
significant increase statistically.
Intermediate risk - secondary prevention
Previous RCTs report that aspirin (81-325 mg/day) imparts a significantly reduced risk (RR = 0.65-
0.96) of adenoma recurrence in patients previously diagnosed with CRC or adenoma, within 3 years
of follow-up (Baron et al 2003, Benamouzig et al 2003, Cole et al 2009, Sandler et al 2003).
Metanalysis of these studies demonstrates an overall statistically significant 21% reduction in the
relative risk of adenoma recurrence (Cooper et al 2010).
Interventional studies
Two recent epidemiological studies also suggest regular aspirin use after CRC diagnosis improves
outcomes and that aspirin could have a role as an adjuvant therapy in cancer (Chan et al 2009)
(Holmes et al 2010). The benefit of aspirin was greatest in those whose tumours overexpressed COX-
2. Furthermore, those who had taken aspirin before diagnosis did not appear to benefit (Rothwell et al
2010). A small trial of only 66 patients evaluated 1200 mg of aspirin daily compared with placebo as
adjuvant treatment for Duke's B2 and C CRC demonstrated a non-significant reduction in HR for
survival 0.65 (95% CI: 0.02-18.06) (Lipton et al 1982). In addition, the recent Capp2 study
examining the role of aspirin in reducing the development of CRC in high-risk groups has already
been discussed and has led to the recommendation of aspirin for chemopreventative use in MMR
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carriers (Burn et al 2011).
Recently, Rothwell et al., (Rothwell and Algra 2012) published a systematic review of all case-control
and cohort studies over a 61 year period that reported associations between aspirin use and risk or
outcome of any cancer. This included more than 77,000 patients in 51 studies. Meta-analyses
demonstrated that aspirin was associated with a reduced risk of CRC (0-62) and the 20-year risk of
death due to CRC. Regular use of aspirin was also associated with a reduced risk in the development
of distant metastasis but not with any reduction in regional spread.
Almost concurrently, Rothwell et al. (Rothwell et al 2012) also published an additional metanalysis
of five large UK randomised trials of daily aspirin (>75 mg daily) versus control for the prevention of
vascular events, specifically looking at the frequency of distant metastasis in aspirin treated versus
aspirin-naive patients who developed cancer during trials of daily aspirin versus control. Aspirin
reduced the risk of developing distant metastasis in all cancers, but with greater effect in
adenocarcinomas. This effect was present at initial diagnosis (HR 0-69) and on subsequent follow-up
in patients without metastasis initially (HR 0-45)(particularly in patients with CRC - HR 0-26). There
was also a reduction in death due to cancer in patients who developed adenocarcinoma, especially in
those without metastasis at diagnosis (HR 0-50).
Dose effect
The epidemiological data and RCTs assessing primary prevention support the notion that the anti¬
cancer effects of aspirin are seen when higher, daily dosages of aspirin are used over longer follow-up
(Chan et al 2005, Chan et al 2008). At higher doses, aspirin is a more potent inhibitor of COX-2 but
interestingly, in the majority of cohort studies, the chemopreventative dose for aspirin is at a dose of
aspirin much higher than that required to prevent the Cox activity (Frantz and O'Neill 1995). Some
exceptions have been reported (Thrombosis Prevention Trial, Swedish Aspirin Low Dose Trial)
(Rothwell et al 2010). Baron et al. detected the maximum RR effect with adenomas at 81mg OD
dosage (RR 0.81 CI 0.69-0.96) compared to the 325mg OD dosage (RR 0.96 CI 0.81-1.13) (Baron
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2003). A recent case-control Scottish study has also demonstrated preventative effects at levels as low
as 75mg Aspirin daily (Din et al 2010).
Of note, in the previously discussed paper looking at the frequency of distant metastasis in aspirin
treated versus aspirin-naive patients who developed cancer during vascular event prevention RCTs
(Rothwell et al 2012), low-dose formulations of aspirin (designed to inhibit platelets but to have little
systemic bioavailability) were as effective as higher doses. Previous reports have also found that
whilst aspirin reduced the 20-year risk of CRC (HR= 0-7) and that benefit increased with scheduled
duration of treatment, such as allocation to aspirin of 5 years or longer, there was no increase in
benefit at doses of aspirin greater than 75 mg daily (Rothwell et al 2010).
There are a number of ongoing studies due to report in the next few years which aim to elucidate the
relationship of aspirin dose and its effect on adenoma formation, CRC recurrence and CRC survival.
These include The Systematic Evaluation ofAspirin and Fish Oil polyp prevention (SEAFOOD)
(evaluating adenoma number in high risk individuals; EPA and 300mg aspirin/d), the Japan Colorectal
Aspirin Polyps Prevention (J-CAPP) study (new CRC in those who have had previously undergone
resection for CRC; lOOmg aspirin/d) and Aspirin for Dukes C and High Risk Dukes B Colon Cancer
Trial (ASCOLT) trial (evaluating disease free survival in those with previous Duke's C or high risk
Duke's B CRC) (reviewed in Chan et al 2012). The future CAPP3 study will report on findings made
in previous CAPP studies and aims to recruit 3000 high risk gene carriers into a dose inferiority study
to test the relative chemopreventative benefits of lOOmg, 300 or 600mg daily doses (Burn et al 2013)
Animal studies
In addition to epidemiological studies, the anti-neoplastic properties of aspirin and related NSAIDs
have been consistently reported in animal (mainly rodent) models of CRC. In carcinogen-induced
(DMH (1,2-dimethylhydrazine) or AOM (azoxymethane)) CRC models it has been shown that
animals have reduced of adenomas following NSAID administration (Fukutake et al 1998, Haanen
2001, Pollard and Luckert 1981, Reddy et al 1993, Shiff and Rigas 1997). In the Min (APC"/+) mouse
(which has an autosomal, dominant heterozygous mutation of the APC gene leading to spontaneous
62
intestinal neoplasia) aspirin has also been shown to reduce adenoma formation (Barnes and Lee 1998,
Chiu et al 1997, Giovannucci 1999, Jacoby et al 1996). NSAIDs (Goldman et al 1998, Williams et al
2000) also suppress CRC cell growth in the nude mouse xenograft model (where cultured CRC cells
are xenografted onto the flanks of nude (athymic) mice) (Gupta and Dubois 2001).
Aspirin has previously demonstrated a CRC cell-specific ability to both reduce the viability of CRC
cancer cells in vitro and induce apoptosis, in comparison to its effects on cells originating from other
tissues (Din et al 2004), (Piazza et al 1995). Recent evidence from CRC cell lines also suggests the
increasing importance of aspirin's effects on inducing cell cycle arrest as a predominant mechanism in
aspirin-induced apoptosis (Thorns et al 2007a). Further details of these mechanisms will be explored
in chapter 1.4.
Side Effects
Long-term aspirin use is consistently associated with a statistically significant elevated risk of
gastrointestinal bleeding (RR 1.6- 2.5) and increased risk of adverse gastrointestinal symptoms, such
as nausea and dyspepsia (OR, 1.7) (Dube et al 2007). The side effects ofNSAIDs are associated with
inhibition of Cox-1. Therefore, selective Cox-2 inhibitors were developed. It was found that the
incidence of perforation, ulceration or bleeding was significantly lower, but not negligible, with
rofecoxib (Cox-2 specific inhibitor) than with traditional NSAIDs in a metanalysis of patients taking
these medications for arthritis (cumulative incidence 1.6% vs. 3.1%, p < 0.001) (Watson 2004). Based
on these data, the agents were licensed in the US for use in conditions associated with high numbers
of adenomatous polyps. However, in 2004, after analysis of a RCT of the Cox-2 inhibitor, rofecoxib
in patients with adenomas, there was still a higher level of perforations, ulcer obstructions or GI
bleeding episodes in this group compared to placebo treatment (relative risk, 3.8) (Lanas et al 2007).
Furthermore, the use of these agents was associated with significant cardiovascular thrombotic events
(Bresalier 2005). This safety profile was such that Rofecoxib (Vioxx) was withdrawn from
recommended use (Rostrom 2007) (Topol, 2004; Samoha and Arber, 2005). Similar findings were
reported from evaluation of a trial of celecoxib, which also demonstrated significant cardiovascular
side effects, especially in high-dose groups (Solomon et al., 2005).
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The mechanism linking the use of COX-2 inhibitors to an increased incidence of thrombotic vascular
events has not been precisely elucidated. However one theory is that Prostaglandin 12, derived from
COX-2, has previously been shown to be the predominant cyclooxygenase product in endothelium,
inhibiting platelet aggregation, causing vasodilatation, and preventing the proliferation of vascular
smooth-muscle cells in vitro. In vitro these effects contrast with those of thromboxane A2, the major
COX-1 product of platelets, which causes platelet aggregation, vasoconstriction, and vascular
proliferation. Whereas aspirin and traditional NSAIDs inhibit both thromboxane A2 and prostaglandin
12, the coxibs leave thromboxane A2 generation unaffected, but suppress formation of prostaglandin
12 potentially predisposing patients to myocardial infarction or thrombotic stroke (Fitzgerald 2004).
1.3.8 Combination Approach
In addition to the above individual potential agents, authors have suggested that two or more agents in
combination may provide a better chemopreventative action than one recommended agent alone. In a
trial in the APCMln/+ mice model of intestinal polyposis, the use of the EGFR kinase inhibitor, EKI-
785, in addition to a NSAID (Sulindac) caused a 50% regression of adenomas compared to untreated
controls (Torrance et al 2000) and further studies have postulated the benefits of COX inhibitors in
addition to P13-Kinase, PPARy inhibitors or 15-PGDH inhibitors (Markowitz 2007). Another
example utilizes the polyamine synthesis pathway. Arginine, a precursor of ornithine, induces
polyamine synthesis via ornithine decarboxylase (ODC). Polyamines enhance colonic tumourigenesis
while inhibition of ODC inhibits carcinogenesis. Combination of an inhibitor of ODC with sulindac,
which inhibits polyamine biosynthesis, was found to have strong chemopreventative effects on
sporadic colorectal adenomas (Meyskens et al 2008).
1.3.9 Conclusions
The agents described above are in no way exhaustive and many ongoing trials continue to search for a
reliable and safe means of chemopreventative therapy in CRC. The importance in understanding the
mechanisms of action of those agents that have demonstrated most promise cannot be underestimated,
as it is through this understanding that safer, more effective agents may be designed. Hence, whilst
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aspirin and related NSAIDs are some of the best characterised agents, they are also some of the most
toxic and urgent priority must be given to research aimed at understanding more about intracellular
events stimulated and modified by aspirin administration.
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1.4 Putative mechanisms of aspirin's chemopreventative effects
1.4.1 Background
Tissue mass is critically affected by rates of cell proliferation and cell death (by apoptosis), and the
colonic mucosa in both normal and pathological states is not an exception. Exploration of aspirin's
molecular effects on colonic mucosa would therefore aid in the development of more effective and
safer chemopreventative agents.
1.4.2 COX-2-dependent mechanisms of aspirin induced chemoprevention
One of the most notable effects of aspirin and the majority of NSAIDs is their ability to inhibit
activity of cellular COX (cyclo-oxygenase) enzymes. A basic schematic of the pathway is seen in
figure 1.3 but briefly, these enzymes provide the rate-limiting step in the synthesis of eicosanoids,
such as prostaglandins E2 and D2, from arachidonic acid. Arachadonic acid is released from
membrane phospholipids by phospholipase A2 and converted by COX-1 or COX-2 into prostaglandin
(PG) G2 and then to PGH2 by peroxidase catalytic activity. Production of PGs (PGE2, PGD2, PGI2,
PGF2a and thromboxane A2) from PGH2, the precursor of all PGs, is catalysed by a specific isomerase
(Brown and DuBois 2005). PGE2 levels are elevated in colorectal tumours and adenomas compared to
normal adjacent mucosa (Backlund et al 2005) and it has been suggested that these elevated levels of
prostaglandins accelerate the growth and invasion of cancer (Easty and Easty 1976). Indeed, it has
been demonstrated that certain oncogenes induce prostaglandin synthesis (Levine 1981) and addition
of prostaglandins to CRC cell lines promotes tumour growth, resistance to apoptosis, secretion of pro-
angiogenic molecules and promotion of cell proliferation (Oshima and Taketo 2002, Sakamoto 1998,
Seno et al 2002, Sonoshita et al 2001) (Cha and DuBois 2007). Furthermore, 15-PGDH (15-
Prostaglandin Dehydrogenase), a potent suppressor of the prostaglandin pathway, inhibits tumour
growth in murine models of CRC, is abolished in the majority of colon cancers (Markowitz 2007).
COX-1 and COX-2 are homodimers of similar molecular weight, approximately 70 (576 amino acids)
and 72 kDa (581 amino acids) respectively. Both contain three high mannose oligosaccharides, a
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fourth oligosaccharide, present only in COX-2, regulates its degradation. Each subunit of the dimer
consists of the epidermal growth factor domain, the membrane binding domain and the catalytic
domain comprising the bulk of the protein (containing a cyclooxygenase and peroxidase active sites).
COX-1 is coded for by Ptgs-1, who's mRNA is relatively stable unlike the COX-2 gene Ptgs-2, which
is activated by a wide variety of stimuli, and produces a relatively unstable mRNA (Smith et al. 2000).
COX-1 provides prostaglandins involved in homeostasis (including gastric cytoprotection and
haemostasis), whereas COX-2 plays a role during inflammation and tumorigenesis.
Aspirin is an approximately 150- to 200-fold more potent inhibitor of the constitutive enzyme COX-1
than the inducible isoform COX-2. This explains the different dosage requirements of aspirin as an
antithrombotic (COX-1) and an anti-inflammatory drug (COX-2), respectively (Schror K. et al.
1997). Aspirin is the only clinically used NSAID that covalently modifies the COX protein. All other
NSAIDs act non-covalently and most can be classified as either rapidly reversible, competitive
inhibitors or slow, tight binding inhibitors. The kinetics and mechanism of inhibitor binding were
recently reviewed in detail (Rouzer and Marnett 2009). The substitution of isoleucine at position 523
in COX-1 with valine in COX-2, allows for selective inhibition via binding of drug molecules, such
the coxibs. Because COX-2 is usually specific to inflamed tissue, there is much less gastric irritation
associated with COX-2 inhibitors, with a decreased risk of peptic ulceration. (Blobaum and Marnett
2007).
COX-1 is a constitutively and widely expressed "house-keeping" enzyme which supplies tissues with
the prostaglandins required to maintain physiological function i.e. renal blood flow and cytoprotection
of the gastric mucosa. COX-1 is expressed in platelets and gastric mucosa and inhibition of this
enzyme, following NSAID administration, potentially leads to ulceration and bleeding (Patrignani
2000). COX-2 is an inducible form of the COX isoform, which is upregulated in injury/inflammation
and serves to sensitise nocioreceptors and increase inflammatory mediators (Backlund et al 2005,
Brown and DuBois 2005, Gupta and Dubois 2001, Janne and Mayer 2000). It is induced by a wide
variety of agents including cytokines, mutagens and growth factors and increases new blood vessel
growth and survival in tumours by, in some cases, decreasing apoptosis (Tsujii and DuBois 1995).
Elevated levels of prostaglandins in CRC are attributed to increased COX-2 activity. In fact, multiple
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lines of evidence indicate that this enzyme acts as a tumour promoter in this and other cancers. For
instance, COX-2 mRNA and protein are found to be upregulated in over 90% of colorectal cancers
and 40% of adenomas compared to normal mucosa (Fujita et al 1998, Patrignani 2000, Sano et al
1995). There is increased COX-2 expression found in adenomas from FAP patients (Giardiello et al
1998) and in CRCs from inducible cancer animal models (Williams and DuBois 1996), (Boolbol et al
1996). Both gene disruption and pharmacological inhibition ofCOX-2 have been shown to reduce the
number and size of polyps in aPCA716(+A) knockout mice (Oshima et al 1996) and inhibition of COX-2
leads to increased levels of arachidonic acid, which in turn stimulates apoptosis (Chan et al 1998,
Janne and Mayer 2000). Furthermore, in COX-1- or COX-2-deficient APC deficient mice, the
tumourigenic effect of the APC mutation is decreased by 80% (Chulada et al 2000).
Given the evidence that COX-2 contributes to colorectal carcinogenesis, it is not surprising that the
anti-tumour activity of NSAIDs has been attributed to their ability to inhibit these enzymes. Aspirin,
unlike other NSAIDs (Mitchell et al 1993), inhibits both COX-1 and COX-2 activity by irreversibly
acetylating the proteins (Taketo 1998, Vane 1996), although there is preferential inhibition of COX-1
(Simmons et al 2004). Acetylation of COX-2 by aspirin switches COX-2 induced promotion of
prostaglandins (PGE2) to promotion of the antitumourigenic 15-epi-lipoxin-A4 (LXA4) or 'aspirin-
triggered lipoxin (ATL). ATL inhibits proliferation of carcinoma cells (Claria et al 1996) and is
induced at low, antiplatelet doses of the agent (Morris et al 2009). In addition to irreversible
acetylation ofCOX-2, it has been suggested that NSAIDs modulate COX-2 activity through induction
of the NSAID activated gene-1 (NAG-1). Expression of this gene is induced by NSAIDs and this
expression correlates with reduced levels ofCOX-2 activity and increased apoptosis. Furthermore,
over expression of NAG-1 mediates apoptosis of colorectal cancer cells while anti-sense NAG-1
causes attenuation of NSAID induced apoptosis and suppression of xenografted tumour growth in
nude mice (Baek et al 2010, Eling et al 2006). High expression of COX-2 in human CRC tumour
tissue is related to low expression ofNAG-1, suggesting a reciprocal relationship (Iguchi et al 2009).
It is suggested that increased COX-2 expression in CRC tumours suppresses NAG-1 but that
induction of NAG-1 by aspirin and non-aspirin NSAIDs might constitute a possible
chemopreventative mechanism.
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Evidence from recent clinical trials supports the notion of the existence of a subpopulation of colon
tumours or polyps which express higher levels of COX-2 are more responsive to the anti-tumour
effects of aspirin/NSAIDs (Chan et al 2007). Earlier case control studies also suggested that NSAIDs
reduce the relative risk of adenomatous polyps, especially in those cases showing high COX-2 mRNA
levels (Haile et al 2005). However, there is also considerable evidence that NSAIDs have COX
independent mechanisms of action.
1.4.3 COX-2 independent mechanisms of aspirin induced chemoprevention
There remains intense debate remains over whether a COX-independent mechanism is responsible for
the anti-cancer effects of aspirin and related NSAIDs (Levy 1997, Rigas and Williams 2002).
Evidence that COX-2 independent pathways may be responsible comes from several sources.
Important discoveries have been made in CRC cell lines that do not express COX-2 or NSAIDs that
have no known anti-COX 2 activities. Smith et al. (Smith et al 2000a), investigated the action of
aspirin, indomethacin and NS-398 (a COX-2 specific NSAID) in a panel of COX-2 expressing and
non-expressing CRC cell lines, found that whilst NS-398 had no effect on the COX-2 negative cell
lines, indomethacin induced cell cycle arrest and apoptosis in both COX-2 positive and negative cell
lines, irrespective of their COX-2 status. Hanif et al., demonstrated that aspirin exhibits a dose-
dependent inhibition of growth in CRC cell lines irrespective of their COX-2 expression profile
(Hanif et al 1996). Piazza et al., reported dose-related induction of apoptosis in sulindac treated colon
cancer cell lines, independent of COX inhibition (Piazza et al 1997b). Furthermore, mouse embryo
fibroblasts that do not express either COX isoforms show similar sensitivity to high dose NSAID
treatment (Zhang et al 1999).
In animal models of colonic carcinogenesis, many COX-2 inhibitors continue to demonstrate an anti-
tumour effect despite possessing no anti-COX activity (Kawamori et al 1998, Oshima and Taketo
2002, Yoshimi et al 1999). The R-enantiomer of Flurbiprofen retained chemopreventative activity in
the APC Min Mouse Model of intestinal polyposis despite no known anti-COX activity (Wechter et al
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1997) and sulindac sulphone (a metabolite of sulindac which does not inhibit COX activity) inhibited
AZO induced colonic cancer in rats (Piazza et al 1997a).
In epidemiological studies, data suggests that the chemopreventative action of aspirin is observed at
doses higher than that required to reduce E2 and F2 prostaglandins synthesis in the intestinal mucosa
(Ricchi et al 2003, Tegeder et al 2001). These data suggest that important anti-tumour cell
mechanisms are induced at higher dosages (>100 fold higher) than the amount required to inhibit
prostaglandin production (Kralj et al 2001, Smith et al 2000b)(Chiu et al 1997, Qiao et al
1998a)(Ricchi et al 1997).
Taken together, these data suggest that NSAIDs may have COX-independent mechanisms of action
against colorectal cancer cells. Several alternative pathways have been suggested as putative targets
for the anti-tumour mechanism of these agents (Elwood et al 2009, Jankowski and Anderson 2004).
The most studied of these pathways will be discussed in detail below.
1.4.4 The MAP kinase pathway
The MAPK/ERK stress response pathway includes ERK-1, -2, p42, p44 MAP Kinase, c-Jun N-
terminal Kinase (JNK) and p38 Map kinase. These pathways regulate inflammation, proliferation and
cell survival. MAPKs are activated by MAPK kinases (MAPKKs or MAP2Ks). MAPKKs are in turn
activated by a family of serine-threonine kinases called MAPKK kinases (MAPKKKs, MAP3Ks or
MEKKs) (Saklatvala 2004). Activation of MAPKs occurs in times of cell stress with the eventual
activation of p38, leading to resultant changes in cell cycle progression and apoptosis (Thorns et al
2007b) Classically, activation of MAP kinases is associated with cell survival and proliferation and
even transformation (Mansour et al 1994), (Xia et al 1995) however, their importance to the induction
of apoptosis and cell cycle arrest have now also been noted, and importantly, depend on the cellular
context (Thorns et al 2007b) (Stanciu et al 2000).
Sodium salicylate inhibits JNK and ERK activity in human fibroblasts and other cellular contexts
(Pillinger et al 1998, Rice et al 2001, Schwenger et al 1998, Wang and Baldwin 1998). However,
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individual MAP kinase family members respond to aspirin and related-NSAIDs with variation
depending on cellular context. For example, Sodium Salicylate can activate ERK 1, 2 and p38 MAPK
and increased apoptosis (Schwenger et al 1998). Salicylates also induce apoptosis in eosinophils via
activation of c-JNK and p38 MAPK (Wong et al 2000). In human colon cancer cells, treatment with
NS-398, a NSA1D, caused sustained activation of ERK, associated with apoptosis (Elder et al 2002)
and chemical inhibition of these kinases blocks the effects of the salicylates-induced apoptosis (Lee et
al 2003).
The host laboratory have previously reported that a very early response to aspirin in colorectal cancer
cells is activation of the p38 MAP kinase and that this activation is critical for the pro-apoptotic effect
of the agent. They demonstrated that upon aspirin-mediated activation, p38 induces degradation of
Cyclin Dl, inhibition of CDK 4, activation of the NF-kB pathway, repression of NFkB transcription
and induction of apoptosis, with inhibitors of MAPK blocking these effects (Thorns et al 2007a) (see
below for more details). These data suggest that MAP kinase signalling could be a primary target of
aspirin and related NSAIDs.
1.4.5 Cyclin-dependent kinases (CDKs)
Cell cycle progression is promoted by cyclin-dependent kinases (CDKs) which complex with cyclins,
driving the cell forward through the cell cycle (Schwartz and Shah 2005). Progression mediated by
cyclin/CDK complexes is monitored at several positions, known as cell cycle check points (Collins
and Garrett 2005). The activity of the CDK/cyclin complex is further negatively regulated by a
number of CDK inhibitors (CDKIs), including p21 (wafl/clpl) and p27 (klpl) (Vermeulen et al 2003a).
A range of NSAIDs have been reported to induce cell cycle arrest by altering of CDK expression
particularly within Go/Gi phases (Qiao et al 1998b) (Maier et al 2004, Shifif et al 1995, Shiff et al
1996). NSAIDs also up-regulate CDKIs, such as p27kipl and p21wafl/cipl (Jung et al 2005, Marra et al
2000, Ricchi et al 2003, Yang et al 2001). As mentioned above, the host laboratory has previously
demonstrated that inhibition of CDK4 can mimic aspirin effects on the NF-kB pathway and mediate
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apoptosis. It was shown that this effect was independent of the effects of the agent on the cell cycle
(Thorns et al 2007b).
1.4.6 PPARy /Alternative targets
PPARy is a ligand-dependent transcription factor that is highly expressed in breast and CRC. PPARs
are members of the nuclear hormone superfamily, including steroid hormones, thyroid hormone and
retinoid nuclear hormone receptors (He et al 1999). PPARy agonists induce differentiation and
apoptosis in CRC cell lines (Vandoros et al 2006) and some CRC are associated with a PPARy loss of
function mutation (Tegeder et al 2001). Indomethacin and other NSAIDs directly bind to PPARy (He
et al 1999, Jaradat et al 2001, Lehmann et al 1997), thus suggesting a putative direct molecular target
for NSAIDs. However, genetic ablation of PPARy in CRC cells does not alter their sensitivity to
sulindac-induced apoptosis, (Park et al 2001). Other targets which have been postulated as regulating
NSAID-induced effects in colon cancer are Ribosomal S6 Kinases, STAT-1, catabolism of
polyamines, caspase induction and many others (Tegeder et al 2001)(Din 2012).
Whilst the above alternative pathways have been highlighted as potential targets for the anti-tumour
mechanism of NSAIDs, studies from the host laboratory have identified activation of the NFkB
transcription factor as critical in this regard. Therefore, the remainder of this chapter will be focused
on this mechanism as this is of direct relevance to the work outlined in this thesis.
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1.5. NF-kB transcription factor and its activation
The NF-kB (Nuclear Factor Kappa B) family of transcription factors comprises of NFkBI (pi05
precursor cleaved to p50), NFkB2 (pi00 precursor cleaved to p52), RelA, C-Rel and RelB (Gilmore
and Herscovitch 2006). These NF-kB proteins form a variety of homo and heterodimers that bind to
target DNA sequences and regulate a large spectrum of genes including immunoregulatory and
inflammatory genes; anti-apoptotic genes; genes that positively regulate cell proliferation; and genes
that encode negative feedback regulators of NF-kB itself (Karin et al 2002); (Campbell et al 2006).
Each member of the NFkB transcription factor family contains an amino-terminal region of
approximately 300 bases long called the Rel homology domain (RHD). This domain is responsible for
the DNA binding potential of the proteins, protein dimerisation and nuclear localisation. In addition to
their Rel homology domain, RelA, C-Rel and RelB have a C terminal transactivation domain, which
is not observed in p50 or p52. The dimerisation domain has an area called the called the nuclear
localisation signal (NLS) and an additional binding site for NF-kB inhibitors.
NF-kB proteins are found ubiquitously in all human cells but are normally retained in the cytoplasm
by their inhibitory proteins, Inhibitors of NFkB (IkBs). The IkB family of proteins includes IkBci,
IkBP, IkBs, IxBy, Bcl-3, plOO and pl05 (Ravi and Bedi 2004) and are characterised by their multiple
ankyrin repeats The ankyrin repeats allow IkBs to bind NF-kB, which are characterised by multiple
ankyrin repeats to provide protein-protein interaction sites with NF-kB (Ghosh and Karin 2002),
which masks the NLS ofNF-kB, thus retaining the protein in the cytoplasm, by inhibiting the NLS of
NF-kB (Thanos and Maniatis 1995); (Stancovski and Baltimore 1997). Most stimuli activating the
NF-kB transcription factor do so via induced phosphorylation of the IkBcc protein on serine/threonine
residues (32/36). The IkB proteins are then targeted for polyubiquitinisation and eventual proteosomal
destruction. This unmasks the NLS of NF-kB allowing it to translocate to the nucleus and activate
target genes (Karin and Ben-Neriah 2000, Perkins 2007). The kinetics of IkB degradation and rate at
which NF-kB translocates to the nucleus depends on the nature of the stimuli and the cellular context,
but can have a direct effect on the range of target genes induced. Activation of NFkB is generally
transient as upon induction, it controls transcription of its inhibitor proteins (IkB, pi05 (NF-kB 1) and
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pi00 (NF-kB2)) (Karin et al 2002). Once transcribed, IkB is translated in the cytoplasm, translocates
to the nucleus and transports NFkB back into the cytoplasm, thus terminating the signal.
Activation ofNF-kB (see Fig 1.5)
A large spectrum of environmental and cellular stimuli activate NF-kB signalling through a number of
different upstream pathways. The most defined of these pathways is the classical or canonical
pathway. When the canonical pathway is stimulated, a 700-900-kDa-protein complex, known as the I-
Kappa B kinase (IKK) complex, phosphorylates IkBcx at two critical serine (Ser) residues, Ser32 and
which unmasks the NLS on RelA, allowing nuclear translocation of NF-kB. The IKK complex
comprises IKKa, IKK|3 and the non-catalytic regulatory scaffolding protein NEMO (IKKy) (NF-kB
Essential Modifier) (Karin and Ben-Neriah 2000). 1KK(3/NEM0 and IKKa have distinct signal
transmission and disparate regulation. The proteins are phosphorylated at conserved serine residues
within their activation loop by one or more of a large number of putative upstream kinases. Proteins
proposed to act as IKK kinases include Caspase-8 (Skrzydlewska et al 2005), (3-catenin (Lamberti et
al 2001), Cyclin D1 (Kwak et al 2005), HIF-2a (Bracken et al 2005), NIK (Ling et al 1998, Regnier et
al 1997), and c-Src (Huang et al 2003a), in diverse cellular environments and following various
stimuli (reviewed in Scheidereit) (Scheidereit 2006).
The non-canonical or pi 00 processing pathway is activated by a limited number of stimuli and
selectively requires IKKa. It is characterised by NIK (NFKB-inducing kinase)-dependent processing
of the pi 00 precursor to p52 (Beinke et al 2004, Hayden and Ghosh 2004). Several physiological
inducers of the non-canonical pathway are well known, including lymphotoxin A, BAFF (B-cell
activating factor)), and CD40. These activate NIK/ IKK1 inducing plOO phosphorylation,
ubiquitinisation and 26S proteosome proteolytic processing to yield p52. Activation is important for
lymphoid organ development and the adaptive immune responses (Delhalle et al 2004).
The non-canonical pathway cross-stimulates the canonical pathway and the activation of both
cascades are linked. However, the non-canonical pathway has slower activation kinetics, requiring
hours to initiate a response following specific stimuli, compared to that of the canonical pathway,
which is stimulated within seconds to minutes. (Reviewed in (Perkins 2007).
75



































An additional alternative activation pathway exists which has been shown to play a role in NF-kB
activation following atypical agents such as UVB/UVC light, radiation, hypoxia, and certain
chemotherapeutic agents (etoposides and anthracyclines (daunorubicin and doxorubicin)). In this
response, both IKK-dependent and independent mechanisms of activation have been suggested
(Campbell and Perkins 2004, Perkins 2004) (Campbell et al 2006, Perkins and Gilmore 2006). This
pathway does not depend on utilising the IKK kinase function to phosphorylate the IkB protein. In
some cases direct phosphorylation of alternative serine residues (UVC) (Kato et al 2003) or the use of
the IKK complex as a scaffold structure only, occurs (Campbell and Perkins 2004, Perkins 2004)
Reports suggest that yet another route to activation of NFkB involving IkBoi tyrosine 42
phosphorylation. This type of phosphorylation has been reported in response to pervanadate, (Fan et al
2003, Imbert et al 1996), redox stress (Schoonbroodt et al 2000), silica (Kang et al 2000, Kang et al
2006) and in some contexts, TNFa (Abu-Amer et al 1998). These routes of activation occur with
slower kinetics and may or may not be associated with IKBa degradation (Campbell and Perkins
2004, Campbell et al 2006, Perkins 2007). The tyrosine kinase candidates proposed to be responsible
for this response are p56lck (Imbert et al 1996, Livolsi et al 2001, Mahabeleshwar and Kundu 2003); c-
Abl (Kawai et al 2002); Syk (Takada et al 2003) and c-Src (Abu-Amer et al 1998); (Fan et al 2003,
Kang et al 2006).
RelA is known to possess a number of critical phosphorylation sites and can be directly targeted by a
number of kinases. Phosphorylation affects several functions of RelA, including DNA binding and
transactivation potential (Chen and Greene 2004). For example, phosphorylation of RelA at Ser276 by
protein kinase A (PKAC) occurs in response to LPS, increasing RelA binding to cAMP response
element-binding (CREB) protein (CBP)/p300 in the nucleus, resulting in increased acetylation and
transactivation (Zhong et al 2002). Interleukin-1 (IL1) or TNFa induced activation of Protein kinase
C-C, (PKCQ triggers phosphorylation of S311. TNFa and IL1 also induce phosphorylation of serine
529 through stimulation of casein kinase II (CKII). TNFa stimulates mitogen-and stress-activated
protein kinase-1 (MSK1), resulting in enhanced NF-kB transcriptional activity (Vermeulen et al
2003b). S536 phosphorylation occurs following activation of IKK and the RelA c-terminus is also a
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target of GSK-3p and PI 3-kinase (Chen and Greene 2004, Schmitz et al 2004, Schwabe and Brenner
2002). In summary, activation of the NFkB pathway is highly complex, involves a number of distinct
upstream kinases and downstream co-regulators and is highly dependent upon the stimuli and the
cellular context.
RelA is also regulated by reversible acetylation. For example, RelA can be acetylated on lysines 122
and 123 by p300/CREB-binding protein (CBP)-associated factor (PCAF) and p300/CBP respectively,
which decreases the transcriptional activity of RelA by reducing the binding of RelA to the kB
enhancer. Conversely, acetylation of K221 by p300/CBP increases transcriptional activity and DNA-
binding affinity of RelA for the kB enhancer (Quivy and Van Lint 2004, Schmitz et al 2004)]. Histone
acetyl transferases (HATs) acetylate histone tails, allowing access of transcription factors to
promoters. NF-kB transcription depends upon coactivators, such as CBP/p300, p300/CBP-associated
factor (PCAF) or steroid receptor coactivator-1 (SRC-1), which possess histone acetyl transferase
(HAT) activity (Gerritsen et al 1997, Perkins et al 1997, Sheppard et al 1999, Zhong et al 2002)
(Quivy and Van Lint 2004).
1.5.1 The role of the NF-kB transcription factor in CRC.
Although NF-kB is involved in the regulation of both anti-apoptotic and pro-apoptotic genes, it is
generally thought to have anti-apoptotic properties and contribute to carcinogenesis. This notion is
based on a number of findings. Firstly, aberrant NF-kB activity is observed in numerous tumour cell
types, including leukaemia, lymphoma, myeloma, breast and colon (Basseres and Baldwin 2006,
Bharti and Aggarwal 2002, Kucharczak et al 2003).
In resected CRCs, NFkB is constitutively activated in the majority of tumour tissue, but not normal
mucosa and activation correlates with tumour progression from adenoma to carcinoma and with
tumour stage and invasion (Kojima et al 2004). In the majority of CRC cell lines, NF-kB is
constitutively active, and has been postulated to regulate anti-apoptotic mechanisms, conferring
resistance to radiotherapy and chemotherapy (Basseres and Baldwin 2006). However, whilst some cell
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lines have increased promotion of survival as a result of NF-kB activation (Barger et al 1995),
suppression ofNF-kB signalling inhibits proliferation, causes cell cycle arrest, and leads to apoptosis.
Genes that promote growth (c-Myc, p53, and COX-2) and inhibit apoptosis (BCL-XL and BCL-2) of
CRC are regulated by NFkB. Furthermore, activation of NFkB confers resistance to radio and
chemotherapy in CRC (Bharti and Aggarwal 2002).
Thus, the NF-kB signaling pathway is a strong potential candidate for the anti-tumour effects of
NSAIDs in the colon (LaCasse et al 1998).
1.5.2 Aspirin effects on NF-kB activity in CRC
Kopp and Ghosh were the first to report the inhibitory action of sodium salicylate and aspirin on NF¬
kB activity (Kopp and Ghosh 1994). They found that these agents inhibited cytokine-mediated
degradation of IkB and nuclear translocation of NF-kB and concluded that inhibition of NF-kB
signalling is a critical mechanism for the anti-inflammatory effects of the agents. Following these
initial studies, it was suggested that salicylate-induced inhibition of NFk|3 nuclear translocation might
confer sensitivity of cancer cells to apoptosis-inducing treatments or stress and there followed
suggestions that salicylate-induced inhibition ofNF-kB nuclear translocation might confer sensitivity
of cancer cells to apoptosis-inducing treatments or stress (McDade et al 1999). Yin et al. (Yin et al
1998), subsequently reported that sodium salicylate and aspirin) inhibited stimulus(TNFa, NIK, TAX
or MEKK1) -induced activation of NF-kB by directly binding IKKP, thus reducing its ability to bind
ATP. They also found that sulindac and its derivatives inhibited IKK activity in colorectal cancer
cells and suggested that this mechanism account for the anti-tumour properties of the agents
(Yamamoto, 1999).
Following these initial studies there have been a wealth of papers suggesting that NSAIDs inhibit
tumour cell growth by inhibiting activation of the NFkB pathway. However, in the majority of these
studies, cells are pre-treated with aspirin or related NSAIDs for a short period prior to stimulation with
a powerful cytokine such as TNF or IL-1. These experimental conditions are unlike those used to
demonstrate the induction of apoptosis by NSAIDs, where colorectal cancer cell lines are treated with
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NSAIDs for a prolonged period in the absence of any additional cytokines. Under these conditions,
aspirin and related NSAIDS have been found to activate the NF-k|3 pathway. For example,
Niederberger et al., found that celecoxib mediates activation of NF-kB through a direct interaction
(Niederberger et al 2001). Cho et al. (Cho et al 2005), also demonstrated in some settings that
diclofenac induced degradation of IkBcc, supported by similar findings from Smartt et al., who
reported the COX-2-selective inhibitor, NS-398 caused degradation of IkBoi (Smartt et al 2003).
Studies from the host laboratory have confirmed the importance of activation the NF-kB pathway to
the anti-tumour activity of NSAIDs in CRC. The demonstrated that aspirin (Stark et al 2007),
sulindac, sulindac sulphone and indomethacin (Loveridge et al 2008) activate the NF-kB pathway by
phosphorylation of IKBa at serine residues 32/36 causing degradation of the protein complex.
Inhibiting nuclear translocation of NF-kB using a super-repressor IkBcx (blocked from
phosphorylation and degradation by mutagenesis), effectively blocked aspirin-induced cell death
confirming that aspirin-induced apoptosis is due, at least in part, to nuclear translocation of NF-kB
(Stark 2001). In subsequent studies they have shown that this NFkB response to NSAIDs is cell type
dependent, as it was not observed it in a panel of non-CRC cell lines (Din, 2004). However, it was
found that the response was independent of basal IkBoc, RelA and COX-2 expression levels and APC,
beta-catenin, p53 or DNA MMR gene (specifically HMLH1) mutational status (Din FV 2005). These
in vitro data have been supported by data from advanced models of colon cancer, including
xenografited HT29 tumours in mice, APC+/- mice adenomas (Stark 2007) and patient rectal biopsy
explants (Stark LA 2001). These In vivo studies suggested that NFKB-mediated apoptosis in response
to aspirin is much more accentuated in neoplastic tissue compared to normal mucosa (Stark LA 2007).
Following aspirin-induced RelA translocation to the nucleus, it localises in the subcellular/ nuclear
compartment of the nucleolus (Stark and Dunlop 2005). This response was also noted in common
with other pro-apoptotic known stimuli of NFkB, including UVC, serum withdrawal and radiation
(Stark and Dunlop 2005). Nucleolar localisation of RelA following aspirin treatment is paralleled by
increased apoptosis and a reduction in NF-kB driven transcription (Stark and Dunlop 2005),
(Loveridge et al 2008). The host laboratory utilised site-directed mutagenesis to create a deletion
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mutant of RelA (deletion of amino acids 27-30) which interfered with the nucleolar localisation signal
(NoLS) and prevented its targeting to the nucleolus (Stark and Dunlop 2005). This had the effect of
abrogating aspirin and NSAID-induced repression of NFicB-driven transcription and the induction of
apoptosis (Loveridge et al 2008, Stark and Dunlop 2005). These data demonstrated the importance of
nucleolar accumulation of RelA in NSAID-mediated apoptosis.
Recent work from the host laboratory (see above) has shown that activation of the p38 MAPK
pathway is implicated in the NF-kB response to aspirin (Thorns et al 2007a). As mentioned above, it
was shown that aspirin stimulates the p38 MAP kinase pathway within minutes of exposure and that
this activation causes the phosphorylation and proteosomal degradation of cyclinDl. It was shown
that specific inhibition of p38 signalling using chemical inhibitors or siRNA knock-down attenuated
aspirin-mediated degradation of IkB, nuclear/nucleolar translocation of RelA and apoptosis in SW480
CRC cells, while mimicking cyclinDl degradation, using a CDK4 inhibitor mimicked aspirin effects
on NFkB signalling and apoptosis.
In summary, there is compelling evidence that aspirin induces Serine 32/36 phosphorylation and
proteosomal degradation of IicBa, translocation of the RelA transcription factor to the nucleus then
the nucleolus, causing repression of NFrcB-driven transcription. There is also compelling evidence
that this pathway is critical for the apoptotic effects of the agents in CRC cell lines. The data is further
supported by experiments in other models of CRC cancer. However, the exact upstream mechanisms
by which aspirin stimulates the NFkB pathway remain unclear. To achieve more targeted
chemotherapeutic strategies, elucidating these upstream mechanisms is of vital importance.
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1.6 c-Src and the NFkB pathway; relevance to CRC Chemoprevention
As described above, aspirin induces a time dependent NF-kB signalling response in CRC cells in vitro
and in colorectal neoplasia in vivo. However, this response has a significantly delayed kinetics
occurring hours, rather than minutes after administration. Hence, it is therefore likely that aspirin acts
through intermediate upstream kinases to induce the NF-kB response. One upstream candidate kinase
is the proto-oncogene product, c-Src.
c-Src is upregulated and activated in CRC progression and metastases and c-Src activation is well-
reported to induce NF-kB signaling in response to a wide variety of inflammatory mediators, bacterial
stimuli and other chemical stimulants (Chang et al 2004, Fan et al 2003, Funakoshi-Tago et al 2005,
Jalal and Kone 2006, Kang et al 2005, Lin et al 2006, Liu et al 2001, Lluis et al 2007, Mendez-
Samperio et al 2007). The remainder of this theiss will therefore described the rationale and
experimental exploration undertaken to detect and understand the role ofc-Src in the aspirin induced
NF-kB signaling and apoptotic reponse in CRC.
1.6.1 c-Src structure and function
c-Src is the human cellular equivalent of the viral oncogene v-Src. v-Src was discovered by Peyton
Rous in the late 20th century in a series of experiments describing the infective agent causing
transmissible soft tissue sarcomas in chickens (named RSV (Rous Sarcoma Virus)). The Src Family
of tyrosine Kinases (SFKs) have multiple cellular functions of importance to cancer, including control
of proliferation, survival, migration and adhesion (Frame 2002, Schwartzberg 1998, Thomas and
Brugge 1997). The SFK members include Src, Lyn, Fyn, Lck, Hck, Fgr, Blk and Yes and whilst some
of the SFK members are broadly expressed (i.e. Src, Fyn, Yes) others have a more specialised tissue
expression (i.e. Hck, Blk, Lck) (Thomas and Brugge 1997).
c-Src signaling affects cell growth and differentiation in the intestine, where it is thought to play a role
in villin-induced regulation of cell migration (Mathew et al 2008). Previous studies have demonstrated
that c-Src activity is elevated in colonic polyps, particularly malignant polyps and those greater than
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2-cm that contain a villous structure and severe dysplasia (Cartwright et al 1990). Additionally, c-Src
activity and expression is elevated in malignant and severely dysplastic epithelia in ulcerative colitis,
and is 6-10-fold higher in mildly dysplastic than in nondysplastic epithelia. Thus, c-Src activity is
elevated in premalignant UC epithelia and in polyps that are at greatest risk for developing cancer.
The data suggests that activation of the c-Src proto-oncogene may be an early event in the genesis of
CRC (Cartwright et al 1994).
Over-expression or activation of c-Src is believed to contribute to the progression of breast and CRC
(Biscardi et al 2000). The activity of c-Src is increased in >80% of CRCs (Bolen et al 1987,
Cartwright et al 1989, Talamonti et al 1993) and further increases are seen in metastases relative to
primary tumours (Mao et al 1997, Termuhlen et al 1993). Furthermore, c-Src activity increases
through progressive stages of the disease and is predictive of poor clinical prognosis (Maurer et al
2007). However, whilst c-Src activating mutations have been reported in some primary colon cancers
(Irby and Yeatman 2000), other studies did not show correlation with CRC and c-Src mutations, thus
activating mutations are rare. More common are those mutations that lead to increased expression
rather than activity (Biscardi et al 2000).
c-Src is regulated by a complex series of phosphorylation and de-phosphorylation (see figure 1.5). c-
Src dephosphorylating (inducing c-Src activation) proteins such as PTPa, SHP-1 and PTP1B have
been detected at elevated levels in some cancers, including epidermal and breast. Conversely, proteins
such as Csk and Chk that inactivate c-Src by phosphorylation ofTyr527 have been detected at reduced
levels in other cancers and are thereby considered to have a tumour-suppressing ability. The complex
mechanisms behind the regulation and activation of its tyrosine phosphorylation and kinase abilities is
outlined in figure 1.4/1.5. An intricate auto-regulation has evolved amongst SFKs which allows for
tight control of these functions. (Reviewed by (Boggon and Eck 2004, Frame 2002).
Strucure and activation (see figures 1.4 and 1.5)
The structure of c-Src includes; a SH4 n-Terminus, a membrane targeting region, a Unique Domain
(this varies amongst SFKs) and SHI, 2 and 3 (Src Homology) Domains. The conserved residue within
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the SH2 Domain at Arginine 175 is critical to the phospho-tyrosine recognition process. In the auto-
inhibited form, the SH2 domain is configured to bind to the phosphorylated Y537 on the c-terminal
tail of c-Src and prevent any protein-protein interactions with c-Src substrates. However, it also
contains a non-catalytic domain of about 100 residues which is functionally important in substrate
protein recognition (Pawson 1995). This domain has two pockets, one that recognises the
phosphorylated tyrosine and one that binds to one or more hydrophobic residues at the c-terminal of
the target protein. The former is conserved and the latter has variety across the Src family members
and accounts for differing substrates and functions of family members and their interactions
downstream. The SH3 (Src Homology 3) domain in the auto-inhibited form binds to the linker region
of the Type 2 helix between the Kinase and the SH2 domain. This domain again modulates protein-
protein interactions with substrates, specifically, it contains a recognition site for prolene-rich
sequences.
c-Src kinase activity can be controlled by phosphorylation of the c-terminal Y527 or through protein-
protein interactions in the SHI (Src Homology 1) domain. Phosphorylation of the Y416 residue within
the SHI domain causes intra-protein conformational displacement and "opening up" of the kinase
domain. When there is phosphorylation of c-terminal Y527 (phosphorylated by CSK (C-Src Kinase)
or de-phosphorylated by SHP-1), inactivation occurs through the previously described interaction of
SH2 with Y527. Direct protein/protein interactions are also important and both platelet-derived
growth factor (PDGF) and focal adhesion kinase (FAK) are able to bind to the SH2 domain, causing
c-Src to open up independently into the active form. The auto-inhibited c-Src is therefore a
precariously set "mousetrap" (Boggon and Eck 2004) and small perturbations can be sufficient to
spring the kinase into active conformation allowing the substrate access to its kinase site.
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1.6.2 Activation and substrate interaction with c-Src
c-Src is associated with the cellular membrane, the nuclear membrane and mitochondria. At the cell
membrane, it is closely related to membrane receptors, especially EGFR and VGF receptors.
Activation occurs by a number of molecular interactions with other kinases, such as via SH2 domain
interaction with the tyrosine-phosphorylated receptor of PDGF (Kypta et al 1990), SH3/SFI2
interaction with FAK (Thomas et al 1998) or activation of SH3, as in Hck's interaction with the HIV
protein, Nef (Moarefi et al 1997). The ability of Src to be "turned on by touch" (Boggon and Eck
2004) is important for maintaining specificity and fidelity in initiating signalling cascades.
Engagement of the c-Src SH3 and SH2 domains, with molecular ligands such as FAK, pi30 (CAS)
and Paxillin (proteins found in focal adhesions complexes), results in high affinity bonds with c-Src
and activation the kinase by inducing conformational changes (Thomas et al 1998, Walter et al 1999).
Active dephosphorylation of Y527 forms an important mechanism for c-Src activation. PTPa is a
transmembrane phosphatase, and its over expression has been shown to activate c-Src in vivo and can
induce cellular transformation (Zheng et al 2000). PTP1B (SHP-2), a kinase that plays an important
role in integrin signalling, has also been suggested as another possible candidate to activate c-Src via
dephosphorylation of Y527 (von Wichert et al 2003). A list of some of the more investigated
candidate substrates for c-Src are discussed in the next sections, with particular focus on NF-kB.
1.6.3 c-Src and FAK
FAK was first identified as a c-Src associated protein in v-Src transformed cells (Kanner et al 1991).
Amongst the first clues that c-Src was involved in FAK/ integrin signalling was the localisation of
temperature-sensitive v-Src to focal adhesions. The SH3 domain was fundamental to this localisation
(Kaplan et al 1994). In contrast, the localisation of non-activated c-Src is primarily perinuclear and in
cellular endosomes (Kaplan et al 1994, Schaller et al 1999, Timpson et al 2001). FAK contains
phosphotyrosines and prolene rich regions that bind to the SH2 and SH3 domains, respectively.
Following phosphorylation at FAK Y397, there is association with c-Src, resulting in increased
protein tyrosine kinase activity of c-Src (Schlaepfer et al 1994). FAK tyrosine 397 residue is therefore
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vital for initial recruitment of c-Src and following this, c-Src continues to phosphorylate FAK on 5
further tyrosine residues 406, 577, 576, 861 and 925. Whilst a degree of FAK phosphorylation is
known to occur in the absence of c-Src, in c-Src negative cells FAK largely remains un-
phosphorylated. Authors suggest it is possible that the c-Src SH2 domain may stabilise the
phosphorylation of FAK via direct interaction with the phosphorylated protein, thus protecting the
FAK phosphorylated residues from cellular phosphatases (Brunton et al 2005). However, tyrosine 397
also serves as a binding site for PI3K, Grb7 and Phospholipase C gamma and therefore some
competition of association between substrates may form part of cellular control in downstream
signalling (Chen and Guan 1994). PI3K is a known regulator of apoptosis downstream of Growth
Factor Receptor (GFR) signalling and has also been shown to bind to FAK 397. As Y397 is a c-
Src/PI3K binding site, it is possible that c-Src plays a role in mediating this process (Howe and
Juliano 2000).
c-Src dependent phosphorylation of FAK promotes detachment at the trailing edge of a migrating cell
(Brunton et al 2005). Phosphorylation of FAK Y925 is dependent on c-Src kinase function and lack of
phosphorylation at this site is associated with an inability of the cell to extend and retract protrusions
associated with cell adhesions (Liu et al 2002). c-Src induced phosphorylation of FAK is linked with
proteolytic cleavage of FAK by Calpain (Carragher et al 2001), which is required for both focal
adhesion turnover and migration. c-Src located at peripheral cell adhesions therefore plays a key role
in cell motility (Fincham et al 1995, Kaplan et al 1994).
FAK and c-Src interaction seems to play a key role in apoptosis avoidance and persists as long as cells
are in contact with the extracellular matrix (Defilippi et al 1993). As part of a signal transmitted
through FAK, c-Src and PI3 Kinase function to impair mitochondrial translocation of Bax and thus
blocks apoptosis when cells are adherent (Gilmore et al 2000). c-Src associates directly with the p85
subunit of PI3 Kinase (Fincham et al 1995) and this association is sufficient to activate AKT, which is
critical in inducing anoikis resistance (Windham et al 2002). Detachment of normal epithelial cells
from the extra-cellular matrix leads to FAK dephosphorylation and dissociation of the FAK: Src
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complex (Frisch and Francis 1994). This is followed by rapid Caspase 3-mediated, degradation of
FAK, cessation of P13 Kinase-mediated survival signals and anoikis (Weiner et al 1993).
1.6.4 c-Src and the EGF Receptor Family
Members of the EGFR family regulate differentiation, proliferation, survival, motility, angiogenesis
and cancer initiation and progression (Holbro and Flynes 2004). c-Src physically associates with such
receptors when they are activated (Maa et al 1995), and becomes transiently activated itself,
phosphorylating downstream targets (Osherov and Levitzki 1994). One target of c-Src activation is
EGFR itself, which can be further phosphorylated on multiple residues, most notably Y845 (Biscardi
et al 2000).
Phosphorylation of EGFR Y845 activates two signals; one that promotes EGF-induced cell
proliferation through STAT 5B and another that enhances cell survival through upregulation of COX-
2. Given that the phosphorylation of this residue is c-Src and not EGFR activation dependent, it
allows for the possibility that cascades downstream of EGFR can be activated by stimuli that activate
other receptors, which in turn activate c-Src. EGFR transactivation in response to integrins and
GPCRs activation requires c-Src. Other stimulants of these pathways include clathrins and dynamin,
proteins involved in the internalisation of multiple types of membrane receptors (including EGFR)
and importantly regulate intracellular adhesions in colonocytes (Ishizawar and Parsons 2004) (see
chapter 4).
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1.6.5 c-Src and apoptosis
Activation of c-Src is primarily regarded as inhibiting apoptosis. For example, it inactivates the
Caspase 8-APAF-apoptotic pathway (De Toni et al 2007), and blocks TNFa and NSAID induced
apoptosis (Bernardi et al 2006, Park et al 2004). Reports also suggest reduced rates of apoptosis are
observed in cells with high or activated c-Src (Irby and Yeatman 2000). v-Src (viral truncated form of
cellular c-Src), the constitutively active form of c-Src, activates several kinases that can inhibit cell
death, including ERK and PI3K (Johnson et al 2000). In rat intestinal epithelial cells, v-Src expression
is sufficient to induce anoikis resistance via BCL-XL expression (Coll et al 2002). Additionally, it has
been reported that TGFa inhibits anoikis through a c-Src mediated pathway (Fodde et al 2001a).
However, the consequences of increased cellular c-Src activity appears to be pleiotropic, and mimics
the behaviour of the NF-kB pathway, i.e. the response of c-Src to either stimulate survival or
apoptosis may be both cell environmental and stimulant specific. For example, c-Src induced c-Myc
expression in other cell environments suggests a likely pro-apoptotic signal (Aziz et al 1999) and v-
Src transformed cells are associated with loss of actin reorganisation and reduced cell-extracellular
matrix adhesion, leading to cell rounding and cell detachment. (Fincham et al , Jones et al). In cells
partially transformed by c-Src over-expression, sensitivity to apoptotic stress is increased (Zhong et al
2003). In CRCs with high innate c-Src activity, a PI3 Kinase inhibitor sensitises cells to anoikis and
whenever the functions of Ras and PI3 kinase are inhibited, v-Src transformed Rat fibroblasts
undergo apoptosis (Windham et al). This suggests v-Src generates a pro-apoptotic signal that under
normal circumstances is counterbalanced by survival signalling through Ras and PI3 Kinase and is
only revealed when the activities of these proteins are inhibited. v-Src expression can also down-
regulate the CDK inhibitor p27, suggesting that deregulation of the cell cycle machinery by Src may
be involved in the apoptotic process (Fincham et al 1995, Frisch and Francis 1994, Zhong et al 2002).
Further details of c-Src and its relevance to apoptosis are described in the discussion of chapter 3.
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1.6.6 c-Src and the NF-kB Pathway
Many stimuli of c-Src-dependent pathways are classically also associated with NF-kB activation, and
suggest a linkage/co-operation between these cellular pathways. c-Src is one of the many known
upstream activators ofNF-kB and members of the NF-kB family are well known as substrates of c-
Src. What emerges is a complex picture of c-Src's multiplicity in relation to activation of the NF-kB
transcription pathway and a multitude of cellular environments in which NF-kB signalling is
dependent on upstream c-Src activation. It would be obviously advantageous, given the disregulation
of the NF-kB pathway and the upregulation of c-Src in many human cancers, to further investigate
this linkage in the setting of CRC. These reports describe a multitude of cellular environments in
which NFKB signalling is dependent on upstream c-Src activation. It would ohviously be
advantageous, given the disregulation of the NFkB pathway and c-Src in many cancers, to further
investigate this linkage. A further discussion of the crossover between the NFkB and c-Src pathways
can be found in the introduction of chapter 3.
1.6.7 c-Src and NSAIDs
Initial evidence suggesting NSAIDs target c-Src was observed in the search for early c-Src chemical
inhibitors. Ramdas et al. tested 43 compounds from 5 different chemical families, including NSAIDs,
to evaluate their effect on the tyrosine kinase activity of c-Src (Ramdas and Budde). NSAIDs were
demonstrated to confer inhibition of c-Src kinase activity. Many studies have examined the
importance of c-Src in platelet responses, specifically in response to aspirin (one of the best known
anti-platelet agents). Propylgallate is a platelet agonist that causes platelet aggregation, protein
tyrosine phosphorylation and platelet factor 3 activities. It induces phosphorylation of c-Src in this
process, but this phosphorylation is inhibited by aspirin, thus putatively accounting for some of the
anti-platelet actions of the agent (Rao et al).
Several reports have suggested NSAIDs interferes with c-Src dependent molecular responses. For
instance, treatment of bronchial cell lines with IL-8, which normally induces STAT through a c-Src
dependent process, was inhibited after pre-treatment with NSAIDs (Perez-G et al). Additionally,
angiotensin II and PDGF induced COX-2 production in cardiac fibroblasts, another process also
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involving c-Src activation, is inhibited, by pre-treatment with salicylate (5-20mMol) (Wang and
Brecher). Lu et al., examined the transformation of chicken embryonic fibroblasts to neoplastic cells
following infection with v-Src. The authors reported that, in common with other studies, transfection
of the cells with v-Src induced an independent apoptotic signal causing 11-23% of cells to undergo
apoptosis. However, when they added diclofenac, a well-known NSAID, the level of apoptosis
approached 100%. They concluded "NSAID-induced apoptosis" in neoplastic cells, "proceeds through
a c-Src/Myc-dependent pathway" (Lu et al 1997).
Previous work from the host laboratory investigated effects ofNSAIDs on c-Src and NF-kB signalling
pathways in CRC. As part of her PhD project, Dr Loveridge performed a number of experiments with
direct relevance to the rationale behind our onward investigation. In time-course experiments, CRC
cells treated with sulindac, sulindac sulfone and indomethacin, demonstrate increased phosphorylation
of c-Src Tyr 416 (signalling activation of the kinase) at 1-2 hours after NSAID administration.
NSAIDs induced c-Src activation prior to degradation of IkB and nucleolar translocation of RelA
suggesting a possible causal link. Chemical inhibition of c-Src activity (utilising PP2) blocked
NSAID-mediated nuclear/nucleolar localisation of RelA. It was also found that cells expressing a
kinase dead form of c-Src were resistant to NSAID-mediated apoptosis. These earlier data suggested
NSAIDs activate c-Src in CRC cells and that this activation may be involved in the NF-kB and pro-
apoptotic response to the agents. However, the effect of the most commonly used NSAID, aspirin,
was not examined in these studies.
Together these data represent a compelling basis in which to further explore the role of c-Src in
aspirin-related molecular effects in CRC. c-Src represents a dynamic kinase which is upregulated in
CRC, is prognostically relevant and the regulation and control of which is reasonably well
characterised. This kinase interacts with a diverse range of pathways of theoretical importance in
carcinogenesis, and has reported roles in survival, migration and apoptotic signalling. Critically, this
kinase is also known to function as an upstream agonist ofNF-kB signalling activation in a variety of
cellular settings and transmits molecular signals to the NF-kB signalling pathway through a variety of
interactions with NF-kB members.
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Additionally, c-Src plays a key role in the control of apoptosis and is known to be modulated by
NSAIDs directly. Furthermore, preliminary data from the host laboratory has suggested evidence of a
dependency between c-Src activation and NF-kB signalling in response to NSAIDs treatment of CRC
cell lines. Taken together, these data provide compelling rationale for further studying the role of c-
Src in the NFkB and apoptotic response to aspirin in colorectal cancer.
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1.7 Experimental Approach
Initial work concentrated on characterising the response of the c-Src signalling pathway to aspirin in
CRC cell lines. I utilised c-Src kinase assays and phospho-specific antibodies against known markers
of c-Src activation to detect any agent-induced change to the activity or levels of c-Src. Furthermore, I
evaluated other surrogate markers of c-Src activity, such as detecting the phosphorylation of substrate
tyrosine residues and changes to cell adhesion dynamics. I attempted to characterise the kinetics of the
aspirin-induced c-Src response, and its relationship to the known kinetics of aspirin-induced effects on
the NF-kB pathway in CRC cell lines. I also attempted to detect physical molecular interaction
between c-Src and NF-kR following aspirin exposure.
In order to evaluate if there is any dependency between c-Src activation and NFkB activation, I
utilised various experimental tools, such as chemical and genetic interference with c-Src activity.
Finally, given the importance ofNF-kB signalling in aspirin induced apoptosis, and the known role of
c-Src in other settings, I evaluate the c-Src dependency of the aspirin-induced pro-apoptotic response
using the molecular and genetic tools above (chapter 3).
Initial experimentation above involves the use of CRC cell lines, including the SW480 CRC cell line,
which is very well characterised in the host laboratory and in which a wealth of data has been
generated indicating the cellular responses to aspirin. However, I also developed and studied a
complex organ culture model that goes some way to re-capitulate the human situation in vivo.
Optimisation of an in vitro organ culture model of human ex vivo colonic mucosa with comparison
and evaluation of previous culture methodologies was undertaken. Early investigation within the
model was undertaken in order to decipher the molecular mechanisms controlling growth and
differentiation. This has begun to allow me to explore the relevance of in vitro findings in the in vivo
setting. Specifically, I evaluate the effects of aspirin, its influence on c-Src and NF-kB signalling
pathways and apoptosis (chapter 4).
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2.1 Cell Culture and Methods
Summary of cell lines used
SW480 cells were obtained from the American Type Culture Collection/European Collection of
Animal Cell Cultures (ATCC/ECACC; number CCL-228). They are an adherent human CRC cell line
that are derived from a Dukes' stage B colon adenocarcinoma from a male Caucasian aged 50 years.
This cancer cell line expresses the oncogenes WT BRAF, WT PTEN, APC Q1338, WT beta-catenin,
myc, ras and p53, but does not express COX and is also known to express low levels of c-Src.
However, the aspirin-induced pro-apoptotic effect of interest (involving non-cox dependent pathways)
has been well characterized in this cell line previously in the host laboratory and low level expression
of c-Src was felt to offer an ideal environment in which to perform over-expression studies (further
detailed in chapter 3.14). SW480 cells constitutively expressing a kinase-dead mutant form of c-Src
(SW480-SrcKD) and equivalent control cells (SW480-pBpuro) were obtained as a kind gift from Prof.
M. Frame (Cancer Research UK Beatson Laboratories, Glasgow). HT29 cells were also obtained from
the American Type Culture Collection/European Collection of Cell Cultures (ATCC/ECACC; number
HTB-38). They are an adherent human CRC cell line derived from a Dukes' stage B adenocarcinoma
from a female Caucasian aged 42 years expressing constitutively high levels of c-Src and COX.
Maintenance of cell lines and media
SW480 cells were maintained in L-15 medium (Gibco BRL), SW480-pBpuro and SW480-SrcKD
cells were maintained in RPMI medium and HT29 cells were maintained in DMEM. All media were
supplemented with 10% foetal calf serum (FCS) and 1% penicillin and streptomycin at 37°C in a
humidified atmosphere containing 5% C02. All cell lines were grown in 25 cm2 or 75 cm2 flasks
(Greiner Bio-one) until a confluent monolayer was formed.
Cells were passaged or seeded for experimentation at a 1:3 —> 1:5 dilution by washing in phosphate
buffered saline (PBS) [137 mM sodium chloride (NaCl), 2.7 mM potassium chloride (KC1), 10 mM
sodium phosphate dibasic (anhydrous) (Na2HP04), 2 mM potassium phosphate monobasic (KH2P04),
pH 7.4], followed by a 5 minute (min) incubation with Trypsin/Versene (T/V)* (1:1).
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To freeze cell lines, 1 ml of appropriate cell culture media was added to detached cells prior to
centrifugation at 200 x g for 5 minutes at room temperature. The media was then discarded and the
cell pellet resuspended in 1 ml freezing media [10% dimethylsulfoxide (DMSO) in FCS] before being
transferred to a cryotube. Cells were subsequently incubated on ice for 1 hour (hr) then stored in liquid
nitrogen. To retrieve frozen cells, aliquots were rapidly thawed at 37°C, cells collected by
centrifugation at 200 x g for 5 min, washed in culture medium then seeded into 25 cm2 tissue culture
flasks.
The modified cell lines were raised in RPMI (10%FCS, l%Pen-strep, 0.75ug/ml puramicin (selection
agent. The cells were defrosted at 37°C in a water bath then transferred to tubes with lOmls of above
medium. The cells were spun at lOOOrpm x 5mins and the supernatant was removed to exclude the
storage solution. The cells were then re-suspended in 5mls of medium and transferred to a small flask
for growth. On day 2 the medium was changed following successful appearance of growth and on day
2 the cells were transferred to a larger flask containing the above medium.
Reagents (aspirin, other stimuli and inhibitors')
Stock solutions of aspirin (Sigma) (0.5 M, pH 7.0), were prepared by solubilising the reagents in
distilled water (dH20), using NaOH to adjust the pH as required. All drugs were filter sterilized using
a 0.2 micron filter (Schleicher and Schuell Microscience) prior to use in cell culture (See figure 2.1a
for chemical structure of aspirin).
Stock solutions of PP2 (10pM)(4-Amino-5-(-4-Chlorophenyl-)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine)
and the c-Src inhibitor SU6656 (0.5 pM) (2-oxo-3-(4,5,6,7-tetrahydro-l H-indol-2-ylmethylene)-2,3-
dihydro-lH-indole-5-sulfonic acid dimethylamide) were obtained as solid from Calbiochem and
dissolved in DMSO prior to administration to cells at the concentration required (See figure 2.1b-2.1c
for chemical structures of inhibitors). Epithelial growth factor (EGF) (Invitrogen, Carlsbad, CA) was
obtained, dissolved in DMSO, and added to the cells as required (20ng/ml, 0.5hrs).
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Figure 2.1 Structure of reagents
Chemical structures of 1. aspirin, 2. Su6656, 3. PP2.
4. plasmids used in transfection.
Treatment protocol
The cells were plated at a density of 0.2 x 105/cm2 and were treated in 0.5% serum when they were
60% to 80% confluent. To study the effects of inhibitors on the response to aspirin, cells were seeded
and grown as above. Once 60-80% confluent, cells were pre-treated with the required inhibitor in low
serum medium for 2 hr prior to continuous treatment with aspirin as specified.
2.2 Generation and amplification of plasmids
The following plasmids were utilised for transformation;
• Src cDNA (Constitutively activated) in pUSEamp (Y529F mutation) (Millipore)
• Src cDNA (kinase defective) in pUSEamp (K297R mutation) (Millipore)
• Src cDNA (Wild type) (Millipore)
• pUSEamp vector only (Millipore)
The plasmids used in these studies are summarised in figure 2.Id.
Transformation of competent cells
In order to generate a sufficient quantity of plasmid, vectors were amplified in E. coli. Each of the
plasmids used carried the gene for ampicillin, allowing selection of bacteria that were successfully
transformed. A single transformed bacterial clone could then be grown in bulk and the required
plasmid subsequently extracted. Initially, the vectors were transformed into E. coli that had been made
chemically competent for transformation. The bacteria used were Subcloning Efficiency™ DH5a™
Competent Cells (Invitrogen Life Technologies) and the method as per the manufacturer's
instructions. Briefly, competent E. coli cells were thawed on ice prior to transformation by the gentle
addition of 10-15 ng of ligated plasmid DNA to approximately 5 x 106 bacteria and incubating cells
on ice for 30 min. Following heat shock at 42°C for 45 seconds, cells were incubated on ice for 2
minutes and 900 pi SOC medium (Invitrogen Life Technologies) [2% tryptone, 0.5% yeast extract, 10
mM NaCl, 2.5 mM KC1, 10 mM magnesium chloride (MgCl2), 10 mM magnesium sulphate (MgS04),
20 mM glucose] was added prior to incubation at 37°C for 60 min with vigorous shaking (225 rpm).
An aliquot (100 pi) of transformed bacteria was plated onto L-agar (Luria Bertani Broth (L-broth)*
[0.1% tryptone, 0.05% yeast extract, 171 mM NaCl] containing 0.15% agar) plates containing the
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appropriate antibiotic [L-agar-Amp* (L-agar containing ampicillin (100 pg/ml)) and the plates were
then incubated at 37°C overnight to allow colony formation.
Growth of transformed E.coli
Following transformations, a single transformed E. coli colony was picked from the plate and grown
in 2 ml L-broth containing the appropriate antibiotics [ampicillin (100 pg/ml)] overnight at 37°C with
vigorous shaking (225 rpm). An aliquot (500 pi) of this culture was used to innoculate 500 mis of L-
broth, containing ampicillin, which in turn was grown overnight to allow large scale amplification of
the plasmid in E. coli. Transformed E. coli colonies were stored on L-agar plates at 4°C for up to one
month or at -70°C in L-broth containing 50% glycerol for longer-term storage. Strains were re-
isolated from glycerol stocks by spreading some of the frozen cells using a sterile loop onto an L-agar
plate containing the appropriate antibiotic and then incubating the plate overnight at 37°C.
Plasmid preparation
Plasmids were harvested from bacterial cells using a purification kit (Qiagen) and reagents provided
by the manufacturer according to their instructions. Briefly, cells were collected by centrifugation at
6,000 x g for 15 min at 4°C. The cell pellet was then resuspended in 10 ml chilled buffer PI [10 mM
ethylenediaminetetraacetate (EDTA), 50 mM Tris-(hydroxymethyl)-methylamine (Tris)-HCl (pH 8.0),
lOOpg/ml ribonucleaese A (RNase A)] and subsequently lysed with 10 ml buffer P2 [200mM NaOH,
1% sodium dodecyl sulphate (SDS)] to allow disruption of the bacterial cell wall. This alkaline lysate
was neutralised with 10 ml chilled buffer P3 [3.0 M potassium acetate (C2H3K02) (pH 5.5)] and then
incubated on ice for 20 min. Cell debris was removed by centrifugation at 20,000 x g for 30 min. The
soluble fraction (including the plasmid DNA) was applied to a pre-equilibrated QIAGEN-tip 500,
which contains a specific Anion-Exchange resin. The plasmid DNA adhered to the resin whilst the
remaining debris, such as RNA, protein and metabolites, was removed by washing the tip with 60 ml
buffer QC [1.0 M NaCl, 50 mM 4-morpholinepropanesulfonic acid (MOPS) (pH 7.0), 15%
isopropanol]. The plasmid DNA was detached from the resin by the addition of buffer QF [1.25M
NaCl, 50mM Tris-HCl (pH 8.5), 15% isopropanol], precipitated with isopropanol and immediately
pelleted by centrifugation at 15,000 x g for 30 min at 4°C. The DNA was then washed with 70%
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EtOH, re-pelleted by centrifugation at 15,000 x g for 10 min at 4°C and allowed to air-dry before
being dissolved in 300 pi TE buffer [lOmM Tris-HCl (pH 8.0), ImM EDTA] and stored at -20°C.
Plasmid DNA was quantified by optical densitometry on a UV spectrophotometer (GeneQuant Pro,
Biochrom Ltd.). 1 pi DNA was diluted with 99 pi dH20 and placed in quartz cuvettes. DNA quantities
were calculated automatically from the measured absorbency at 260 nm (A260) and 280 nm (A280),
taking into account the dilution factor of 100. An A260/ A280 ratio of 1.8 was taken as optimum purity
ofDNA.
2.3 Transient transfection of adherent cells
Cells were grown in 25 cm2 flasks or on sterile cover slips in the wells of 6 well plates until 50-60%
confluent prior to transfection. Transient transfection of cells with plamid DNA was carried out using
a Lipofectamine™ protocol (Invitrogen Life Technologies) as per the manufacturer's instructions.
Briefly, for each transfection, 20 pi lipofectamine was added to 500 pi optimem (Gibco BRL) and
separately 500 pi optimem was added to the 8ug plasmid DNA. Each solution was incubated
separately for 5 minutes then combined at room temperature and incubated for a further 20 minutes.
Cells were washed twice with 2 ml optimem before 3 ml of serum free media was added. 1ml of
cDNA / lipofectamine /optimem mix was then added. Cells were then incubated for 24 hrs at 37°C.
After this incubation, the cells were washed with low serum medium and grown for a further 24 hours
before being harvested or treated .
2.4 In vitro organ culture of human colonic mucosal explants
Harvesting
Ethical approval and permissions were obtained from the Lothian Research Ethics Committee and the
NHS Research and Development office, Lothian University Hospitals Division (LUHD)
(06/F1101/16 & 01/MREC0/5). Patients were identified from those undergoing colonic resection for
colorectal cancer or polyps through prior consultation with the patient's colorectal surgical consultant
(see acknowledgements). Operative resection was performed at the Western General Hospital,
Edinburgh, Scotland and IVOC (In Vitro Organ Culture) was maintained on campus at the Medical
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Research Council's Human Genetics Unit (MRC HGU), Western General Hospital, Edinburgh,
Scotland.
Prior to surgical resection, patients were identified, fully informed and provided written consent. An
anonymous code was generated by the study investigators and used to label the sample from the time
of resection. Matched patient details were stored securely but blinded from MRC HGU investigators
by the study data guardians at the ECMC.
At the time of colonic resection, the resected colonic specimen was immediately transferred to the
investigators. The colon was kept at room temperature throughout the harvesting process. It was then
transported within minutes from the operating theatre to the Department of Pathology, Western
General Hospital. Before and after the tissue dissection process all surfaces and equipment were
decontaminated with vircon and universal precautions were used to prevent cross-contamination and
risk of infection.
In the case of retrieving normal colonic mucosa, the colon was sectioned longitudinally to expose the
colonic mucosa. Pathological areas were noted and prognostically/diagnostically important areas were
excluded from the harvesting process. The colonic lumen was initially gently rinsed with water to
remove superficial debris. A 5x 5 cm section of non-pathogenic colonic mucosa was separated by
sharp dissection with a scalpel from the underlying muscularis layers.
In the case of colonic polyps, the pathologist examined the colon and provided non-
pathologically/diagnostically relevant polyps, by dissecting the polyp by sharp dissection from the
underlying muscularis layer. In the case of CRC, a section of non-prognostically/diagnostically
relevant tumour was separated from the tumour mass by the pathologist using sharp dissection.
At the time of retrieval, all colonic specimens were then rinsed briefly x 3 in sterile water and then
immediately transferred to a universal container containing pre-warmed transport culture media (see
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below) at 37°C. The residual non-harvested colonic specimen was placed in formalin and entered the
normal clinical and diagnostic standard of care protocols for resected colonic specimens.
The universal container was placed on ice within a sealed, marked biohazard box and transferred to
the IGMM within 10 minutes by trained investigators or study nurses. There, the sample was
transferred directly to Containment Level 2 facilities where awaiting investigators took the process
further. The sample details (tissue type, location of colon, time since resection, anonymous identifier)
were recorded on arrival.
Under CL2 conditions, the sample was removed from the universal tube. Under sterile conditions,
using a scalpel, explants were then cut into smaller sections of roughly 0.5 cm x 1 cm in size. Explants
were then gently drawn across and mounted on sterilised porous plain weave stainless steel wire gauze
(0.224mm diameter pores) (United Wire, Edinburgh) and placed submerged within culture dishes
containing pre-warmed media at 37°C (BD Organ culture dishes 60 x 15 mm, www.
Scientificlabs.co.uk). The explant culture was then loosely covered and placed with others in a sealed
modular incubator container (Billups-Rothenberg, Del Mar, CA). The container was purged with 95%
oxygen/5% C02 (BOC) for 2 minutes. The sealed container was then incubated at 37°C and gently
horizontally rotated at 5 cycles per minute (see figure 2.2 for details of in-vitro culture set-up).
The gas and media phase were changed daily. At the time of explant harvest, explants for use in
histology were rinsed briefly in PBS and then placed initially in 4% Formaldehyde solution (Sigma)
overnight prior to transfer to 70% alcohol for longer term storage until later fixation in paraffin
blocks. Explants for use in protein analysis were taken from culture, briefly rinsed in PBS and then
placed immediately in dry-ice prior to storage at -80°C.
Waste material and contaminated materials/ consumables are placed in Virkon™ solution overnight
and then marked for disposal for incineration the next day in accordance with strict protocols for






Base ofBillup chamber with samples
(Pressure seal roof not in place) Pressure seal roof in place
Figure 2.2 IVOC set-up
a. Stretching out mucosa on metal grid - view from above.
b. Side view of explant set-up.
c. View ofmultiple explants within billup chamber (central explants were infected).
d. View of sealed billup chamber with roof apparatus in place.
and recorded in the register. All material not used or superfluous to demand must be returned to
storage or disposed ofwith disposal recorded in the register.
Maintenance
Medium
Non-supplemented (serum-free) RPMI media (Gibco), modified CMRL media (Gibco) (Glucose 15
mM, methionine 7 micromolar, tricine buffer 20Mm, hydrocortisone hemisuccinate 1.5 micromolar,
(retinyl acetate 1 microgram/ml, glutamine 3 mM, 5% Bovine Serum Albumin, 1.5% DMSO,
Penicillin 100 units/ml, streptomycin 100 units/ml, gentamicin 50 micrograms/ml, amphotericin
0.25micrograms/ml) (Autrup 1980) or modified Waymouth's media (Gibco MB752/1) (Foetal Calf
serum 10% (Gibco), ascorbic acid 300ug/ml (Sigma A4544), Hydrocortisone-21-sodium succinate 3.0
microg/ml (Autogen Bioclear cat no K3520), ferrous sulphate 4.5pg/ml, penicillin/ streptomycin 100
units/ ml (Gibco), antimycotic/antibiotic mix 1/100 (Sigma)) (Senior et al 1982) were used to culture
colonic mucosal explants. Explants were transported to the laboratory in 50 mis of their respective
long-term culture media. When added, lithium chloride (LiCl2)(0.5mM) was added as a supplement to
Modified Waymouth's media on a daily basis throughout the culture process and timelines (Li et al
2011). Dibenzazepine (DBZ) (lOpM) (Calbiochem) was added once daily for 5 days prior to harvest
(Ootani et al 2009). DMSO was added as a carrier control in these experiments.
Medium changes
On a daily basis, inside a class II microbiological safety cabinet (msc), fresh, labelled organ culture
dishes containing 3mL pre-warmed medium was prepared. Any additional supplements (e.g. drug
treatments) were added at this stage using sterile filter tips and all stocks removed from msc to reduce
risk of cross contamination.
The Billups chamber was gently removed from heated shaker/incubator and placed in msc. Pressure
was slowly released using inlet/outlet clips and the metal securing clip was opened. Culture dishes
were removed individually and place on a sterilised metal tray inside the msc. Any samples to be
'harvested' were set aside. Using fine forceps, pre-sterilised in 15ml Barrycide and rinsed in 2 x
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50mL sterile PBS (Lab services), gauzes were transferred to the appropriately-labelled fresh dishes.
After completion, the samples were placed inside the Billups container and resealed. The container
was purged with 100% oxygen (BOC Cat No 299031 AV-PC 95% oxygen 5 % C02) for 20 sees the
chamber was transferred to the incubator shaker as above. Samples for harvest were either transferred
to PBS/formaldehyde 4% or -80 °C for storage.
Reagents and treatment protocols
Lithium chloride (LiCh) (Sigma) (0.5mM) was added as a supplement to Modified Waymouth's
media on a daily basis throughout the culture process timelines (Li et al., 2011a). Dibenzazepine
(DBZ) (lOpM) (Calbiochem) was added once daily for 5 days prior to harvest (Ootani et al., 2009).
DMSO was added as a carrier control in these experiments. Aspirin 0.5M stock was prepared as
before and added at the concentration specified.
2.5 Protein biology
Kinase assays
In the KineActive ELISA method, a cellular extract is added to the wells of an antibody-capture plate.
This is followed by addition of a kinase-specific antibody, which binds to the plate and captures the
kinase of interest (c-Src). After the unbound proteins are washed away, a biotinylated,
unphosphorylated peptide substrate is added in the presence of ATP. The immobilized kinase
phosphorylates this substrate peptide, which is subsequently also captured by the addition of a second
antibody that is specific for the phosphorylated form of the substrate peptide. Addition of streptavidin-
HRP and subsequent developing solution provides a quantitative colorimetric readout that is directly
proportional to the activity of the kinase
Detection of the kinase activity was performed using the KineActive Src kit (Invitrogen)
manufacturer's instructions. Briefly, cells were treated as above. At harvest, cells were washed with 8
mis ice cold PBS x 2. Cells were scraped into 3 mis ice cold PBS then centrifuged at 1000 rpm x
lOmins at 4°C. 3x volume of Complete Lysis Buffer was added with additional lul DDT + 10 ul
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Protease inhibitor/ ml of Lysis buffer was also added. The mixture was mixed with a pipette several
times and incubated for 30 mins. Following this, the mix was again centrifuged for 20 mins at 14,000
rpm at 4 degrees and supernatant was collected and stored at -80°C with a Bradford assay performed
to detect protein concentration.
Assay strips were prewashed with 3 x 200ul of wash buffer, dried and the diluted capture antibody
was added. The protein sample (20|ig) was added and incubated for 1.5 hours at room temperature on
a shaking platform (60 rpm). The kinase mix was prepared; including 1:500 antibody, 1:500 peptide
substrate and 5x ATP buffer 1:5 in dH20. The plates were washed after incubation with 5 x 200 ul of
wash buffer. lOOul of kinase reaction mix was added to each well and the mixture was further
incubated for another 1.5 hours at 30°C with agitation. After incubation the wells were washed x 5
with 200ul of wash. lOOul of Streptovidin: HRP antibody solution was added and plates incubated for
30 mins at room temperature with gentle agitation. One final round of washing 5x200ul of wash
buffer was performed before developing the colour. lOOul of developing solution was added and the
mix incubated for 10 minutes (protected from sunlight) until the colour was moderate to dark blue.
lOOul of the Stop solution was added turning the solution yellow and the absorbance was read within
5 minutes on a spectrometer at 450 nM with optimal reference wavelength of 655 nm.
Preparation of cytoplasmic extracts from cells
Treated cells were washed with 2ml PBS prior to harvesting by scraping the cells into 5ml PBS. Cells
were subsequently pelleted by centrifugation at 1000 rpm for 2 min and then lysed for five min at 4°C
in approximately 3 X cell volume of lysis buffer [50 mM NaCl, 10 mM N-(2
hydroxyethyl)piperazine-N'-2-ethanesulfonic acid (HEPES) (pH 8.0), 500 mM sucrose, ImM EDTA,
0.5 mM spermidine, 0.15 mM spermine, 0.2% triton X-100] containing Complete™ protease inhibitor
cocktail (Roche Applied Science) at 1:1250 dilution, 1 mM pepstatin A (Sigma) and 100 mM
Pefabloc SC (Roche Applied Science). Phosphatase inhibitors [100 pM sodium fluoride (NaF), 10
mM p-glycerophosphate, 10 mM NaaVCL] were also added where appropriate, that is for the analysis
of phosphorylated proteins. The mixture was then further centrifuged at 6000 rpm for 20mins and the
106
supernatant was transferred to fresh eppendorfs and the protein concentration of the samples was
measured with storage subsequently at -20 °C.
Preparation of whole cell extracts from cells
Treated cells were washed with 5ml PBS prior to harvesting, which was then discarded. Then cells
were scraped into 1 ml PBS and placed on ice. Cells were subsequently pelleted by centrifugation at
13,000rpm for 15 sees. The supernatant was then removed and cells were incubated for 30 minutes on
ice following resuspension in approximately 3 X cell volume of lysis buffer [lOOuL/mL Cell Lysis
Buffer xlO Cell Signalling #9803, 40uL /mL Protease Inhibitor Complete Roche # 11697498001 x25
in dH20, luL /mL Pepstatin A Santa Cruz sc-45036, 20ul / mL (10 mM) Sodium orthovanadate
(Sigma s-6508) 500mM stock, lOuL / mL (10 mM) P -glycerophosphate (Sigma g-6251),l uL/mL
(100 pM) Sodium Fluoride (Sigma s-7920), lOuL/mL PEFA Bloc SC, AEBSF (4-(2-aminoethyl)
benzenesulphonyl fluoride hydrochloride lOOmg/ml stock in H2O (Sigma 76307). 10 uls PMSF was
added for every 1 ml of buffer. The mixture was vortexed occasionally throughout the incubation.
Cells were then pelleted at 13,000 rpm for 5mins at 4°C. The supernatant was transferred to fresh
eppendorfs and the protein concentration of the samples was measured with storage subsequently at -
20 °C.
Preparation ofwhole cell extracts from tissue
Tissue was removed from -80 °C freezer and samples were cut to size on dry ice. The samples were
rinsed with ice cold PBS and diced into pieces using a sterile scalpel. The samples underwent 3 cycles
of freeze-thawing and were homogenised by use of a mini homogeniser. The homogenate was then
centrifuged at 13,000rpm 5 min at 4°C. The supernatant was then collected and stored on ice.
Protein concentration determination
Bradford Reagent (Bio-RAD) was diluted 1:5 with dH20 and filtered using Whatman filter paper (27.0
cm) prior to use. 1 pi protein sample was added to 200 pi Bradford Reagent in the wells of a 96 well
plate. A concentration curve was included in each experiment using BSA standards (0.2 pg/pl, 0.5
pg/pl, 0.8 pg/pl, 1.0 pg/pl, 1.5 pg/pl and 2.0 pg/pl). The standards were loaded in duplicate and
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samples loaded in triplicate. Following a 10 min incubation at room temperature, the absorbance was
measured at 595 nm (A595) using an ELISA (enzyme-linked immunosorbent assay) plate reader. The
protein concentration was calculated from the A595 automatically by the plate reader, taking into
account the standards. The average of the 3 readings for each sample was determined and
subsequently used.
2.6 SDS Polvacrvlamide Gel Electrophoresis (PAGE)
A tenth of the volume of Sample Buffer [20% glycerol, 2% SDS, 0.25% bromophenol blue, 1 X
Stacking Buffer [500 mM Tris, 0.4% SDS, pH 6.8], 5% P-mercaptoethanol] was added to protein
samples (10-30 pg) prior to boiling at 95°C for 5 min and then placing on ice. The Protean II mini-gel
apparatus (Bio-RAD) and a two-tier gel system, comprising a lower resolving gel and upper stacking
gel, were used to resolve protein extracts by denaturing SDS PAGE. c-Src is 62 KDa, therefore, an
8% polyacrylamide was used.
Resolving Ge/;_4.02ml-distilled H20, 1.48 ml 40% Acrylamide, 1.9 mis, 4x Resolving Buffer, 112 ul
10% APS and 5 ul ofTEMED)
Stacking gels were; 1.081mis of Distilled H20, 0.444 ml of 4X Stacking Gel, 0.218 mis of 40%
Acrylamide, 28ul of 10% APS, 5ul of TEMED). lOpl of Kaleidoscope pre-stained molecular weight
standards (Bio-RAD) were loaded in a single well of each gel and run in parallel with protein samples
to aid the identification of proteins of interest. Gels were electrophoresed in 1 X Running Buffer [25
mM Tris, 0.2 M glycine, 0.1% SDS] at 160 volts for approximately 1 hr.
Western blot
Antibodies used for Western blot analysis and details of the host species they were raised in, dilutions,
incubation time and manufacturer are summarised in Table 2.1. Western blot analysis was carried out
using standard procedures. Briefly, protein extracts were resolved on SDS PAGE gels as described in
section 2.7. Proteins were then transferred to Hybond PVDF membrane (Bio-RAD) using a semi-dry
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blotter (Bio-RAD) with 1 X semi-dry transfer buffer [47 mM Tris, 40 mM glycine, 0.037% SDS, 100
mM methanol]. Gels were included in a stack which included 3x Whatman blotting paper 7x9cm
layers and lxHybond PVDF membrane 7x9cm, lx gel then 3xWhatman blotting paper 7x9cm. Gels
were run at 12 volts for 45 minutes as per manufacturers instructions. The membrane was then
blocked in TBS (1 L Distilled H20, 2.42g Tris base, 8.77g NaCl pH 7.4) containing 0.1% TWEEN®
20 (Sigma) (TBST) plus 5 % dried milk (TBSTM) for 1 hr at room temperature or overnight at 4°C
prior to the addition of primary antibody for 2 hr at room temperature or overnight at 4°C (See table
2.1). The membrane was subsequently washed with TBST (3X10 min) before being incubated with
the appropriate secondary antibody conjugated to horseradish peroxidase for 30 min at room
temperature (See table 2.8). The membrane was then washed with TBST (3 X 10 min) before
detection of specifically bound antibody by chemiluminescence. ECL reagents (Santa Cruz
Biotechnology) were mixed 1:1, applied to the membrane for 1 minute, excess removed, then the
membrane covered with cling film and exposed to Hyperfilm (Amersham Biosciences) for the time as
appropriate for the antibody signal to be captured. Films were subsequently developed using an SRX-
101A X-ray processor (Konica Minolta, Medical + Graphic Inc.).
Stripping Membranes
Membranes were stripped in a fume hood with 50 ml strip buffer [62.4 mM Tris, 2 % SDS, pFi 6.7],
which was pre-warmed in a glass dish to 60°C using a heat block. One or two membranes were placed
into the buffer and 400 pi p-mercaptoethanol added and gently mixed prior to heating at 60°C for a
further 30-45 min. The strip solution was then discarded and membranes washed with PBST (3X10
min) before being re-blocked in PBSTM for 1 hr or overnight at 4°C. Membranes were then re-probed
with primary antibody as above.
Whilst it is possible to quantify western blot output by densitometry methods, the output from this
assay is by definitely qualitative in nature. Recent reviews of densitometry have heavily criticized this
methodology for inaccuracy, openness to bias and lack of uniform protocols (Gassman 2009).
Different densitometry procedures applied to the identical Western blots have also revealed wide-
ranging results with poor correlation (Gassman 2009).
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Given the known weaknesses regarding this methodology, in addition to the published nature of the
majority of western blot data presented within this thesis, without densitometry, it was not felt that
this methodology would provide robust or additional strength to the cumulative data presented.
2.7 Annexin V -F1TC assays
Staining for cell surface phosphatidyleserine was used as a marker for apoptosis and was carried out
using an AnnexinV-FITC apoptosis detection kit (Calbiochem), as per the manufacturer's instructions.
Briefly, the media from a flask of treated adherent cells was transferred to a 15 ml conical tube and
placed on ice. Adherent cells were then washed with 2 mis PBS (which was added to the 15ml conical
tube) prior to incubation with 1ml T/V (per 5cm2 flask) at 37°C for 5 minutes and until cells appeared
to be detached. Cells were then released from flasks with firm tapping and subsequently resuspended
in the media that was initially removed. The number of cells/ml was determined by haemocytometric
counts then cells were resuspended at a concentration of approximately 1 x 106 cells/ml. 0.2 ml cell
suspension (1 x 106 cells) was then transferred to a 1.5 ml eppendorf along with 20 pi media binding
reagent (Calbiochem) and 0.5 pi Annexin V-FITC. Cells were incubated for 15 min at room
temperature in the dark, pelleted by centrifugation at 2000rpm/l ,000 x g for 5 min at room
temperature and then resuspended in 0.2 ml cold 1 X binding buffer (made by diluting 5 X binding
buffer (Calbiochem) with dFFO). lOul cell solution was placed onto a glass slide and 5ul of
Vectashield-DAPI was placed onto a coverslip. The coverslip was placed over the cell solution. The
percentage of cells undergoing apoptosis in the population was determined using fluorescent
microscopy. The total number of cells per field of view was determined using DAPI to identify viable
cell nuclei then the number of apoptotic cells quantified using the FITC channel. For all cases, at least
200 cells from a minimum of 10 independent fields of view were analysed.
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Table 2. 1 - Antibodies used for western blot analysis.
Antibody Host Species and
Antibody Type
Dilution Incubation Time Manufacturer
c-Src (Y416) Rabbit
(Monoclonal)
1:1000 in TBSTM 2 hour (RT) or 16





1 : 500 in PBSTM
(PBS+ 0.1%
TWEEN®20
(Sigma) + 5% dried
milk)




1:1000 in TBSTM 2 hour (RT) or 16




1:1000 in PBSTM lhour (RT) BD Pharmingen
Anti-lKBa Sheep
(Polyclonal)
1 : 4000 in PBSTM 1 hr at room
temperature (RT)
Gift from Ron Hay
Anti-Actin Mouse (IgM)
(Monoclonal)
1 : 15,000 in
PBSTM


























Antibodies used for immunocytochemistry and details of the host species in which they were raised,
dilutions, incubation time and manufacturer are summarised in Table 2.2. Cells were grown on
sterilised coverslips in 6 well plates until 60-80% confluent then treated as specified. After treatment,
cells were washed briefly with TBS then fixed in 1 : 1 methanol : acetone at -20°C for 20min. Cells
were subsequently washed with TBST (2X10 min) prior to incubation with 10% donkey serum
(Sigma) for 30 min to block non-specific binding. After blocking, cells were incubated with primary
antibody diluted in 10% donkey serum for 1 hr and washed with TBST (2X10 min) prior to
incubation with secondary antibody diluted in 1.5% donkey serum for 30 min. Cells were washed with
TBS (2 X 10 min) then coverslips mounted in Vectastain (Vector Laboratories) containing DAPI
(4',6'-diamido-2-phenylindole) (1 pg/ml) (Sigma) to stain DNA.
Quantification of nuclear RelA
In order to quantify the induced nuclear translocation of RelA, individual exposure channels for each
immunocytochemistry image field were captured and stored using identical exposures throughout
image collection and across treatment arms of the experiment. Later image analysis created nuclear
outline masks in DAPI channel images, which were subsequently transposed onto the matched F1TC
channel exposures for that field of view. The mean intensity of nuclear RelA staining within
previously defined DAPI masks were then quantified in at least 3 separate experiments, in least 15
random fields per experiment.
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Table 2.2 Antibodies used in immunocytochemistry
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Paxillin Mouse
(Monoclonal)



































1 : 100 JacksonImmunoresearch
2.9 Immunohistochemistrv
4 micrometer widths sections were cut from paraffin embedded tissue and fixed on glass slides. For
fluorescence immunohistochemistry, slides were heated at 60 °C for 45 minutes then submerged twice
for 5 minutes in Xylene. Samples were then rehydrated through 2 sequential steps of 100% ethanol
and then 70 % ethanol, each for 5 minutes. Samples were rinsed with deionised water x 2 for 5
minutes each, prior to microwave induced boiling in citrate buffer for 25 minutes. After cooling
samples to room temperature for 1 hour, samples were washed again in deionised water and placed in
sequenza clips. Samples were permeabilised in 1% Triton-x 100 in PBS for 20 minutes. Following 2
further 10 minute washes in PBS, the samples were then placed in protein block overnight at 4 °C
(10% Donkey Serum (Sigma), 5% Bovine Serum Albumin (Sigma, St Loius, MO) in PBS with 1 %
Tween).
Antibodies used for immunocytochemistry and details of the host species in which they were raised,
dilutions, incubation time and manufacturer are summarised in Table 2.3. Primary antibodies were
added in blocking solution at the concentration specified for the time specified followed by 3x 5
minute washes with T/PBS containing 1% Tween. The relevant fluorescent secondary antibodies were
then added at the concentration specified. Following incubation, protected from light, the samples
were washed 3 times in T/PBS 1% tween for 5 minutes each and then air dried. Cover slips were
applied to the samples after 10 microlitres of DAPLVectashield (Vector Lab Inc., Burlinghame, CA)
had been added. Samples were stored at 4 °C until ready to be viewed by immuno-fluorescence
microscopy.
Primary antibodies included Ki67 (1:500) (DakoCytomation, clone MIB-1), PCNA (1:100) (Santa
Cruz, clone C-20), Active Caspase-3 (1:300)(BD Pharminogen, clone C92-605), TUNEL "In Situ cell
death detection" kit (concentration as per manufacturers instructions) (Roche) , mouse anti-p-catenin
(1:250)( BD Transduction Labs ), rabbit anti-chromogranin A (1:50) (Autogen Bioclear Cat no
ABJ1411), Mouse anti-Vil-1 (1:100)(Lifespan Biosciences), mouse anti-Muc-2 (1:100) (Genetex Inc),
mouse FITC-conjugate, anti-a-smooth muscle actin (Sigma), rabbit anti-LGR5 (1:100) (MBL
International Corporation, Woburn, WA), mouse anti-BMI-1 (l:100)(Abcam abl4389-25) and mouse
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anti-CD133 (Prominin 1 )(#SC-130127; Santa-Cruz Biotechnology Inc). Secondary antibodies used
were anti-rabbit FITC (5:1000) and anti-mouse Texas-red (5:1000) (Jackson Laboratories).
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-Table 2.3 Antibodies used in immunohistochemistry
























Anti-Hu villin 1 Mouse 1:100 Lifespan
biosciences
Anti- P-catenin Mouse 1:250
BD Transduction
labs
Anti-Muc-2 Mouse 1:100 Genetex Inc.
Anti-Chromogranin
A




Anti-BMI-1 Mouse 1:100 Abeam
Anti-Lgr5 Rabbit 1:100 MBL
Anti-PCNA Mous e 1:250 Santa cruz
Anti-active caspase -
3
Rabbit 1:250 BD Pharminogen
TUNEL In situ cell
death kit
-- As per kit Roche






























For brightfield colour imaging using a monochrome camera, the imaging system comprises a
Coolsnap HQ CCD camera (Photometries Ltd, Tucson, AZ) and Zeiss Axioplan II fluorescence
microscope with Plan-neofluoro objectives (Carl Zeiss, Welwyn Garden City, UK). Colour additive
filters (Andover Corporation, Salem, NH) installed in a motorised filter wheel (Ludl Electronic
Products, Hawthorne, NY) were used sequentially to collect red, green and blue images that were then
superimposed to form a colour image. Image capture and analysis were performed using in-house
scripts written for IPLab Spectrum (Scanalytics Corp, Fairfax, VA). White adjustment was performed
once per session on a representative slide using a non-tissue section of the slide. For fluorescence
imaging, the imaging system comprises a Coolsnap HQ CCD camera (Photometries Ltd, Tucson, AZ),
Zeiss Axioplan II fluorescence microscope with Plan-neofluar objectives, a 100W Hg source (Carl
Zeiss, Welwyn Garden City, UK) and Chroma #83000 triple band pass filter set (Chroma Technology
Corp., Rockingham, VT) with the excitation filters installed in a motorised filter wheel (Prior
Scientific Instruments, Cambridge, UK). Image capture and analysis were performed using in-house
scripts written for IPLab Spectrum (Scanalytics Corp, Fairfax, VA).
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Tissue damage scores
The "C3 tissue damage scale" was developed to describe ex-vivo mucosal colonic histological
changes within the IVOC system. Further examples of scoring and an explanation of the system can
be found in figure 2.4.The score describes 3 main histological qualities noted within explant samples
(a) Crypt density (0= high crypt density /inter-crypt regions narrower than the crypts), 1= Medium
crypt density (inter-crypt regions the same width as crypts), 2= Low crypt density (inter-crypt regions
larger than the crypts), 3= no obvious crypt structures present (b) Epithelial Continuity (surface and
crypts) (0= continuous superficial epithelial layers, 1= minor surface epithelium breaks, 2= major
discontinuity of surface epithelium) plus (0= continuous epithelial layers within crypts, 1= Some
crypts have epithelium breaks, 2= major discontinuity or absence of epithelium in crypts) or
alternatively, 5= little or no continuous epithelium in the field) (c) Composition ofcrypt cell
population (0= goblet cells in all crypts throughout, 1= few goblet cells in some crypts, 2= No goblet
cells apparent but epithelial cells present, 3= no epithelium present). All scores represented were
derived as an average from 3 trained and blinded participants. Scores ranged from 0 to 11 with a mean
difference in participant's scores across experiments of 0.72 (SD = 0.47). R-squared values ranged
from 0.81-0.86. Initial preparation to evaluate the strength of relationship between rater's scores was
undertaken. Further analysis was undertaken in order to evaluate levels of agreement between
independent blinded reviewers of the base data (i.e. sample of 200 explant histology pictures) to
ensure that scoring was similar across reviewers. As this was, in the first instance, categorical data and
3 reviewers were involved, a Light's kappa analysis was undertaken as this computes Light's Kappa as
an index of inter-rater agreement between more than 2 raters on categorical data (Conger 1980).
The results of this analysis, corresponding to the agreement between raters, with squared weights was
0.898. This is judged as a "very good" strength of agreement according to Altman's scale (Altman,
1991).
Mann-whitney U testing has been performed throughout to compare C3 Damage scores, following
statistician advice. Chi-Squared testing was undertaken to compare outcomes for the categorical data




0=High crypt density /inter-crypt regions narrower than the crypts
1= Medium crypt density (inter-crypt regions the same width as crypts)
2= Low crypt density (inter-crypt regions larger than the crypts)
3= No obvious crypt structures present
Eplthelai Continuity
Surface 0= Continuous superficial epithelial layers
1= Minor surface epithelium breaks
2= Major discontinuity of surface epithelium
Crypt 0= Continuous epithelial layers within crypts
1= Some crypts have epithelium breaks
2= Major discontinuity or absence of epithelium in crypts
Both 5= Little or no continuous epithelium in the entire field
Composition of crypt population
0= Goblet cells in all crypts throughout
1= Few goblet cells in some crypts
2= No goblet cells apparent but epithelial cells present







Crypt Population C3 score
Surface Crypt
0 0 0 0 0
1 0 0 1 1
1 0 0 2 3
2 0 2 1 5
2 1 2 2 7
3 - 5 - 3 1 1
Figure 2.4. The C3 scoring scale
a. Tabular representation of the C3 score, b. Some examples of the scoring in practice
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Previously, the host laboratory has established that pharmacologically relevant concentrations of
aspirin induce a concentration and time dependent molecular response characterized by degradation of
IkBcx and nuclear translocation ofNF-kB in colorectal cancer cells in vitro and in colorectal neoplasia
in vivo, and that this NF-kB response is essential for the pro-apoptotic effects of the agent (Stark et al
2001, Stark et al 2007). However, the aspirin induced response differs from the canonical pathway
described above in that, firstly, there is a significant delay in the kinetics observed between aspirin
administration and the activation of the NF-kB pathway. Secondly, the agent induces a sustained
reduction in cytoplasmic IkBcx, initially caused by a serine 32/36 phosphorylation-dependent,
proteosome-mediated degradation of the protein (Din et al 2004, Stark et al 2001, Stark et al 2007).
Finally, following aspirin treatment, unbound RelA translocates to the nucleus and is subsequently
sequestered in the nucleolar compartment of the nucleus. These key molecular events result in a
paradoxical response characterised by initial activation of the NF-kB pathway but the subsequent
RelA nucleolar sequestration is paralleled by a decrease in basal levels of NF-kB transcriptional
activity. RelA is therefore causally involved in the induction of apoptosis stark (Stark and Dunlop
2005).
As discussed, in contrast to the in vitro kinetics of TNF-a, the NF-kB response to NSAIDs is delayed,
occurring hours rather than minutes after administration. Hence, it is likely that aspirin, rather than
targeting IkBoi directly, acts through the induction of intermediate upstream kinase signalling
pathways. Previously, the p38 MAP Kinase was identified as a potential candidate as it is activated
within minutes of aspirin administration and inhibition of p38 attenuates the aspirin induced NF-kB
response (Thorns et al 2007a). However, due to the delay between p38 MAP Kinase activation and the
NF-kB response, it is unlikely that there is direct interaction between p38 MAP Kinase and the NF-kB
pathway members and that further intermediate candidate kinases are involved.
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One such candidate kinase is the proto-oncogene product, c-Src. c-Src is upregulated and activated in
CRC progression and metastases and c-Src activation is well-reported to induce NF-kB signaling in
response to a wide variety of inflammatory mediators, bacterial stimuli and other chemical stimulants
(Abu-Amer et al 1998, Huang et al 2003a) (Chang et al 2004, Fan et al 2003, Funakoshi-Tago et al
2005, Jalal and Kone 2006, Kang et al 2005, Lin et al 2006, Liu et al 2001, Lluis et al 2007, Mendez-
Samperio et al 2007).
The mechanisms suggested for c-Src activation of NF-kB are diverse and have been described in
many settings. In some reports, c-Src is involved in the direct phosphorylation of IkBcx tyrosine
residues (Y42) in response to stimulants such as pervanadate, hypoxia or VEGF, which result in
nuclear translocation ofNF-kB in the absence of IkBci degradation (Elder et al 2002, Fan et al 2003,
Grosjean et al 2006, Imbert et al 1996, Koong et al 1994). Alternatively, c-Src-induced NF-kB
activation is also known to occur more indirectly, through induced stimulation of intermediate kinase
pathways, such as Protein Kinase C Alpha (PKCa) and the IkBoi kinase (IKK) signaling pathways.
These activation pathways classically induce NF-kB signaling by IkBoi serine 32/36 residue
phosphorylation and subsequent proteasomal-mediated IkBoc degradation (Huang et al 2003a,
Mendez-Samperio et al 2007) (Lin et al 2006). Furthermore, reports also describe a mechanism by
which c-Src acts as a scaffold for the IKK complex itself and contributes to signal-mediated
degradation of IkBoi in a manner that does not require the c-Src tyrosine kinase domain or function
(Chang et al 2004, Funakoshi-Tago et al 2005).
Critically, in support of the notion that c-Src acts as an intermediary in aspirin/NSAID activation of
the NF-kB pathway, NSAIDs and aspirin are also reported to effect the activity of c-Src in a variety of
cellular contexts (Perez-G et al 2002, Ramdas and Budde 1998, Wang and Brecher 2001). Wang et al.
have reported that salicylates alter the phosphorylation state of c-Src by inducing a modification of the
intra-cellular calcium/redox state. Kunte et al., (Kunte et al 2008) reported that the NSAID, sulindac
sulfide, modifies c-Src activity in CRC cells while Casanova et al. reported that another NSAID,
Celecoxib, modified c-Src activity in acute myeloid leukaemia cell lines, together with the induction
of a subsequent pro-apoptotic response (Casanova et al 2008).
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In summary, c-Src plays a critical role in CRC initiation and progression and NSAIDs are known to
modulate the activity of kinase. Therefore, there is a compelling case to further investigate the role of
c-Src in the aspirin-induced NF-kB response in CRC cells.
3.2 Detection of native c-Src in CRC cells
SW480 colorectal cancer cells are a well-characterized experimental system in which to dissect the
molecular responses to aspirin (Din et al 2004, Stark et al 2001, Stark and Dunlop 2005, Thorns et al
2007a). As such, this was a logical choice as an available model in which to pursue my line of
investigation. However, whilst activation of c-Src is a consistent early finding in CRC (Bolen et al
1987, Cartwright et al 1989, Talamonti et al 1993, Termuhlen et al 1993), the protein expression
levels amongst different CRC cell lines have been reported as being highly variable (Dehm et al
2001).
Previous reports have demonstrated that CRC cell lines such as SW480, SW620, HCT-116, HCT-15
and DLD-1 have low levels of c-Src mRNA, intermediate levels of c-Src protein expression and low
levels of c-Src kinase activity, compared to CRC cell lines such as HT29, WiDr, COLO201 and
COLO205, which display high levels of SRC transcriptional activation (Dehm et al 2001).
Furthermore, even those cells which express very low levels of c-Src expression have been previously
documented to exhibit high levels of phosphorylated / activated c-Src (Serrels et al 2006). Therefore,
given these previous reports, my first objective was to confirm that c-Src could be detected in SW480
cells.
Using extracts from the SW480 cell line and the HT29 CRC cell line (a CRC cell line which is known
to constitutively express higher levels of c-Src, utilised as a positive control), I found that native c-Src
was detectable by western blot analysis in SW480 whole cell extracts (figure 3.1a). However, in
keeping with previous reports, c-Src levels were reduced in SW480 cells compared to HT29 cells. To





Figure 3.1. Detection of native c-Src in CRC cells
a+b. Anti-c-Src western blot analysis was performed on whole cell extracts
from a. SW480 cells and HT29 cells (positive control) or b. SW480 cells transfected with a
wild-type c-Src expression vector (WT). Actin was used as a protein loading
control (n=3) c. Anti-c-Src immunocytochemistry was performed on SW480 cells.
DAPI was used as a nuclear marker. c-Src localises to a peri-nuclear rim
(red arrow) and to aggregates at the cell peripheries (yellow arrow) (n=5).
cells that had been transiently transfected with an expression vector to overexpress the wild-type form
of c-Src (figure 3.1b).
Immunocytochemistry confirmed the expression of c-Src within the cell cytoplasm and primarily
around the peri-nuclear envelope however, some peripheral aggregates were also noted at the cell
membrane, (figure 3.1c). This is consistent with the known c-Src cellular location in CRC cell lines
and invasive tumours (Kaplan et al 1992, Reynolds et al 1989).
3.3. Detection of aspirin-induced c-Src kinase activity
Having established that SW480 cells expressed c-Src, I then utilised this cell line to determine the
effect of aspirin on the tyrosine kinase activity of c-Src. Initially, I aimed to measure c-Src activity
using a commercially available kinase assay specific for c-Src activity ("c-Src kineactive" kit ®). In
the KineActive ELISA method, a cellular extract is added to the wells of an antibody-capture plate.
This is followed by addition of a c-Src-specific antibody, which binds to the plate and captures c-Src
from the extract. After the unbound proteins are washed away, a biotinylated, unphosphorylated
peptide substrate is added in the presence of ATP. The immobilized c-Src phosphorylates this
substrate peptide, which is subsequently also captured by the addition of a second antibody that is
specific for the phosphorylated form of the substrate peptide. Addition of streptavidin-HRP and
subsequent developing solution provides a quantitative colorimetric readout that is directly
proportional to the activity of the kinase (see methods). Cytoplasmic extracts of SW480 cells were
utilised in time course experiments with aspirin.
Results initially indicated that aspirin induced c-Src tyrosine kinase activity in SW480 CRC cells, and
that this activation peaked 4 hours after treatment (Figure 3.2). Unfortunately, shortly after
optimisation of this assay, the manufacturer withdrew the kit from the market for financial reasons.
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Figure 3.2 Detection of aspirin-induced c-Src kinase activity
SW480 cells were untreated (NT) or aspirin treated (5mM) for the times specified. Cell extracts
were processed by c-Src kineactive assay kit and fluorometric output (equivalent to kinase
activity) was recorded. Values are presented as a fold increase compared to base-line SW480
activity (NT). Fluorometric output increased following aspirin treatment, peaking at 4 hours
following administration. Fluorometric outputs were normalised to untreated SW480 c-Src
kinase activity baseline levels. Recombinant Src protein (+) and lysis buffer (-) were used
as positive and negative controls. Data are the average of 4 independent experiments
(+/- standard error).
undertaken. Further attempts to obtain the kit or elements of the kit by alternative means were not
successful. I therefore sought to detect c-Src kinase activation by alternative means.
3.4 Aspirin induces phosphorylation of c-Src Y416 in CRC cells
Intermolecular auto-phosphorylation of the Y416 residue on the activation loop of c-Src induces
internal protein displacement and conformational opening of the kinase domain, permitting access of
substrates and signifying activation of the c-Src tyrosine kinase (Brown and Cooper 1996).
Phosphorylation of this residue is widely used as a surrogate marker of c-Src activation and increased
c-Src tyrosine kinase activity (Roskoski, Jr. 2005)(Frame 2002). A further detailed description of the
mechanism of c-Src regulation and function are presented in chapter 1.6 (figure 1.6).
Given the difficulties experienced with the c-Src kinase assays, I next examined phosphorylation of
the c-Src Y416 residue as a surrogate marker for activation of the kinase. A commercially available
phospho-specific antibody that detects phosphorylation of the Y416 residue on c-Src was obtained to
assess cellular c-Src activation status and specifically to characterize the effect of aspirin.
Time-course studies indicated Y416 phosphorylation increased 4-6 hours following aspirin (5mM)
administration (figure 3.3a). Furthermore, the kinetics of this activation were in keeping with the
kinetics of those observed previously when using the "c-Src kineactive" kit ®. The c-Src (phospho-
Y416) activation signal corresponded to a protein size of 60 kDa and extracts from cells transiently
transfected to over-express the wild-type form c-Src protein were used as a control for phospho-
protein specificity. Following stripping, membranes were subsequently reprobed with an antibody to
detect native c-Src. This revealed that the previous Y416 antibody detection signal also matched
native c-Src in regards to molecular weight. Notably, in contrast to the increase observed with
activated c-Src, the level of native c-Src protein expression remained unchanged in response to aspirin
administration.
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Figure 3.3 Aspirin induces phosphorylation of c-Src Y416 in CRC cells
SW480 cells (a, b), HT29 cells (e) or SW480 cells which were transiently transfected with a wild type
c-Src expression vector (c, d) were aspirin treated (5mM) for the times specified (a, c, e) or 0-5mM,
4hrs (b, d)). (a-e) Western blot analysis was performed on whole cell extracts using antibodies to
phosphorylated c-Src (Y416) and IkBoi. Blots were stripped and reprobed for endogenous c-Src.
Lysates from wild-type transfected cells were used as positive controls. SW480 cells transfected
with a wild type c-Src expression vector (WT) were used as a positive control. Actin was used as
a control for protein loading. Aspirin induces a dose- and time-related increase in phosphorylated
c-Src (Y416) and time-dependent decrease in levels of IkBcc (n>3).
Next, the dose-dependency of aspirin-induced c-Src activity was examined. SW480 cells were treated
with 0-5mM aspirin for 4 hours, then whole cell extracts were analysed for activation of c-Src using
Y416 phosphorylation as a marker of activation. I found activation of c-Src occurred in a dose
dependent manner. Subsequent probing demonstrated that levels of native c-Src remained unchanged
irrespective of the dose of aspirin administered (figure 3.3b).
Given the relatively low levels of c-Src expression in SW480 cells, the strength of the antibody signal
obtained was weak and small changes in protein phosphorylation were difficult to detect despite using
high total protein concentrations. In order to maximise antibody signal detection, dose and time-
course experiments were replicated in SW480 cells that had been transiently transfected to over-
express the wild-type form of c-Src. In this setting, a time and dose -dependent increase in phosphor-
Y416 c-Src levels was again observed, confirming data observed from the endogenous protein setting
(figures 3.3c and 3.3d).
The commercial antibody used in these experiments can cross-react with c-Src Y416 residues and
with other SFK members. However, the c-Src over-expression experiments confirmed that c-Src is
indeed activated after aspirin administration. These data also indicate that the level of c-Src
expression within CRC cell lines is not a relevant factor in whether a cell has a c-Src response to
aspirin, as the response was observed in both high (transiently transfected) and low (native cells) c-Src
expression environments.
To determine the generality of the c-Src response to aspirin with regard to CRC cells, the response
was assessed in HT29 cells, which as discussed previously, expresses high levels of native c-Src.
HT29 cells were treated in time course experiments. Aspirin induced a time-dependent increase in c-
Src Y416 phosphorylation, consistent with results from SW480 cells (figure 3.3e). These data
demonstrate that the aspirin induced response is of relevance to CRC cell lines more generally.
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3.5 Aspirin-induced cellular relocalisation of c-Src is consistent with c-Src activation
In previous reports, native c-Src localises primarily to the peri-nuclear envelope (Reynolds et al 1989).
However, c-Src activation is associated with remodelling of the actin cytoskeleton and a profound
change in its normal cellular location, characterised by rapid translocation from the perinuclear area to
peripheral focal adhesions/cell membrane. This "trafficking" putatively occurs along actin fibres
facilitating relocation of c-Src to membrane protrusions/lamellipodia (Fincham et al 1995).
I therefore used immunocytochemistry to determine the location of native and active c-Src within the
cell before and after aspirin treatment. Following aspirin treatment, the native c-Src signal was of
increased intensity at the cell periphery, approximating to the location of the cell membrane (Sakai et
al 1998)(Figure 3.4a).
These studies were repeated using antibodies to detect the phospho-Y416 c-Src signal. Prior to aspirin
treatment phospho-Y416 was found in relatively low levels around the perinuclear area. However,
there were also numerous phospho-Y416 staining aggregates localising at the cell membrane (Figure
3.4b). These aggregates were reminiscent of the appearance and location of focal adhesions.
Therefore, co-staining for activated c-Src and anti-FAK (Focal Adhesion Kinase) was undertaken.
I found that peripheral aggregates contained a central dense FAK-rich core surrounded by active an
intensely staining phospho-Y416 ring (Figure 3.5a and figure 3.5b). These appearances were
consistent with the known characteristics, appearance and molecular structure of focal adhesions/focal
complexes (Worth and Parsons 2008). The localisation of activated c-Src within focal adhesions is
well described (Howell and Cooper 1994). Activated c-Src genetic mutants are known to associate in
podosomes, which are areas of the cell in which there are components of focal adhesions (Kaplan et al
1994).
In contrast to the tightly-structured appearance, I found that aspirin caused a dramatic breakdown in
focal adhesions. This breakdown, from larger active c-Src aggregates to smaller c-Src foci, occurred
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Figure 3.4 Aspirin-induced cellular relocalisation of c-Src is consistent with c-Src activation
Immunocytochemistry utilising antibodies against endogenous c-Src (a) phosphorylated
c-Src (Y416) (b) was performed on SW480 cells at baseline or 4 hrs after treatment with aspirin
(5mM) a. Aspirin induces migration of endogenous c-Src to the cell membrane (n=5), Yellow arrows
denote increased staining intensity at teh cell membrane b. Focal aggregates
of densely staining c-Src Y416 are observed at the cell periphery prior to aspirin treatment.
In response to aspirin levels of phosphorylated c-Src (Y416) were increased and distributed diffusely (n=5).
Merge FAK Src Y416
Figure 3.5 Aspirin-induced cellular relocalisation of FAK is consistent with c-Src activation
Immunocytochemistry utilising antibodies against endogenous c-Src (a) phosphorylated c-Src
(Y416) (b,c) or FAK (a, b, c) was performed on SW480 cells at baseline (a,b) or 4 hrs (c) after
treatment with aspirin (5mM) a. Anti-c-Src and anti-FAK immunocytochemistry was performed
on untreated cells. Endogenous c-Src localises primarily to the peri-nuclear region but a smaller
proportion localises closely to membrane aggregates that are FAK rich (yellow arrows). DAPI was
used as a nuclear marker. (n=3) b. Phospho-c-Src Y416 localises primarily to membrane aggregates
that have a FAK rich core. DAPI was used as a nuclear marker. (n=5) c. Larger FAK dense aggregates
undergo dissolution after aspirin treatment and become more numerous (n=3).
simultaneously with the increase in c-Src activation observed using western blot analysis. It also
correlated with the appearance of membrane ruffles and lamellipodia. The small c-Src foci appeared
to align along the edges of these membrane protrusions and remain co-localised with smaller FAK
aggregates. There was a time-dependent re-localisation of activated c-Src staining from dense focal
adhesion-like structures, to smaller, more numerous aggregates at the cell periphery in areas which
resembled the appearance of membrane ruffles and laminopodia-like protrusions (figure 3.5c).
Whilst c-Src is known to play a central role in focal adhesion assembly, deregulated c-Src activity also
has a destructive effect on these structures and on cell-matrix adhesion (Volberg et al 2001). Previous
studies report that in addition to inducing disassembly of focal adhesions and relocation of the protein
to membrane ruffles/podia, activation of c-Src also induces rearrangement of certain cytoskeletal
elements (Westhoff et al 2004).
Eukaryotic cells contain three main kinds of cytoskeletal filaments; microfilaments, intermediate
filaments, and microtubules. These cytoskeletal elements interact extensively and intimately with the
cellular membranes (Doherty and McMahon 2008). Microtubules are highly dynamic and comprise of
polymers of a and p-tubulin. To examine aspirin effects on the cytoskeleton in relation to the
activation of c-Src, we performed immunocytochemical analysis with antibodies to the major
cytoskeletal component P-tubulin. I found that aspirin treatment induced significant changes in p-
tubulin staining and structure, with loss and deterioration of staining of peripheral fibres, disordered
fibre structures and less numerous fibres overall. This occurred following the reduction in the number
and intensity of c-Src phospho-Y416 aggregates and dissolution/disassembly of FAK staining
membrane bodies (figure 3.5f).
The changes observed in Src/FAK localisation and membrane structure were similar to those observed
for the known activator of c-Src, Epidermal Growth Factor (EGF) (Figure 3.6a). EGF is known to
cause an increase in c-Src kinase activity, relocalisation of c-Src to the cell periphery and
phosphorylation of FAK in the carcinoma cells (Brunton et al 1997) (Figure 3.6b).
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Taken together, these data confirm that aspirin activates c-Src in CRC cells. They also reveal the
interesting observation that aspirin causes early changes to the cell cytoskeletal and membrane
structures.
3.6 Aspirin induces Y118 phosphorylation of paxillin
Paxillin is a multi-domain scaffold protein that localizes to the intracellular surface of sites of cell
adhesion. It was first identified as a c-Src substrate when it was identified as the 68-kDa protein that
exhibited increased tyrosine phosphorylation following the transformation of chick embryonic
fibroblasts with the v-Src-expressing Rous sarcoma virus (Glenney and Zokas 1989). As one of the
earlier identified members of the focal adhesion "proteome", it has a number of widely recognised c-
Src phosphorylation sites and is therefore of key interest, both in relation to its potential role in focal
adhesions and also its use as a surrogate marker of c-Src activity (Serrels et al 2006). In addition to its
structural role linking the ECM with the actin cytoskeleton (Brown and Turner 2004), it is also
involved in many other cellular signalling functions, including survival signalling (Deakin and Turner
2008).
To further analyse aspirin effects on the c-Src pathway, I next utilised phospho-specific antibodies
raised against paxillin phosphorylated at tyrosine residue 118, a known c-Src specific site (Sachdev et
al 2009). In keeping with data showing activation of c-Src in response to aspirin, western blot analysis
demonstrated a time-dependent increase in phosphorylated Y118 paxillin. Furthermore, this response
occurred in parallel with the kinetics of the Y416 phosphorylation of c-Src noted previously (figure
3.7a). Similarly, the level of phospho-Y118 paxillin signal also increased concurrently with dose of
aspirin administration (figure 3.7b).
Next, immunocytochemistry was used to examine the localisation of phosphorylated paxillin in
relation to FAK and Y416 c-Src. Prior to aspirin treatment, the cellular distribution of phosphorylated
Y118 paxillin in relation to p-tubulin and FAK was similar to that observed with c-Src Y416 (figure
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3.7c and 3.7d). However, following aspirin treatment, there was an increase in the intensity of the
antibody signal at the cell membrane in concert with dissolution of FAK rich aggregates. Furthermore,
there was a redistribution of Y118 phosphorylation along the cell membrane similar to that observed
with c-Src (figure 3.7e). These findings suggest that aspirin induces phosphorylation of paxillin Y118
and that this may lie downstream of the effects of the agent on c-Src. The data also suggest that the
phosphorylation of paxillin Y118 could therefore have potential utility as a surrogate marker of
cellular c-Src-mediated tyrosine phosphorylation. However, whether paxillin Y118 phosphorylation
occurs as a result of c-Src activity, or as a result of an unknown alternative kinase or is indeed a
reflection of a more global effect of aspirin, in which there is tyrosine residue phosphorylation on
many different cellular proteins, was at this point undetermined.
3.7 Aspirin induces c-Src activation prior to NF-kB activation
Having established that aspirin activated the c-Src pathway, I next wished to determine whether this
was linked to the effects of aspirin on activation of NF-kB signalling in CRC cells. To begin to
establish if there was a relationship, I firstly examined the kinetics of the response.
Aspirin-induces IicBa degradation before the nucleoplasmic accumulation of RelA (Stark et al 2001).
In order to further clarify the link between c-Src and the effects on the NF-kB pathway, western blot
analysis was performed on cytoplasmic extracts to analyse aspirin effects on cytoplasmic levels of
IkBcc (as a marker for activation of the NF-kB pathway) in relation to activation of c-Src and
phosphorylation of paxillin in time-course studies. Figure 3.8a demonstrates that aspirin-induced
activation of c-Src and phosphorylation of paxillin precedes the effects of the agent on degradation of
IkBcc (see also figure 3.4c and 3.7a). This response was also confirmed in the HT29 CRC cell line
(Figure 3.3e).
Upon IkBcx degradation, RelA relocates to the nucleoplasm of the cell. Therefore, I next used
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pathway. Quantification of nuclear levels of RelA demonstrated that following aspirin administration,
there was a trend for increased levels of nuclear RelA protein at 8 hours after administration of the
agent. This time-point was subsequent to the observed kinetics of both aspirin-induced c-Src Y416,
paxillin Y118 phosphorylation and aspirin-induced IkBoc degradation (Figure 3.8a).
I next quantified the levels of nuclear RelA and confirmed that nucleolar localisation of RelA
occurred at 10 hours following administration of the agent. This time-point confirmed aspirin-induced
nucleolar targeting of RelA occurred subsequent to c-Src pathway activation (Figure 3.8c). Taken
together, these lines of evidence suggest that aspirin activates c-Src upstream of the effects of the
agent on NF-KB signalling.
3.8 c-Src complexes with IkBo but not RelA
Several studies have described a functional role for c-Src in a protein complex involved in initiating
the degradation of IxBa (Abu-Amer et al 1998, Fan et al 2003, Jalal and Kone 2006, Kang et al 2005,
Rang et al 2006, Lluis et al 2007). Therefore, in view ofmy results suggesting that aspirin activated c-
Src prior to effects of the agent in the NF-KB pathway, I wished to determine if a direct physical
interaction between c-Src and members of the NF-KB family occurs in CRC cells in response to
aspirin treatment.
Immunoprecipitation experiments were undertaken to detect the presence of RelA/c-Src or iKBa/c-Src
protein complexes in SW480 cytoplasmic cell extracts, before and after 4 hours treatment with 5mM
aspirin. 1 found that c-Src was physically associated in immunoprecipitation complexes with IkBcx
before and after treatment with aspirin, but it was not found to physically precipitate in complexes
with RelA (Figures 3.9a and 3.9b).
Flowever, despite multiple attempts at replicate experiments, it was not possible to reliably report
whether this interaction was quantitatively increased or decreased after aspirin treatment.
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Figure 3.9 c-Src complexes with IkBo but not RelA
SW480 cells were treated with 5mM aspirin for 0 and 4 hours and then immunoprecipitation (IP) experiments
were performed with antibodies to c-Src (a) or RelA (b). a. IicBa is present in complexes with c-Src before
and after aspirin treatment. Input control lanes, Rabbit (R) IgG and light chain signals are given for negative
and loading controls. (n=3) b. RelA complexes with IkBoi before and after aspirin treatment but not with c-Src.
Input control lanes, Rabbit IgG and light chain signals are given for negative and loading controls (n=3).
R=Rabbit, M=Mouse, S=Sheep.
aspirin - + + +
Additionally, as discussed previously, in some reports, c-Src is involved in the direct phosphorylation
of IicBa tyrosine residues (Y42) in response to a range of stimulants (Elder et al 2002, Fan et al 2003,
Grosjean et al 2006, Imbert et al 1996, Koong et al 1994). Attempts to assess the Y42 phosphorylation
status of IkBcx with antibodies raised against the phosphorylated form of IkBcx Y42 were unfortunately
not found to yield interpretable results due to technical difficulties with the specific antibody.
3.9 Chemical inhibition of c-Src inhibits aspirin's molecular effects
Having established that aspirin activates the c-Src pathway upstream of effects on the NF-kB
pathway, I further explored this relationship using chemical inhibitors of c-Src. PP2 (4-amino-5-(4-
chlorophenyl)- 7-(f-butyl) pyrazolo [3,4-t/] pyrimidine), is a widely used (but relatively non-specific)
inhibitor of SFKs (Hanke et al 1996, Nam et al 2002). SU6656 (2-oxo-3-(4,5,6,7-tetrahydro-lH-indol-
2-ylmethylene)-2,3-dihydro-lH-indole-5-sulfonic acid dimethylamide) is a more specific SFK
inhibitor, with a high affinity to block c-Src. Modelling of SU6656 in the ATP binding pockets of c-
Src suggests it functions as a competitive inhibitor (Blake et al 2000). These chemical inhibitors affect
the kinase domain function of c-Src but not the Y418 phosphorylation status (Blake et al 2000).
Therefore, I utilised phosphorylation of paxillin Y118 as a surrogate readout of the effective inhibitory
dose of PP2/SU6656 on c-Src activity. For PP2, a dose of 10 pM was found to be effective, in keeping
with the published therapeutic window of this agent (Lu et al 2008) (Figure 3.10a). Similarly, 0.5pM
SU6656 was demonstrated as the most effective inhibitory dose on aspirin-induced phosphorylation of
paxillin Y118 (Blake et al 2000) (figure 3.10b).
Inhibition of aspirin-induced phosphorylation of paxillin Y118, by PP2/SU6656 pre-treatment,
suggested that the aspirin-induced phosphorylation of paxillin Y118 was c-Src dependent, occurred
downstream of aspirin-induced c-Src tyrosine kinase activity and was not a result of a non-specific
global phosphorylation of tyrosine residues ofmany cellular proteins by aspirin.
Having established the c-Src inhibitors blocked aspirin-induced increases in the kinase activity of c-






























Figure 3.10 Chemical inhibition of c-Src inhibits aspirin's molecular effects
SW480 cells were untreated (-) or pre-treated for 2 hrs with PP2 50pM (+) (a) or 10 pM (c,e,f), 2hr)
or SU6656 (Su) (0.5 pM) (b, d) then either untreated (-) or aspirin (Asp) treated (+) (5mM), 4hrs (a, b),
8 hrs (c+d ) or 16 hrs (e, f)) (a, b, c, d) Western blot analysis was performed on cell extracts using
antibodies to phosphorylated paxillin (Y118) (a, b) or IicBa (c, d). Blots were stripped and reprobed
for native paxillin. An antibody to actin was used as a control for protein loading,
a+b. Aspirin induces an increase in phosphorylated paxillin (Y118) which was abrogated by
pre-treatment with PP2 (a) or SU6656 (b) (n=3) c+d. Aspirin-induced IicBa degradation was abrogated
by chemical inhibitors of c-Src. (n=3) e. The nucleolar localisation ofRelA was examined using anti-RelA
immunocytochemistry as above. At least 200 cells in at least 5 random fields of view were analysed
and the proportion showing RelA in the nucleolus determined. Data are the average of 3 independent
experiments (+/- standard error) (n=5). g. Representative fields of view (x63 objective). Aspirin-induced
RelA nucleolar location is abrogated by c-Src chemical inhibition over a range of aspirin dosages.
indicated that both SU6566 and PP2 blocked aspirin-mediated degradation of IkBcx at a similar dose
to that which blocked aspirin-induced phosphorylation of Y118 paxillin (Figures 3.10c and 3.1 Od).
Next, using immunocytochemistry with antibodies directed against RelA and the nucleolar protein
fibrillarin, I found that PP2 pre-treatment also inhibited aspirin-induced RelA nucleolar sequestration
at 16 hours. This inhibition was observed over a range of aspirin dosages (figures 3.10e and 3.1 Of).
The above evidence suggests that c-Src plays a key role in transmitting an activation signal stimulated
by aspirin to induce Y118 phosphorylation of paxillin, degradation of IkBcx and nuclear/nucleolar
localisation ofRelA.
3.10 Genetic inhibition of c-Src inhibits aspirin's molecular effects
In common with many competitive ATP inhibitors, both PP2 and SU6656 have "off target" non¬
specific inhibitory actions/side effects affecting other SFK members or other protein tyrosine kinases.
Therefore, further dissection of the relationship between c-Src and NF-kB signalling responses to
aspirin was undertaken utilising genetic methods.
Firstly, to further investigate the role of c-Src in the NF-kB response to aspirin, I utilised vectors that
over-expressed either a wild-type form of c-Src or a kinase-dead equivalent. Empty control pUSEamp
vector was used as a control (Figure 3.1 la). SW480 CRC cells were transiently transfected with the
vectors then western blot analysis was used to analyse aspirin effects on cytoplasmic levels of IkBol
Consistent with the results obtained from c-Src chemical inhibitory studies, IkBcx degradation after
aspirin treatment was inhibited in cells expressing the kinase-dead form of c-Src but was maintained
in those over-expressing wild-type protein or control vector (figure 3.11b). Of note, wild type c-Src
cells expressed constitutively lower levels of IicBa at base line.
Furthermore, immunocytochemistry with antibodies to c-Src (to identify transfected cells) and anti-
RelA indicated that the increase in the number of cells showing nuclear RelA localization in cells
expressing the control vector or wild-type protein, was abrogated in cells expressing the mutant
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observation (figure 3.1 lc and 3.1 Id). These results confirmed that c-Src kinase function played a key
role in aspirin-induced degradation of IkBcx and the RelA response to aspirin.
3.11 Active c-Src activates NF-kB independently of aspirin
Whilst the above results suggested a role for c-Src kinase function in the aspirin-induced NF-kB
response, I also aimed to determine whether this response was specific to aspirin induced stimulation
of c-Src. Utilising cells which were transiently transfected with a vector to over-express a
constitutively active form of c-Src, c-Src (Y529F) effects on NF- kB signalling where assessed.
Firstly, I confirmed that the active mutant was effective by performing immunocytochemistry for
Y118 phosphorylated paxillin. Active c-Src over-expression induced widespread phosphorylation of
paxillin Y118 within the cell, producing a dramatically different appearance in contrast to those cells
expressing the wild type protein or the kinase-dead c-Src mutant, K297R (Figure 3.12a). The
membrane distribution was similar in nature to that observed following EGF treatment but of much
greater intensity. These data confirmed the activity of the mutant. On examination of NF-kB
signalling, I found that over-expression of the active form of c-Src mimicked aspirin-induced
molecular effects by inducing degradation of iKBa in SW480 cells after 24 hours (figure 3.12b).
Those cell populations which expressed the empty pUSEamp vector, or those expressing the wild type
form of c-Src, did not demonstrate an independent effect on IkBcx levels. Immunocytochemical
analysis demonstrated that expression of active c-Src induced an increase in nuclear RelA.
Computerised quantification of images confirmed that whilst wild-type c-Src transfected cells did not
independently induce RelA nuclear translocation, activated c-Src (Y529F) induced high levels of
nuclear RelA within transfected cells (figure 3.12c). Whilst expression of active c-Src induced nuclear
RelA, further analysis utilising the latter endpoint of RelA nucleolar targeting was undertaken.
Examining individual c-Src(Y529F) expressing cells demonstrated that c-Src (Y529F) did not appear
to induce RelA nucleolar localisation (figure 3.12d). As this is highly related to the pro-apoptotic
response to aspirin, there may be a requirement for an, as yet unknown, additional aspirin-induced co-
factor and/or other cellular response within the nucleus that targets RelA to the nucleolus.
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Figure 3.12 Active c-Src activates NF-kB independently of aspirin
SW480 cells were transiently transfected with an empty pUSEamp vector, kinase-inactive c-Src
expression vector (Src K297R), wild-type c-Src, or constitutively active c-Src (Src Y529F)
and harvested forty eight hours after transfection a. Anti-paxillin (Y118) immunocytochemistry.
Phosphorylated paxillin Y118 is highly expressed, primarily at the cell periphery in cells expressing
Src Y529F. This activation was in a pattern similar to that observed with aspirin and EGF
stimulation. pUSE Src K297R-and wild-type c-Src expressing cells demonstrated much-reduced
paxillin Y118 expression levels. DAPI was used as a nuclear marker. (n=3) b. Anti-lKBa western blot
analysis was performed. Src Y529F induced a decrease in the cytoplasmic levels of IicBa
that was not observed in the Src K297R, wild-type c-Src or pUSEamp vector transfected
cells (n=4) c. Anti-RelA/anti-c-Src immunocytochemistry was used to examine effects of expression
vectors on RelA localization (yellow arrows = transfected cells, yellow circles = nucleoli; areas
devoid ofDAPI surrounded by a hyperchromatic ring). Src Y529F induced RelA nuclear
but not nucleolar localisation. (n=4) d. The nuclear localisation of RelA in c-Src transfected cells was
quantified, using anti-RelA immunocytochemistry, as described in Figure 3.7. Src Y529F
induced RelA nuclear localisation (n=4).
3.12 Chemical inhibitors of c-Src inhibit aspirin's apoptotic effects (PP2/SU6566)
As NF-kB signalling is a key element in the aspirin-induced pro-apoptotic effect in CRC cells, and
experimentation to date has suggested a c-Src dependency in aspirin-mediated NF-kB activation,
further investigation was required to explore the role of c-Src role in the aspirin-induced pro-apoptotic
response.
Previous studies have demonstrated that nuclear fragmentation and classical apoptotic bodies are
rarely seen in conjunction with aspirin-induced apoptosis in SW480 CRC cells (Castano et al 1999,
Stark et al 2001). However, aspirin does induce an increase in the percentage of cells showing
externalization of phosphatidylserine (PS), a marker for apoptosis detected by FITC-AnnexinV
binding (Stark et al 2001). Apoptosis in the following studies was therefore detected using an
AnnexinV apoptosis assay kit which has been well characterised in the host laboratory.
Firstly, experiments were performed to confirm a pro-apoptotic response to aspirin in SW480 cells
(figure 3.13a). In order to assess the role of c-Src in the apoptotic response to aspirin, SW480 cells
were pre-treated with c-Src chemical inhibitors, prior to aspirin administration. PP2 pre-treatment was
partially effective in inhibiting aspirin-induced apoptosis over a range of aspirin doses. In addition, the
inhibitory effect of PP2 was of a similar dose to that which had inhibited aspirin-induced paxillin
Y118 phosphorylation, IkBo degradation and RelA nucleolar localisation (figures 3.13b and 3.13c).
Further confirmatory studies utilising the alternative c-Src chemical inhibitor, SU6566, also
demonstrated an inhibitory effect on apoptosis following aspirin at a dose which also previously
demonstarted an inhibitory effect on aspirin-induced paxillin Y118 phosphorylation, IkBoi degradation
and RelA nucleolar targeting (figure 3.13d).
3.13 Genetic modulation of c-Src function mediates aspirin-induced apoptosis
In keeping with the above data, I found that expression of kinase-dead c-Src also partially inhibited
aspirin-mediated apoptosis, compared to empty vector or wild-type protein expression. However,
there was also a slight increase in baseline apoptosis in cell populations expressing Src K297R,




























Figure 3.13 Chemical inhibitors of c-Src inhibit aspirin's apoptotic effects (PP2/SU6566)
SW480 cells were either untreated (-) or pre-treated with chemical inhibitors PP2 (b, c) or SU6656
(d) prior to aspirin (0(-), 5 (+) mM, 16hrs (a-d) or dose stated. The percentage
of cells in the population undergoing apoptosis was determined using AnnexinV-FITC apoptosis
assays. Data presented is the minimum of 3 independent experiments (+/- standard error),
a. Aspirin induces a dose-related pro-apoptotic trend in SW480 cells (n=4) b. PP2 reduced aspirin-
induced apoptosis over a range of PP2 dosages (n=5). c. SW480 cells were either untreated (-) or
pre-treated with PP2 (10 prn) for 2hrs prior to treatment with aspirin (5 or 10 mM). PP2 partially inhibited
aspirin induced apoptosis over a range of aspirin dosages. (n=4) d. SW480 cells were either untreated
(control) or pre-treated with SU6656 for 2hrs prior to treatment with aspirin (0(-), 5(+) mM; 16hrs).































Figure 3.14 Genetic modulation of c-Src function mediates aspirin-induced apoptosis
SW480 cells were transiently transfected with c-Src expression plasmids as described in
figure 3.10, (a, b) or SW480-SrcKD or SW480-pBpuro cells (c) were treated with aspirin (0 (-) 16hrs (+)).
The percentage of cells in the population undergoing apoptosis was determined using AnnexinV-
FITC apoptosis assays. Data presented is the minimum of 3 independent experiments
(+/- standard error), a. Src K297R expression partally inhibited the aspirin induced pro-apoptotic response (n=8).
b. Src Y529F expression induced a trend towards a pro-apoptotic response independent of aspirin effects (n=3)
c. SW480-SrcKD cells were resistant to the aspirin-induced apoptotic response whilst the response was
preserved in SW480-pBpuro cells (n=6).
The observation that over-expression of wild type c-Src does not affect the magnitude of the aspirin-
induced apoptotic response but that expression of an inactive form of the protein does inhibit this
response again confirms that the level of c-Src expression in CRC cells was less relevant to aspirin-
induced apoptosis than the functionality and level of c-Src activation.
Fig 3.14 demonstrates that there is a trend towards increased mean apoptosis in cells which were
transfected with Y529F active c-Src construct, compared to cells transfected with the empty vector.
However, this trend was not statistically significant. Aspirin induced an apoptotic response in both
those cells transfected with an empty vector and in those Y529F transfected cell populations, with a
partial trend towards a higher response in those cells transfected with the active c-Src construct and
treated with aspirin. Therefore, I found that this mutant produced a pro-apoptotic effect that increased
baseline levels of apoptosis, mimicking the pro-apoptotic effects of aspirin treatment. This effect was
increased further when aspirin was administered (figure 3.14b). Taken together, the above data
provides potential evidence that activation of c-Src can induce NF-kB signaling and function as a pro-
apoptotic stimulus in CRC cells.
As there is variation in transfection efficiency with transient transfections and concerns over the
potential for the confounding effect of non-transfected cell sub-populations, 1 investigated the use of
stably transfected SW480 cell engineered to express a kinase dead form of c-Src (SW480-Src KD), (a
gift from Professor Margaret Frame, Edinburgh Cancer Centre). Control cell were those stably
transfected with the pBpuro empty vector alone (SW480-pBpuro). To determine whether kinase-dead
c-Src also blocked the apoptotic effects of aspirin in this system, Annexin V apoptosis assays were
performed on SW480, SW480-SrcKD and SW480-pBpuro cells. Figure 3.14c demonstrates aspirin-
induced apoptosis was abrogated in SW480-SrcKD cells, compared to the control SW480-pBpuro cell
line. However, the aspirin-induced apoptotic response was also blunted in the control cell lines
transfected with the empty SW480-pBpuro vector. There are a number of possible explanations for
this, including that the inhibitory effect in these cells may not be c-Src specific, may relate to
contamination of the cell populations, or as a consequence of the vector transfection process or of the
specific vectors used.
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In further attempts to characterise these cell lines, the aspirin-induced RelA nucleolar targeting
response was assessed. Contrary to expectations, neither SW480-SrcKD nor SW480-pBpuro KD cell
lines demonstrated an aspirin-induced NF-kB response. Therefore, further experimental work in these
cell lines was abandoned in lieu of their further characterisation.
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3.14 Discussion
The present studies were undertaken to determine the upstream mechanisms by which aspirin
stimulates the NF-kB pathway and mediates apoptosis with specific emphasis on the role of the c-Src
tyrosine kinase. The work presented here provides new insights into the anti-tumour activity of the
agent. Firstly, I demonstrate that aspirin induces phosphorylation of c-Src and activates c-Src tyrosine
kinase activity. Secondly, 1 show that the NF-kB response to aspirin is mediated through c-Src and
finally, demonstrate that the apoptotic effects of aspirin are dependent upon the activation status of the
c-Src tyrosine kinase. These findings could have implications for the development of novel
chemopreventative agents and specifically, those that modulate c-Src kinase activity.
The evidence presented here suggests that aspirin induces c-Src activity in SW480 CRC cells, as
determined by Y418 phosphorylation of the protein and phosphorylation of the recognised c-Src
substrate, paxillin Y118. However, these data are in contrast to those of Kunte et al., (Kunte et al
2008) who reported that sulindac sulfide activates the negative regulator of c-Src, CSK, to inhibit c-
Src activity in HT29 CRC cells. This apparent difference may in fact relate more to the dose and type
ofNSAID used in his study and the particularly prolonged duration of exposure to the agent (72hrs).
Casanova et al., (Casanova et al 2008) also reported that the NSAID, Celecoxib, inhibits c-Src activity
in acute myeloid leukaemia cell lines. However, interestingly, in 4 out of the 5 cell lines presented
within his report, there was actually an apparent transient increase in c-Src Y418 phosphorylation at 4
hours following agent administration. Furthermore, this appeared to occur concurrently with the
proteolytic cleavage of Poly (ADP-ribose) polymerase (PARP) and activation of caspases. It is likely
that aspirin and NSAID effects on c-Src activity are related to the cellular context, chemical class,
timing and concentration used. Notably, these differential effects are consistent with the variation in
aspirin/NSAID-induced effects observed on NF-kB pathway signalling in different cell environments
and treatment conditions. For example, following TNFa pre-treatment of CRC cells, certain NSAIDs
inhibit activation of NF-kB signalling however, in the absence of TNFa pre-treatment, the converse
molecular response is observed (Stark et al 2001, Yamamoto et al 1999).
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Inhibiting c-Src activity, using chemical inhibitors or a kinase-dead mutant, reduced aspirin-mediated
degradation of IicBa and nuclear translocation of RelA, suggesting a relationship between these two
events. A variety of putative mechanisms for c-Src-mediated activation of the NF-kB signalling
pathway have been reported. Fan (Fan et al 2003) describes an IKK-independent pathway in which c-
Src directly interacts with IkBcx and directly phosphorylates the protein on tyrosine residue 42. They
suggested that this phosphorylation event leads to nuclear translocation of NF-kB in the absence of
IkBcc degradation. This response follows a c-Src physical interaction with IicBa. Other authors have
suggested that c-Src-induced tyrosine phosphorylation of IkBoi may potentially play a role in
controlling an alternative activation pathway concerning NF-kB (Lluis et al 2007). Kang et al., (Kang
et al 2005, Kang et al 2006) also suggested a physical interaction between c-Src and IkBcx is required
for LPS- and pervanadate-induced NF-kB activation. They also demonstrated that chemical and
genetic inhibitors of c-Src blocked this interaction. Kang et al., (Kang et al 2006) also described how
silica-induced NF-kB activation required tyrosine phosphorylation of IkBcx in macrophages. An effect
again blocked by c-Src chemical inhibitors.
These reports contrast with my results that indicate that c-Src plays a key role in aspirin-induced
degradation of hcBa. Interestingly, c-Src-mediated NF-kB activation has also been shown to involve
stimulation of intermediate kinase pathways, such as Protein Kinase C Alpha (PKCa) and IkBoi kinase
(IKK) signaling pathways. For example, IL-1 induced activation of c-Src has been linked to sustained
Serl 77/181 phosphorylation of IkBoc Kinase (IKKP), which in turn phosphorylates IkBoi at Ser 32/36,
leading to its polyubiquitination and proteosomal degradation. The Ser/Thr phosphatase PP2A,
dephosphorylates Ser 177/181 IKKp following IL-1 stimulation, thus allowing re-accumulation of
IkBol Interestingly, PP2A is a known substrate of c-Src. c-Src induces Tyr307 phosphorylation of
PP2A, which subsequently inhibits the activity of the phosphotase, causing sustained IkBoi
degradation and therefore NF-kB activation (Barisic et al 2008). Sustained IkBoi degradation is a
notable feature of aspirin-induced NF-kB responses and, in the context of previous studies evaluating
aspirin's chemopreventative potential in colorectal cancer cells, it has also been found to inhibit PP2A
(Bos et al 2006). These putative mechanisms classically induce NF-kB signalling by IkBoi serine
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32/36 residue phosphorylation and subsequent proteosomal-mediated IkBoc degradation (Mendez-
Samperio et al 2007) (Huang et al 2003a) (Lin et al 2006).
c-Src has also been described to be an integral part of the IKK complex. In work looking at the
NFxB-dependent COX-2 and ICAM-1 promoter activity, Huang et al. (Huang et al 2003b)) reported
that TNFa activated a c-Src dependent pathway, through activating NIK, which resulted in the
physical association of c-Src with IKK, phosphorylation of IKK tyrosine residues 188 and 199, and
NF- kB activation. Chemical and genetic inhibition abrogated this association and blocked the
activation of downstream NF-kB activity. Similarly, Lin et al. (Lin et al 2006) reported that Thrombin
induced a physical complex of PKC, c-Src and IKKa/p and that PKC chemical inhibition or over-
expression of a dominant negative c-Src blocked IkBoi degradation and NF-kB signalling induced by
thrombin. It will now be of extreme interest to identify the pathway that links c-Src to IkBcx
degradation in response to aspirin and NSAIDs. One potential mechanism may involve NF-kB
activation following aspirin-induced c-Src-mediated effects on the cytoskeleton.
CRC chemopreventative drugs are known to modify integrin-mediated signaling pathways, including
those responsible for motility and survival (Weyant et al 2000). c-Src has a key role in focal adhesion
turnover, and its role in invasion and motility is one of the best characterised (Serrels et al 2006).
Upon integrin engagement (as previously discussed in chapter 1.6.3), Focal Adhesion Kinase (FAK)
becomes phosphorylated at Y397, creating a high-affinity binding site for c-Src, which then further
phosphorylates FAK on other specific residues. The resultant c-Src/FAK complex phosphorylates a
number of other proteins, including Grb2 and other focal adhesion proteins, such as paxillin on Y118
and talin, causing the recruitment of other signalling proteins to the FAK complex. NSAIDs, such as
sulindac sulfide, have been shown to cause rearrangement of the actin cytoskeleton and the attendant
loss of focal adhesion plaques (Weyant et al 2000). These findings suggest that aspirin may stimulate
factors upstream of c-Src, potentially involving the extra-cellular matrix, through pathways that are
mediated by integrins and FAK. Further identification of these responsive elements would be
advantageous to fully characterizing if a specific receptor or molecular element exists which is
responsible for the aspirin-induced effect.
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Previous reports have suggested that c-Src substrates, including MEK/ERK and p38 are involved in
the molecular mechanisms underlying aspirin/NSAID-induced cell cycle arrest and apoptosis (Elder et
al 2002, Thorns et al 2007b). As discussed above, the host laboratory previously demonstrated that
p38 is activated in response to aspirin (Thorns et al 2007a) and that this effect is upstream of effects
on the NF-kB pathway. Since p38 is a known target of c-Src, it is possible that c-Src effects a
response on the NF-kB pathway through p38 signalling. Bernardi et al. reported that activation of c-
Src is required for the anti-proliferative effects of indomethicin in C6 Glioma cells and that chemical
inhibition of c-Src prevented NSAID-induced ERK activation and the pro-apoptotic response
(Bernardi et al 2006). Determining the pathways that link c-Src, p38 and NF-kB is an area where
further dissection of the molecular mechanisms by which c-Src activates or interacts with IkBoi
requires much further work.
Whilst increased c-Src activity has previously been associated with CRC progression and metastasis
(Mao et al 1997, Talamonti et al 1993, Termuhlen et al 1993), here we show that activating
endogenous c-Src using aspirin, or expressing a constitutively active form of the protein, induces
apoptosis in CRC cells. These findings are in keeping with those of Welman et al., who showed that
expression of active c-Src had growth inhibitory effects against FICT116 and SW480 CRC cells
(Welman et al 2006). In early reports in chicken embryoblasts, cells which expressed the
constitutively active form of c-Src induce a pro-apoptotic response and that this effect is further
amplified by the addition of aspirin/NSAIDs (Lu et al. 1997). Using an in situ approach in Drosophila,
it has also been reported that the cellular outcome of altering Src signaling is dependent upon the
degree of activation. Low levels of activation are associated with epithelial cell survival and
proliferation, whilst high levels of activation mediated apoptosis (Vidal et al 2007). Cells which over-
express c-Src, such as neoplastic colonic cells, can become sensitized to apoptotic stress in particular
cellular environments (Vidal et al 2007, Zhong et al 2002). Indeed, serum starvation and RAS/PI3K
inhibition favour pro-apoptotic signaling in cells which over-express activated c-Src (Webb et al
2000). This is of interest, as in my studies, treatment took place in low-serum media.
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Cells which were transiently transfected to over-express active c-Src had activated NF-KB signalling,
and a pro-apoptotic response, but in contrast to aspirin treatment, RelA nucleolar localization was not
observed. This suggests that whilst c-Src may be causally involved in mediating stimulation of the
NF-KB activation, there is a requirement for a further aspirin-induced co-factor to induce RelA
nucleolar localization. Although the nature of this cofactor is unknown at present, putative candidates
have been previously suggested, including NFBP, nucleophosmin/B23 and pl4ARF (Stark and Dunlop
2005). Work on the potential role of these candidates continues in other research streams within the
host laboratory.
Here, I employed the SW480 cell line as an experimental model, as it has been extensively studied in
relevant experiments in the host laboratory and the NF-kB and apoptotic response to aspirin within
this system have been well characterised. Furthermore, it was also felt that such a CRC cell line, with
low levels of c-Src expression, would allow over-expression studies to be carried out without the
confounding effects of high levels of endogenous protein. Research from this laboratory has
demonstrated that the aspirin-induced pro-apoptotic and NF-KB effects occur in a wide variety of
CRC cell-lines, irrespective of the known levels of high and low c-Src expression (Din et al 2004).
Through modification of the genetic expression levels of c-Src within SW480 cells and the use of
alternative cell lines, data presented here confirmed that the level of c-Src protein expression was not
relevant to the aspirin-induced response, rather the cellular activation status of the kinase.
It is clear that the mechanisms by which aspirin acts against CRC cells are complex. The diversity of
biological systems in which c-Src has been implicated suggests that there is unlikely to be a single c-
Src substrate target protein or pathway involved. The work presented here proposes a model for
aspirin/NSAID-induced modulation of NF-kB signalling and apoptosis. In the absence of
aspirin/NSAIDs, NF-kB signalling drives the transcription of anti-apoptotic genes. Following
treatment with aspirin/NSAIDs, c-Src is activated, leading to phosphorylation of paxillin, focal
adhesion disassembly, tubulin reorganisation, and stimulation of intermediate kinase pathways
resulting in downstream degradation of the NF-kB cytoplasmic inhibitor, IkBci. Subsequently,
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RelA/NF-KB complexes undertake translocation into the nucleus/nucleolus. Nucleolar localization of
RelA is causally involved in the repression of NF-kB driven transcription of anti-apoptotic genes
leading to cellular apoptosis (figure 3.15). These data therefore indicate that activation of c-Src is a
key component of the pro-apoptotic effects of aspirin in CRC and invokes molecular mechanisms
through stimulation of the NF-kB pathway.
These findings have relevance to the future development of chemopreventative agents by shedding
further light on the complex nature of the cellular and molecular effects of aspirin on CRC. I next set
out to translate these, and other, aspirin-related molecular findings derived from in vitro

















Figure 3.15 A model for aspirin/NSAID-induced modulation ofNF-kB signalling and apoptosis.
In the absence of aspirin/NSAIDs, constitutive NF-kB signalling drives the transcription of anti¬
apoptotic genes. Following treatment with aspirin/NSAIDs, c-Src induces phosphorylation of
paxillin (Y118), FAK aggregate dissolution and changes in P- tubulin cytoskeletal structure. It
also stimulates intermediate kinase pathways resulting in downstreamdegradation of the NF-kB
cytoplasmic inhibitor, IkBoc. Subsequently, RelA/NF-kb complexes translocate into the nucleus/
nucleolus. Nucleolar localization of RelA is causally involved in the repression ofNF-kb-driven
transcription of anti-apoptotic genes, leading to cellular apoptosis.
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The human intestine is a self-renewing organ, with one of the highest cell turnover rates in the body. It
is composed of stem cells, transit amplifying cells and terminally differentiated cells (including
absorptive enterocytes, mucus secreting goblet cells, hormone secreting entero-endocrine cells and
paneth cells) (Gregorieff and Clevers 2005, Wilson and Radtke 2006). The data described thus far,
was elucidated using in vitro culture of homogenous CRC cell lines. However, cell culture techniques
fail to accurately recapitulate the colonic architectural complexity, the diversity of the differentiated
colonocyte populations or reproduce the important regulatory role played by stroma/epithelial
interactions (Bjerknes and Cheng 2006). Therefore, more representative models are required so that
the in vivo relevance of data obtained in vitro can be explored.
There have been many attempts to produce experimental model systems that mimic normal intestinal
growth and differentiation. Previously, some of the most widely used systems to explore homeostasis
in the intestinal epithelium include animal models. The drosophila mid-gut demonstrates usefulness in
providing a platform for dissection of basic molecular processes (Jiang and Edgar 2011, Jiang et al
2011a, O'Keefe et al 2011, Shaw et al 2010) but fundamentally, experimental results cannot directly
translate findings with relevance to the human in vivo environment. Additionally, even more advanced
models often exhibit significant behavioural differences to the responses reported from research in the
human in vivo setting (Menke et al 2010, Schuller et al 2007). For example, mouse tumour models
clearly demonstrate fundamental differences between mouse and human gut. Humans carrying APC
deletions are susceptible to colon cancer, whereas APC-deficient mice suffer mainly from small
intestinal tumours (Moser et al 1995). Human and animal in vivo studies are also restricted by
important ethical considerations surrounding the toxicity and side-effect profiles of potential chemical
agents (such as inhibitors or agonists) required to dissect the molecular pathways involved in
colonocyte responses to agents and to explore regulation ofmucosal homeostasis.
Organotypic assays are occasionally utilised as they are more biologically relevant than simple
monolayer cell cultures (Honer zu Bentrup et al 2006, Kalabis et al 2008, Ootani et al 2009, Sato et al
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2009). However, these systems are labour-intensive and can be technically challenging. Therefore,
whilst a variety of experimental models continue to generate a wealth of valuable information, there
remains a requirement to translate findings into a more representative human context in order to
discover what is of genuine biological relevance.
Long-term in vitro organ culture (IVOC) of human ex vivo colonic mucosa could provide a more
representative model. One of the first descriptions of successful organ culture of human intestinal
mucosa was described by Browning and Trier in 1969 (Browning and Trier 1969). Prior to this,
experimentation had been limited by the observation of marked mucosal epithelial cell necrosis and
disintegration beyond 2-3 hrs in vitro. In Browning and Trier's experiments, small bowel mucosa was
biopsied from human volunteers and placed on small metal grids within supportive media, with
prophylactic antibiotics, in a high oxygen environment. It was found that explants were maintained to
reasonable architectural integrity within this culture system, for up to 24 hours after biopsy.
Interest in this technique increased, and by the late seventies a series of papers described longer term
intestinal mucosal survival within in vitro organ culture systems. Mak and Chang (Mak and Chang
1978) reported rabbit intestinal mucosa culture for 3 days, Autrup et al. (Autrup et al 1978b) initially
reported rat colonic mucosa maintained in culture for 4 weeks and subsequently human colonic
mucosal culture for up to 22 days in CMRL media (Autrup et al 1978a). Furthermore, Shamsuddin et
al., (Shamsuddin et al 1978) reported the maintenance of rat colonic epithelium within in vitro culture
for up to 9 weeks. Critically, in these early studies, a delayed but progressive and permanent
deterioration in the quality of the explant epithelium was noted, starting from relatively early in the
biopsy period. In fact, studies often reported only a simple monolayer of epithelium was actually
maintained beyond the early post-biopsy days in culture. Thus, undermining the strength of this model
to accurately represent the nature of the human colonic in vivo environment.
In a seminal paper in 1982, Senior et al. reported their experience with long-term in vitro organ
culture of human mucosa in Weymouth's media (Senior et al 1982). This group were the first to
describe "remarkable regenerative changes" within explants. They noted "regenerating crypt cells
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exhibiting intense proliferative activity" within explants after prolonged in vitro culture. This
proliferation led to repopulation of explants with epithelium and goblet cells and the reappearance of
complex architectural features such as cysts and crypts, producing an explant exhibiting features
consistent with baseline in vivo mucosal architecture. These results have been supported by findings
from other centres (Bareiss et al 2008, Schiff and Moore 1980). However, despite these initial
findings and the obvious potential of this model for testing of agents and investigation of the intestinal
regeneration system, reported description of the use of this model system have been relatively rare
over the last few decades (Schuller et al 2007).
The presence of actively proliferating cells and the reported reappearance of a diverse differentiated
colonocyte population, suggests that host colonic stem cells (CSCs) may remain present and active in
this culture system. These cells are defined by their ability for self renewal and the generation of
diverse cell lineages (Wagers and Weissman 2004). The recent identification of putative CSC markers
such as Lgr-5, BMI-1, musashi-1 and aldehyde-dehydrogenase l(ALDH-l) (Barker et al 2007,
Haegebarth and Clevers 2009, Huang et al 2009, Klonisch et al 2008, van der Flier and Clevers 2009,
Vermeulen et al 2008), together with the increasing recognition of the role of CSCs in the aetiology of
human colonic disease, such as CRC (Clarke and Becker 2006, Hill et al 2009), have stimulated much
interest in further characterising CSC regulation and control, differentiation and proliferation within
the human colonic mucosa.
Here, I set out to optimise an in vitro culture of human ex vivo colonic mucosa in order to provide a
more representative model system for testing aspirin-induced molecular responses. I also aimed to
evaluate the presence and dynamics CSC populations within this system.
Furthermore, as discussed in chapter 1, and following the data obtained in chapter 3, epidemiological
and experimental studies have provided strong evidence that aspirin and related NSAIDs have growth
inhibitory effects against CRC. This includes a wealth of evidence derived from studies focusing on
cellular and molecular changes induced by aspirin/NSAIDs within animal and human colonic mucosal
tissue.
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This laboratory has previously investigated agent-induced changes to NF-kB signalling in colonic
mucosa. It was shown that short-term treatment with aspirin induced IkBoi degradation prior to RelA
nuclear localisation in colorectal mucosal tissue and tumours from patients undergoing colorectal
resection (Stark et al 2001). Aspirin treatment studies were subsequently repeated in two animal
models, including a model of HT-29 xenograft tumours and in adenomas from APCMm+/" mice. In
these studies, aspirin mediated a time-dependent increase in phosphorylated IicBa, a parallel decrease
in cytoplasmic levels of the protein and was associated with a time-dependent increase in nuclear
RelA. Aspirin-induced NF-kB signalling in this setting was associated with apoptosis in vivo, in
benign neoplasm and malignant cells (Stark et al 2007). Critically, the aspirin-induced molecular
response observed in these animal studies was restricted to pre-cancerous or carcinomatous tissue, as a
similar response was absent from relevant normal colonic mucosa. This is similar to that reported in
studies examining NO-indomethacin/NO-aspirin induced suppression of AOM-induced p-catenin
expression, in which effects were present in colon adenocarcinoma but not in neighbouring mucosa
(Rao et al 2006). Given that some of the above studies suggest that aspirin induces a targeted effect,
limited to pre-cancerous/hyperproliferative colonic tissue in vivo, further development of the IVOC




4.2 Short-term culture of explants is dependent on culture media
Initial in vitro organ culture (1VOC) studies followed experimental protocols described by Moorghen
et al., (Moorghen et al 1996), who reported on the successful long term culture of human colorectal
mucosa obtained from patients undergoing surgical resections. In that report, colorectal explants,
maintained in serum-free RPMI media, underwent moderate degeneration within the first 24 hours but
epithelial proliferation, and regeneration of the cryptal architecture, was observed from 5- 21 days. Of
note, that report contrasts to those of other authors, who described poor tissue survival of colonic
explants grown in serum free medias (Dame et al 2010). In order to investigate this culture system, I
initially tested the use of non-supplemented RPMI media to culture colonic explants.
Patients, undergoing CRC resection were recruited into optimisation and treatment categories and
provided colorectal tissue, from which epithelial mucosal explants were obtained. Further details of
the recruitment, preparation and culture set-up are described within chapter 2, but briefly, upon
collection, biopsies of normal colorectal mucosa were divided into multiple pieces then plated on steel
wire gauze and bathed within medium-filled plates. Tissue was harvested at 0, 8 hours and 24 hours
following plating. Tissue was fixed in formalin; a citrate buffer retrieval system with microwaving
was used for antigen retrieval. Tissue architecture was analysed initially by H&E staining.
Immunohistochemistry utilizing antibodies directed against known colonic epithelial cell proliferation
markers (PCNA and Ki67) was also undertaken. These antibodies have been reported by previous
authors to be reliable in the setting of formalin-fixed samples and a citrate/microwave based antigen
retrieval (Cattoretti et al 1992, Holt et al 1997). Additional markers of early (activated caspases-3) and
late (Tunel assay) apoptosis were also utilized to evaluate the presence of apoptosis within the
cultured explants.
In the normal colonic mucosal tissue architecture, crypts are aligned parallel to the crypt bases. Crypts
are straight and narrow and mostly unbranched, separated by a thin rim of lamina propria, composed
of loose, areolar connective tissue. The distance between the crypts and the internal diameter of the
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crypts are constant (although slight variation in intercryptal spacing and occasional crypt branching
may occur in some normal biopsies). Crypts are composed of absorptive (tall columnar), goblet and
endocrine cells, with the ratio of tall columnar cells to goblet cells usually 4:1. The proliferative zone
in the base of the crypt is composed of low cuboidal CSCs. The muscularis mucosae is a thin smooth
muscle layer (inner circular and outer longitudinal layer) and the submucosa is composed of loose
connective tissue with collagen and elastic fibres. Meissner's plexus of autonomic nerve fibres with
ganglion cells are present within this.
Initial observations demonstrated that at time 0, the tissue was very similar in appearance to the
normal expected appearance of colonic mucosa described above. However, by 8-24 hours following
retrieval, colonic tissue underwent progressive rapid architectural deterioration, with epithelial layer
detachment, marked apoptosis and decreased proliferation (figure 4.1a). Histological examination
confirmed that this initial architectural disruption and degradation of the epithelium was progressive
and did not resolve in samples maintained in RPMI for 16 days of culture (figure 4.1c).
To determine whether this loss of architecture was associated with changes in cell proliferation, I
utilized immunohistochemistry with antibodies to PCNA and Ki67. Figure 4.1a demonstrates that at
time 0, Ki67 and PCNA staining was as expected, predominantly at the crypt base. However, the
number of cells staining for both markers and the overall intensity of this stain within the explants,
decreased at 8 hours and 24 hours. The use of secondary antibody only controls confirmed the
specificity of both of these antibodies (data not shown).
To examine the presence of apoptosis within the explants cultured in RPMI, I initially utilized
immunohistochemistry with antibodies to active caspases-3. This antibody only detects the cleaved
(and therefore active) form of the protein. I found that there were few positive cells at the tops of
crypts at time 0, in keeping with the expectation that this compartment contains crypt epithelial cells
which undergo apoptosis and are shed. However, the number of positive cells increased dramatically
after 8 and 24 hours. Furthermore, positive cells were also found at the base of the crypts. These data
were confirmed utilizing Tunel assays. This assay detects apoptotic cells on the basis of DNA
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4.1 Explant survival is dependent on culture media
Explants were cultured in either RPMI, modified CMRL or modified Waymouth's media & harvested
at the time points shown. Immunohistochemical analysis was performed on formalin-fixed tissue
using antibodies to proliferation markers PCNA, Ki67 and the apoptosis marker active caspases-3.
Explants undergo a decrease in proliferation and an increase in apoptosis when grown in RPMI
medium. (n=3) b. C3 damage scale scoring of explants after 24 hours by 3 independent and blinded
observers (see chapter 2.9 for further description of the C3 damage scale). (n=4) c. C3 damage scale
scoring of explants after 4 and 16 days in culture in RPMI compared to modified Waymouth's
media (graph represents mean +/- SE) (n=3).
fragmentation. Again I found that there were a small number of apoptotic cells at the top of the crypt
at time 0 and that this number increased substantially from 8 to 24 hrs.
Other authors have reported more success with the use of alternative culture medias, such as modified
Waymouth's or CMRL (Autrup et al 1978a, Schiff and Moore 1980, Senior et al 1982). Therefore, I
next tested short term growth of explants within these alternative media.
In order to aid in the comparison of growth conditions, the "C3"scoring system was devised. This
system is further described in more detail in chapter 2. Examination of H+E stained sections, and
subsequent C3 scoring, suggested that there was less tissue damage in these alternative media after 24
hrs (figure 4.1b). When longer-term outcomes after 16 days of in vitro culture were compared with
RPMI media, there was significantly less tissue damage observed in explants maintained in
Waymouth's media (figure 4.1c).
4.3 Longer-term outcome of explants are dependent on culture media
Given the improvement in tissue quality observed from short-term culture in these alternative media,
direct comparison of cultures maintained in RPMI, Waymouth's, or CMRL were performed to
provide a more a detailed histological assessment of explants in long-term culture utilizing these
alternative medias.
Explants cultured in Waymouth's media showed significantly improved survival over 16 days
compared to RPMI. When Waymouth's was compared to CMRL, I found that there was a gradual loss
of goblet cells, loss of surface epithelial continuity, epithelial detachment and shortening of the crypt
height from day 1 to day 8. However, critically, there was a subsequent divergence of explant
outcomes, dependant on the media (figure 4.2a). After day 8 in culture, explants maintained in CMRL
medium underwent progressive degradation until day 16, similar in nature to the response described
by Autrup et al. (Autrup et al 1978a). However, after 8 days of modified Waymouth's medium, there
was the development of epithelial-lined cystic formations within the stromal layer, surface epithelial
repopulation and the reappearance of complex colonic crypt architecture, containing secretory cells.
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4.2 Longer-term outcome of explants are dependent on culture media
Explants were cultured in either modified CMRL or modified Waymouth's media and harvested
at the time points shown. H+E staining of formalin-fixed tissue was used to analyse tissue
damage as above a. Histological explant structure demonstrated by H&E staining of formalin-
fixed samples b. C3 damage scale scoring of explants at the time points shown (n=3).
When histological sections were scored for C3 damage as previously described, it was clear that
cultures underwent initial crisis in both media but at 8 days in culture, samples plated in Waymoth's
media began to recover, showing demonstrably less damage than samples grown in CMRL by day 12.
This response mimics that previously described by Senior et al., and other groups (Moorghen et al
1996, Schiff and Moore 1980, Senior et al 1982) (figure 4.2b).
An attempt was made to grow biopsies beyond 16 days, however, 1 found that beyond 20 days in
culture, mucosal explants underwent progressive deterioration and loss of architectural maturity and
epithelium, irrespective of the culture constituent media. This was in keeping with previous reports
citing a gradual reduction in the regenerative capacity of ex vivo colonic tissue in prolonged in vitro
culture (Bareiss et al 2008) (data not shown).
These observations suggested that whilst a decline in explant tissue architectural quality occurred in
the early stages of culture within all media, media-specific factors induced the development of
complex architectural structures and cellular repopulation of explants at latter stages. In light of these
findings, focus was placed on optimizing the culture and conditions using Waymouth's media and
further characterising the cellular processes involved in the observed "regenerative changes" (Senior
et al 1982).
4.4 Optimisation of explant culture conditions
Oxygenation
Previous studies reported that the oxygen content of the gas phase is an important variable in
successful organ culture of colonic tissue. That is, explants maintained in normal air have a reportedly
worst outcome, than those maintained in high oxygen concentrations (Schiff and Moore 1980). Autrup
et al., postulated that this was due to reduced tissue lactate, reduced acid production and therefore
reduced tissue damage (Schiff and Moore 1980). However, the toxic effects of high oxygen
concentrations on cell culture are also well described (Wright and Shay 2006).
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To determine whether culturing oxygen concentration affected growth of colonic tissue in our hands, I
initially compared the histology of explants grown in high oxygen phase culture setting (78% 02)
compared with explants maintained in a low oxygen setting (38% 02). There was no significant
difference in explant outcomes between the two oxygen concentrations (figure 4.3a).
Antimicrobials
In the initial stages of optimisation, 65 patients were recruited and entered tissue into the various
optimisation and treatment arms. I found that a proportion of explants became infected with bacteria.
This was detected by visual cloudiness, abnormal colour change of the media (pH sensitive), abnormal
growths on explants, or light microscopy showing bacterial growth. Furthermore, subclinical detection
of infections was also confirmed by analysing subsequent histological slides (figure 4.3b). As explants
were being cultured in media with added prophylactic antibiotics, the development of infection within
this setting caused suspicion that multidrug resistance (MDR) bacteria may be involved. MDR
bacteria are known to be commonly present within the NHS clinical environment and therefore
explants obtained from patients from such environments have the theoretical potential of hosting
bacteria that are resistant to the prophylactic antibiotics in laboratory culture use.
In order to provide antibiotic sensitivities of infecting bacterial species (to detect the presence of
MDR), bacteriological culture of a selection of infected cultures and sensitivity testing of the resultant
bacterial growth was undertaken through an arrangement with the local NHS microbiology laboratory
(Dr Pota Kalima, Department of Laboratory Medicine, Western General Hospital, LUHT, Edinburgh).
Due to labour and costs involved in this process, analysis was limited to 7 explants. 500ul of media
fluid was obtained from 4 infected explants (RBI9, RB21, RB23, RB24) and 3 apparently healthy
explants (RBI7, RB20, RB24). Media was obtained by sterile methods and transported in sterile tubes
at room temperature to the bacteriology laboratory within 24 h. Similar to the process involved in the
normal standard of care for patient samples, swabs were dipped in the media and were inoculated onto








4.3 Optimisation of explant culture conditions
a. Explants were grown in either low (37% 02) or high (78% 02) oxygen conditions then
harvested after 16 days in culture. All results are representative of at a minimum of 3 separate experiments
b. H&E staining of formalin-fixed samples demonstrating appearance of progressive
bacterial infection of explants in prolonged culture, c. Decreased damage scores were observed
in long term culture of explants from left colon. C3 damage scoring (determined as in figure 4.2)
were compared for damage scoring of right- (n=3) and left- (n=16) sided sourced explants in
Waymouths media at 16 days. All measures of damage scale determined by 3 independent and blinded observers.
incubated, one aerobically and the other anaerobically, at 37°C for 48 h. All plates were inspected
daily for visible growth and any microorganisms present were identified using standard laboratory
procedures. Antibiotic sensitivities were assessed using standard antibiotic growth inhibitory discs.
Four of the seven (57%) explants demonstrated bacterial growth. None of the apparently healthy
explants exhibited obvious bacterial growth except for RB24. However, this sample demonstrated no
growth at day 4, but yeasts and anaerobes were identified by 24 days. This later growth was assumed
to be the result of potential cross-contamination within the Billroth chamber from another infected
sample. Of the four samples provided from infected cultures, RBI 9 and RB23 demonstrated infection
with yeast, RB19, RB21 and RB23 demonstrated infection with anaerobes (all sensitive to
metronidazole) and RB21 and RB22 demonstrated infection with Escherichia coli (all resistant to
amoxicillin but sensitive to gentamicin).
In an attempt to increase infection-free yields, in addition to penicillin/streptomycin, which was
routinely added to culture media, a commercial antimycotic/antibiotic mix containing amphoteracin B
and gentamicin was included in the subsequent culture media (see methods section 2.2).
Anatomical harvest site
Analysis of data gathered through the recruitment process suggested that there was an association
between anatomical site of colonic resection and successful, non-infected long-term growth of
explants. It appeared that colonic explants derived from right-sided resections (right hemicolectomies
(77%)) had a trend towards increased incidence of failure due to infection, compared to that from left-
hand sided resections (left hemicolectomies (36%), anterior resections (48%)). Additionally, there was
an association between C3 tissue damage scores at day 16 and the anatomical site of the tissue source.
Right-sided resections exhibited greater explant C3 tissue damage scores compared to left-hand sided
resections (p<0.06) (figure 4.3b). Therefore, a decision was made to focus subsequent recruitment of
mucosa from patients undergoing left sided colonic resections.
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Success of the model system
In total, initial optimisation experiments utilised tissue from 38 individual patients, which were all
maintained in culture for 16 days. Successful explant outcome was defined as the appearance of
organised mucosal epithelial structures (crypts), with epithelialisation of the surface of explants at 16
days, in the absence of infection. Using this standard, the initial overall success rate from these
experiments was 28.9%.
However, following optimisation of the protocol (which included the use of Waymouth's media, the
inclusion of antimycotic/antibiotic, stable oxygenation conditions and a preference for utilising only
tissue derived from left sided colonic sources, the success rate was markedly improved (8/13 cultures
= 62% success). This success rate is higher than the 33% previously observed using IVOC of human
colonic mucosa (Autrup 1980).
4.5 Characterisation of apoptosis and proliferation rates in long-term culture
Given the above histological findings, a more detailed characterization of the role of proliferation and
apoptosis during prolonged IVOC culture was undertaken.
Firstly, using similar techniques described previously involving immunohistochemical markers of
early (active caspase-3) and late (Tunel assay) apoptosis, I examined explants for apoptosis. This was
increased in samples obtained between days 4 and 8 but subsequently there was a decrease in the
levels of apoptotic markers, returning to a level relative to baseline by day 16 (Figure 4.4a and 4.4b).
During the initial stages, apoptotic marker expression was confined to the explant epithelial layer,
particularly the crypt lumen and detached epithelial cells. There was little apoptotic marker expression
within the stroma. Following the initial phase, apoptotic marker expression reduced to return to
baseline levels for the remainder of the culture process.
To quantify explant proliferation, immunohistochemical markers of cell proliferation (Ki67 and
PCNA) were also analyzed. Proliferative markers at baseline were expressed in the lower third of the
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4.4 Characterisation of apoptosis in long-term culture
Explants were harvested at 4 day intervals for the 16 days. To assess apoptosis, immunohistochemical
analysis was performed on formalin-fixed tissue, with antibodies to the apoptosis markers, Tunel and
active caspases-3. Images were captured at x20. Representative immunocytochemistry images
of explants. All results are representative of at a minimum of 3 separate experiments.
b
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4.5 Characterisation of proliferation in long-term culture
Explants were harvested at 4 day intervals for 16 days. To assess proliferation immuno-
histochemical analysis was performed on formalin-fixed tissue, with antibodies to the
proliferation markers, Ki67 and PCNA. Images were captured at x20. a Representative
PCNA immunocytochemistry images of explants. b. The number of Ki67 positive cells
were counted in a minimum of 5 separate fields. Graph represents mean of 3 independent
experiments +/- standard error at the time points shown.
colonic crypt. During the initial apoptotic phase, there were few actively proliferating cells apparent,
however subsequently, the number of cells expressing proliferative markers increased within surface
epithelium and focally within early epithelial cystic structures developing within the stroma. PCNA
expression was strongest in the lower third of crypts and within these early epithelial cystic structures
within the explant stroma. As the crypt architecture developed, PCNA expression was observed
throughout the full length of the crypts (Figure 4.5a). The proportion of Ki67 positive epithelial cells
was evaluated and confirmed that proliferation decreased in the earlier stages of culture, after which
there was a period increased proliferation between days 8 and 12, returning to baseline levels by day
16 (figure 4.5b).
Taken together these data suggest a biphasic process. Firstly, characterised by rapid deteriorl64ation
in explant architecture within the first 24 hours after retrieval and a subsequent apoptotic phase lasting
until days 4-8. During this, cells became detached from the crypts, crypt width was reduced, crypt
height was shortened and there was a loss in secretory/goblet cell numbers. This phase was followed
by progressive repopulation of the explant, and the eventual reappearance of goblet cells within
maturing colonic crypts.
4.6 Differentiated cell population dynamics in long-term culture
Given the subsequent proliferation observed in longer-term culture, cell type-specific
immunohistochemical analysis was undertaken to further characterize the type of cells that
repopulated explants and to assess the diversity of the populations which resulted from this process.
The epithelial cell marker, P-catenin, was employed to determine changes in epithelial cell number
(figure 4.6a). P-catenin staining, and quantification of the number of positive cells, confirmed that
whilst epithelial cell counts reduced during the apoptotic phase of culture, this was followed by a
subsequent rapid increase in the epithelial cell population at later culture time-points (Figure. 4.6b).






4.6 Epithelial cell populations during long term culture
Paraffin embedded formalin-fixed explants were harvested at 4-day intervals for 16 days.
At the times shown, immunohistochemistry was used to identify cells of different lineages
a. P-catenin used to identify epithelial cells, b. The number of P-catenin positive staining cells
reduces before returning to baseline appearance at day 16. These cells were counted in a
minimum of 5 separate fields. Graph is representative of average number of cells
+/- standard error (3 separate experiments).
Differentiated colonocytes with absorptive/sampling function, have a brush border of microvilli to
increase the cell surface area. This is highly positive for the marker protein Vil-1. Within the initial
apoptotic phase at days 4 to 8, enterocytes positive for this microvilli marker became discontinuous,
accompanied by a reduction in overall enterocyte numbers. However, during days 8 to 12, positively
staining cells were present both within epithelial-lined cystic structures and in increasing numbers on
the explant surface. By the latter stages of explant culture (day 16), the pattern of Vil-1 positively
staining cells mirrored that observed within samples at day 0 (Fig. 4.7a).
Muc-2 is a marker of Mucin, produced by colonocytes of the secretory/goblet cell lineage.
Immunohistological analysis demonstrated that the proportion of goblet cells rapidly decreased in
initial stages of culture, with subsequent increases during the later proliferation phase. The goblet cell
proportion of the total epithelial cell population rebounded after initial decline. Cell counts
demonstrated that at day 16, the proportion of Muc-2 positively staining cells within epithelium,
reflected that observed at day 0 (Fig. 4.8a and 4.8b).
There are a small number of entero-endocrine cells within colonic crypts which perform paracrine and
exocrine functions. There were typically 1-2 entero-endocrine cells (positively staining for the marker
Chromogranin A) per crypt at day 0. Whilst the presence of positively-staining cells could not be
detected at culture midpoints (days 4-8), Chromogranin A-staining cells were subsequently observed
in small numbers at day 16 (figure 4.9a).
Whilst immunohistochemistry using the paneth cell marker lysozyme was performed, no positive
staining was detected. However, given that paneth cells are usually only present in the small bowel,
caecum and proximal colon, and that the presence of paneth cells more distally in the colon is usually
only associated with metaplastic change in chronic infection, together with our preference for left-




4.7 Vil-1 positive cell populations during long term culture
Paraffin embedded formalin-fixed explants were harvested at 4-day intervals for 16 days.
At the times shown, immunohistochemistry was used to identify cells which were positive
for the epithelial marker Vil-1 a. Representative micrographs are shown of Vil-1 positive cells.
All results are representative of at a minimum of 3 separate experiments
Days in culture
4.8 Secretory cell populations during long term culture
Explants were harvested at 4-day intervals for 16 days and
then paraffin-fixed for immunohistochemistry
to identify cells of different lineages
a. Representative micrographs are shown of
Muc -2 positive cells, b. The number ofMuc-2 staining
cells reduces before returning to baseline appearance at
day 16. Muc-2-staining cells were counted and compared
with number of epithelial cells in 5 separate fields.
Graph is representative of average number of cells +/-
standard error (3 separate experiments). All results are
representative of at a minimum of 3 separate experiments.
There is rapid initial decrease in the number ofMuc-2
positive cells, before increasing at later stages in culture.
The number ofMuc -2-positive staining cells reduces before














4.9 Entero-endocrine and smooth muscle cell populations during long term culture
Paraffin embedded formalin-fixed explants were harvested at 4-day intervals for
16 days. At the times shown immunohistochemistry was used to identify a. chromogranin—positive
and, b. Smooth muscle a-actin-positive cells.
a. Representative micrographs are shown of chromogranin-A positive cells at baseline and
day 16 in culture with secondary antibody only control (neg).
b. Deterioration in the size and quality of the a-actin positive cells within
the smooth muscle layer (yellow arrows) and decreased peri-cryptal myofibroblasts
over time during prolonged culture (magnification x20). c. High power image (x63)
of crypt base demonstrating crypt surrounding myofibroblasts at time 0 (yellow arrows).
All results are representative of at a minimum of 3 separate experiments
In conclusion, I found that after prolonged culture, explants exhibited a diversity of cell population,
resembling the populations observed at the time of initiation of culture. This suggested the 1VOC
model provided a representative platform of actively proliferating human colonic mucosa at day 16.
4.7 Identification and characterisation of colonic stem cells in IVOC
The presence of actively proliferating cells and the reappearance of diverse differentiated colonocyte
populations within explants suggested the presence and activity of colonic stem cells (CSC). In the
small bowel, it is thought that around 6 CSCs exist either as Crypt Base Columnar cells which over-
express the proliferation marker Ki67 (Barker et al 2007), and are interspersed with basal Paneth cells,
(Bjerknes and Cheng 2005, Sato et al 2009) or reside in the +4 position immediately above basal
Paneth cells (Bjerknes and Cheng 2005). However, less is known about the location and regulation of
large bowel CSCs, particularly in human tissue.
To examine for the presence of CSCs and to investigate their role in long-term culture of colonic
explants, I next used immunohistochemistry with the putative stem cell markers Lgr-5 and BMI-1.
Lgr-5 is a target of active Wnt signalling and has recently been identified as a putative CSC marker
(van der Flier and Clevers 2009). Its expression is restricted to the base of the crypt, in particular, the
crypt basal columnar (CBC) cells (Haegebarth and Clevers 2009). This is particularly interesting as,
described above, positive staining for cell proliferation markers Ki67 and PCNA during days 8-12 of
in vitro culture localised to the lower third of the early colonic crypts (figure 4.5c), akin to the location
of the putative colonic stem cell compartment (Barker et al 2008). Indeed, I found that whilst there
were few positively staining Lgr5+ cells at baseline and throughout the early apoptotic phase, by day
8 there was an increase in positively staining cells localising to the epithelium of early crypt-like
structures. By day 16, Lgr5+ cells were more frequently located at the base of cryptal structure
(Figure 4.10a).
BMI-1 is involved in the self-renewal of neuronal, haematological and leukemic cells but has also
been suggested as a putative marker of intestinal stem cells in vivo (Sangiorgi and Capecchi 2008).






Figure 4.10 Identification and characterisation of colonic stem cells (CSC) in IVOC
Paraffin embedded formalin-fixed explants were harvested at 4-day intervals for 16 days.
Fluorescent immunohistochemistry was used to identify CSC markers a. Lgr-5 and b. BMI-1.
a, b. Immunohistochemistry images of CSC markers during IVOC (white arrows =positively
staining cells) and high power images. Upper panel images were captured at x20, the lower
high panel high power at x63. Positive (tumour) and negative (Neg=secondary antibody only)
control micrographs are also shown. All results are representative of at a minimum of 3
separate experiments
gastrointestinal tract (Sangiorgi and Capecchi 2008). BMI-1 positive cells were found to localise to
nuclei in the lower third of colonic crypts at day 0. However, by day 8, aggregates of positively
staining BMI-1 cells were found within early cryptal structures. By day 16, levels of BMI-1 staining
within the crypt cell nuclei was notably increased, with positive cells populating more than half of the
lower portion of the regenerating crypt, akin to the pattern of Ki67/PCNA distribution described
previously (figure 4.10b).
Previous reports have suggested that stromal elements can produce inhibitory factors that prevent
stem-cell proliferation and modulate differentiation within the colonic crypt (Vermeulen et al 2010).
Many of these factors have been identified to originate from the smooth muscle layer/myofibroblasts
that surround the lower 3rd of crypts. In order to observe if physical changes within this muscle layer
occurred in prolonged culture, immunohistochemistry was performed to detect a-actin, a marker
expressed by smooth muscle cells. Prolonged culture of explants resulted in marked degeneration in
cell numbers and size of this smooth muscle layer in all explants (Figure 4.9b).
4.8 Regenerative cyst characterization
Further examination of the nature of the cystic structures within the regenerating colonic mucosal
tissue in long-term culture was undertaken, as they represented a potential precursor of the later
development of more architecturally-advanced colonic crypt structures. The epithelial walls of the
cysts were composed of a thin layer of epithelium (P-catenin, Vil-1). This demonstrated both high
levels of cells which were positive for proliferative markers (Ki67, PCNA) and the stem cell marker
(BMI-1) and were also composed of both types of differentiated epithelial cell (Vil-1, Muc-2) (Figure
4.11).
Lgr-5 staining of crypts was undertaken but there were no detectable positive staining cells. This may
be due to a. the crypts being lined by highly proliferative cells (as demonstrated by ki-67, PCNA and
BMI-1 staining) but not stem cells or b, the cross-sectioning of the cysts sample missing individual
stem cells positive for the Lgr-5 marker. The experiments were repeated several times but no obvious
Lgr-5 positively staining cells could be detected.
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Having conducted various optimisation phases and characterised this model, I now focused on
assessing the effects of aspirin on the model in the supra-cellular context of the epithelium as an
organ.
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Figure 4.11 Regenerative cyst characterization
Micrographs of immunohistological staining of stromal epithelial cysts from samples at
day 12 in culture stained for markers of proliferation (a. Ki67, b. PCNA, c. BMI-1) and
differentiation (d. beta-catenin, e. Muc-2, f. Vil-l)(n=3).
4.9 Aspirin-mediated modulation of c-Src in colonic mucosal explants
As presented in chapter 3, aspirin induces phosphorylation of c-Src in CRC cell lines and this
phosphorylation plays a key role in the apoptotic effects of the agent. To determine whether aspirin
had a similar effect on colonic mucosa in vivo, I utilized the above protocols developed for growing
human colonic mucosa as explant cultures.
The first aim was to evaluate whether c-Src could be detected in IVOC tissue. Western blot analysis
was initially undertaken to optimise the detection of c-Src within human mucosal tissue. Previous
CRC cell line findings indicate that aspirin activates c-Src in a time-dependent manner through a
mechanism involving phosphorylation of the c-Src Y416 residue. Western blot analysis was initially
utilized to examine the effects of aspirin on day 16 cultures in time-course studies. Similar to CRC
cell lines, 1 found that in 3 of 4 cultures treated, aspirin induced an increased in c-Src Y416
phosphorylation within 4 hours of treatment. There was a return to baseline levels 16 hours after
treatment. This was consistent with the previous kinetics of the transient c-Src activation observed in
CRC cell lines. In contrast to phosphorylated c-Src Y416, re-probing of the membranes revealed no
change in the levels of native protein (figure 4.12a).
Immunocytochemistry in CRC cell lines revealed aspirin induced changes in c-Src cellular location
and activation in response to aspirin (see chapter 3). Therefore, I next performed
immunocytochemistry on aspirin-treated explants. Unfortunately, despite extensive optimization
attempts, detection of native c-Src by immunocytochemistry was not successful, in that the antibody
gave a diffuse, non-specific staining pattern. However, I was able to specifically detect activated c-Src
(Y416 phosphorylated). I found that at time 0, phospho-c-Src Y416 was located primarily at the
luminal surface of enterocytes, lining the upper levels of colonic crypts. High power magnification
demonstrated that the signal for phospho-c-Src Y416 was highest at the plasma membrane, and
focally in aggregates along the membrane surface of these enterocytes. In keeping with a role for c-
Src in cell adhesion structures, this signal was found to be most highly concentrated in aggregates at








4.12 Aspirin-mediated modulation of c-Src in colonic mucosal explants
16 day explants were either untreated (0) or treated with 5mM aspirin for the time points stated
a. Western blot analyis on whole cell extracts from aspirin-treated day 16 explants. Extracts were
probed for phospho-c-Src Y416 and native c-Src. y-tubulin was used as a protein loading control (n=3)
b. Anti-phospho-c-Src Y416 immunohistochemistry was performed on time 0 explants. DAPI was
used as a nuclear marker. Activated c-Src expression localises to the plasma membrane of epithelial
cells lining upper third of colonic crypts (yellow arrow), c. Anti-phospho-c-Src Y416 immuno¬
histochemistry was performed on aspirin-treated explants. DAPI was used as a nuclear marker.
Activated c-Src expression is increased in the epithelium of regenerating crypts but this is less
pronounced in surface epithelium (yellow arrow). Secondary antibody only negative control is
also represented (Neg) (all data minimum of 3 experiments).
Interestingly, enterocytes within regenerating crypts expressed higher levels of activated c-Src on their
cell surface compared to baseline levels (figure 4.12c). c-Src activation is highly associated with CRC
progression and analysis of hyperproliferative and premalignant colonic epithelium within the AOM-
rat model found that prior to the development of neoplastic lesions, the tumor suppressor gene C-
terminal Src kinase (Csk) (a negative regulator of c-Src) was down-regulated, with a concomitant
increase in c-Src activity (Kunte et al 2008). Increased expression within the explant may therefore be
a reflection of underlying epithelial hyperproliferation within regenerating crypts.
Colonocytes on the explant surface demonstrated a change in the pattern of c-Src membrane
aggregates following aspirin administration (figure 4.13a). Namely, both the size and density of
membrane focal aggregates decreased. This pattern had similarity to the aspirin-induced effect on
FAK/phospho-c-Src Y416 aggregates in CRC cell lines (chapter 3.5). Attempts to further characterise
these membrane aggregates were unsuccessful as, despite optimisation attempts, it was not possible to
detect a positive signal in immunohistochemistry of explant tissue utilising the currently available
FAK antibody.
4.10 Aspirin modulation of paxillin in mucosal explants
Given that aspirin induced phosphorylation of c-Src Y416 and changes to its membrane location,
further confirmation of c-Src activation within explants was undertaken. I had previously
demonstrated that phosphorylation of paxillin at Y118 occurs in response to aspirin and that this was
dependent on c-Src kinase activity. Therefore, I next examined paxillin phosphorylation in mucosal
explants.
Immunohistochemical analysis of time 0 explants demonstrated the location of phosphorylated
paxillin Y118 mimicked that of activated c-Src in human colonic mucosa in that the paxillin Y118







Figure 4.13 Aspirin-mediated modulation of c-Src aggregates in colonic mucosal explants
16 day explants were either untreated (NT) or treated with 5mM aspirin for 4 hours
a. Anti-phospho-c-Src Y416 immunohistochemistry performed on aspirin-treated explants.
DAPI was used as a nuclear marker. Focal aggregates of phospho-c-Src Y416 undergo











4.14 Aspirin modulation of paxillin in mucosal explants
Explants were either untreated (NT) (a, b) or treated with 5mM aspirin for the time points stated (c).
a.b. Anti-phospho-paxillin Y118 immunohistochemistry was performed on explants.
DAPI was used as a nuclear marker. Phosphorylated paxillin Y118 signal localises to the
plasma membrane of epithelial cells lining the upper third of colonic crypts (yellow arrow) (n=7)
c. Western blot analyis performed on whole cell extracts from aspirin-treated day 16 explants
(n=3). Extracts were probed for phospho-paxillin Y118, native paxillin and y-tubulin
was used as a protein loading control.
Western blot analysis of extracts from aspirin-treated explants demonstrated increased
phosphorylation of paxillin Y118 at 4 hours following administration of the agent, concurrent with the
above kinetics of the aspirin-induced phosphorylation of c-Src Y416 and consistent with the response
observed in CRC cell lines. However, 16 hours following treatment, the levels of phosphorylated
paxillin Y118 decreased, in parallel with the overall level of the native protein (figure 4.14c). The
reasons for this, when set against the findings for activated c-Src at 16 hours, are unclear at present.
These findings support the earlier data obtained from CRC cancer cell lines, that aspirin induces
phosphorylation/activation of c-Src and phosphorylation of paxillin Y118 within hours in human ex
vivo colonic mucosa.
4.11 Aspirin-induced NF-kB Signalling and apoptosis in human colonic mucosal explants
Previous findings suggested the c-Src-dependent apoptotic effect of aspirin occurred through
modulation of the NF-kB signalling pathway (see chapter 3). Therefore, I next assessed the effects of
aspirin on NF-kB signalling and apoptosis within the colonic mucosal explants.
Firstly, I examined aspirin effects on cytoplasmic levels of IxBa. Western Blot analysis of IkBoi levels
in aspirin-treated IVOC tissue extracts found that these decreased 16 hrs after treatment, subsequent to
phosphorylation of paxillin (figure 4.15a). Next, I examined nuclear levels of RelA using
immunohistochemistry (Stark et al 2001). In aspirin treated samples, increased RelA nuclear staining
of cells was noted along the uppermost mucosal surface of the crypts compared to controls (figure
4.15b). However, due to the nature of the staining, the complexity of the plane of tissue dissection for
mounting and variability of the nuclei, quantification of this effect was not possible.
As NF-kB activation is a key element of the pro-apoptotic effect of aspirin in CRC cells, experiments
to detect aspirin-induced apoptosis, using a known marker of apoptosis, such as activated caspase-3,
was undertaken. Aspirin induced a time-dependent increase in activated caspase-3 at 16 hours after
administration (Figure 4.16a). Furthermore, the increased detection of the apoptotic marker occurred
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subsequent to aspirin-induced phosphorylation of paxillin Y118 and concurrently with detection of
aspirin-induced IkBci degradation (figure 4.15a).
Previous studies from this laboratory have demonstrated that nuclear fragmentation and classical
apoptotic bodies are rarely seen in conjunction with aspirin induced-apoptosis in SW480 CRC cells
(Stark et al 2001). However, histological assessment of aspirin-treated 16-day explants demonstrated
that aspirin induced apoptotic bodies, breaks in epithelium and higher tissue damage scores (figure
4.16b and 4.16c).
4.12 Ex vivo growth of colonic adenomatous polyps
Aspirin appears to prevent the initiation rather than the progression of CRC. Therefore, in order to
further extend the relevance of these studies for testing aspirin and anti-cancer agents, ex vivo culture
of colorectal adenoma tissue was also undertaken. 3 patients were recruited for colorectal polyp
culture optimisation protocols. Ex vivo culture of colorectal adenomas from these 3 patients was
attempted. However, I found that polyps underwent massive apoptosis and tissue destruction both
macroscopically and histologically without subsequent regeneration. Explants were characterised by
detachment of the surface epithelium and disintegration of any remaining epithelium (figure 4.17a).
It became apparent that the growth conditions for these neoplastic lesions were dissimilar to normal
mucosa and would require considerable optimisation. Unfortunately, as outlined in the methodology
section, the material obtained from adenomas was also of insufficient quantity to allow testing of












4.15 Aspirin-induced NF-kB Signalling in human colonic mucosal explants
Explants were either untreated (0) or treated with 5mM aspirin for the time points stated
(a), or 4 hrs (b) a. Western blot analyis on whole cell extracts from aspirin-treated day 16
explants. Extracts were probed for phospho-paxillin Y118, native paxillin, IicBa and y-tubulin
was used as a protein loading control. Results consistent in 3/4 experiments, b. Anti-RelA
immunohistochemistry was performed on explants. DAPI was used as a nuclear marker.
Aspirin induced RelA translocation to the nucleus in surface cells (yellow arrow)(n=3).
+
aspirin
4.16 Aspirin-induced apoptosis in human colonic mucosal explants
Explants were either untreated (0) or treated with 5mM or lOmM aspirin for the time points stated
(a), or 16 hrs (b). a. Western blot analyis on whole cell extracts from aspirin treated day 16 explants.
Extracts were probed with activated caspase-3 and y-tubulin was used as a protein loading control,
b. C3 damage scale scoring of aspirin treated explants (n=3). All measures of damage scale were
determined by 3 independent and blinded observers. Graph representative ofmean score
(+/- standard error), c. Histological explant structure demonstrated by H&E staining of formalin-
fixed samples of aspirin-treated explants (arrows= apoptotic bodies).
day 0 day 4
4.17 Ex vivo growth of colonic polyps
a. Histological explant structure demonstrated by H&E staining of formalin-
fixed samples at day 0 and day 4. (results are representative of 3 independent
experiments.
4.13 Lithium chloride activates colonic mucosal Wnt signalling
Given the failure to maintain polyps in long-term IVOC, in order to further replicate the
hyperproliferative sate at which chemoprevention is most relevant, I next attempted to induce explants
to mimic the hyper-proliferative state found in colonic polyps and tumours.
Wnt signalling is known to be the most important pathway for intestinal epithelial cell proliferation
and plays a critical role in CRC tumourogenesis. Briefly, in the canonical Wnt signalling pathway,
stimulation of the frizzled receptor leads to higher levels of cytosolic P-catenin initially, subsequent p-
catenin nuclear transportation and the stimulation of Wnt-target genes (including Lgr-5 and other
genes involved in cellular proliferation) (van der Flier and Clevers 2009).
Lithium treatment mimics the effects of canonical Wnt signalling by inhibiting glycogen synthase
kinase-3p (GSK-P), leading to reduced GSK3-mediated phosphorylation of P-catenin (including Ser
552), thus preventing its subsequent degradation by the ubiquitin proteosome system. Accumulated
cytosolic P-catenin then localises to the nucleus and promotes the expression of genes regulated by
Lef-Tcf transcription factor (Hedgepeth et al 1997, Klein and Melton 1996, Li et al 2011). These
include c-Myc and cyclin-Dl (Brabletz et al 2009, Kolligs et al 2002), genes that promote
proliferation and survival (Sinha et al 2005). Lithium also affects the inhibitory BMP pathway,
inhibiting Smad 1,5 and 8 phosphorylation (Li et al 2011), thereby inducing stem cell derived
epithelial proliferation.
As lithium chloride modulates major pathways responsible for stem cell activation, I set out to
determine whether this agent could induce proliferation of human CRC mucosa. Firstly, we optimised
the use of lithium chloride in CRC cell lines. Lithium chloride was found to induce a dose-related
increase in expression of c-Myc within CRC cell lines (supplementary data 7.1). Therefore,
experimentation next turned to focus to the effects of daily supplementation of lithium chloride within
the IVOC model system.
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P-catenin is itself a direct target of active Wnt signalling. Immunohistochemistry (fig 4.18b) and
western blot analysis (figure 4.18a) indicated that levels of this protein also increased in mucosal
explants when exposed to lithium chloride. Phosphorylation of P-catenin on Ser 552 residue is a
marker ofWnt activity and results in P-catenin nuclear accumulation with subsequent Wnt-dependent
transcription of Lef-Tcf dependent genes (Fang et al 2007). Lithium chloride addition also resulted in
increased levels of phosphorylation of p-catenin Ser 552 within explants.
Lithium supplementation also increased expression of the downstream Wnt-dependent gene, cyclin
D1 (Kolligs et al 2002) (Figure 4.18a). As Cyclin D1 is a marker of proliferation and cell cycle
progression, these data would suggest lithium chloride stimulates proliferation of explants. In keeping
with these data, immunohistochemistry demonstrated that lithium chloride increased levels of the
proliferation markers PCNA (figure 4.18b and 4.19a) and Ki67 (figure 4.18b and 4.19b). Furthermore,
western blot analysis confirmed a dramatic increase in PCNA expression in explants grown in the
presence of lithium chloride, compared to no lithium chloride controls (figure 4.18c).
In addition, lithium chloride also increased expression of the differentiated enterocyte marker, Vil-1
(Figure 4.18c). Taken together, these data suggest that this agent caused increased proliferation and
differentiation of colonic epithelial cells. Indeed, when H&E sections were scored, it was found that
cultures grown in the presence of lithium chloride had reduced damage scores compared to controls
(figure 4.19c).
Thus, the induction of Wnt stimulation by daily lithium supplementation induces an apparent
hyperproliferative state within the explant that was characterised by Wnt stimulation, increased cell








4.18 Lithium chloride activates colonic mucosal Wnt Signalling (i)
Explants were cultured for 16 days in modified Weymouth's media and were either untreated
(NT), or treated daily with 0.5 mM Lithium chloride (Li) a. Addition of Lithium results in increased
detection of phosphorylated P-catenin and increased expression of the Wnt-dependent gene,
cyclin Dl. y-tubulin is used as a loading control. (n=3) b. Representative images from explants
demonstrate staining for p-catenin, PCNA and Ki67 (n=5). c. Lithium supplementation induces
increased expression ofPCNA, P-catenin and Vil-1. Colorectal tumour tissue (Turn) is used as a




















4.19 Lithium chloride activates colonic mucosal Wnt Signalling (ii)
Explants were cultured for 16 days in modified Weymouth's media and were either untreated (NT),
or treated daily with 0.5 mM Lithium chloride (Li) a, b. The percentage of positively staining cells for
proliferative markers (a. PCNA, b. Ki67) were counted in a minimum of 5 separate fields +/- standard
error (n=3). c. C3 damage scale scoring of explants as determined by 3 independent and blinded
observers (n=3)(+/- Standard error)
4.14 Inhibition of Notch signalling induces goblet cell differentiation
The above data suggested that proliferation within explants could be influenced by the addition of
external Wnt stimulants. Given that control of proliferation could be influenced, I further investigated
whether differentiation within explants could also be modified.
Notch signalling maintains crypt progenitor cells in an undifferentiated state, and it controls
progenitor cell differentiation between secretory and absorptive cell fates (Wilson and Radtke 2006).
The activation of Notch signalling is critically dependent on the transmembrane protease complex y-
secretase (Baron 2003, De Strooper et al 1999, Mumm et al 2000). Following Notch receptor
activation, canonical Notch signalling leads to Hesl upregulation and Atohl/Hath 1/Math 1 down-
regulation (Zheng et al 2011). The Atohl transcription factor induces differentiation towards a
secretory cell lineage. As Notch signalling down-regulates Atohl, it is implicated in maintaining
colonocytes in a progenitor state, inhibiting goblet cell differentiation (reviewed in (Katoh and Katoh
2007)).
Previous studies have demonstrated that genetic disruption of Notch signalling in the intestinal crypt
compartment, or Notch inhibition by chemical antagonists, induces colonic epithelium to differentiate
towards a secretory/goblet cell phenotype (resulting in increased Muc-2 expression) (Coant et al 2010,
Okamoto et al 2009). Indeed, in a recent human preclinical study of y-secretase inhibitors as a trial
treatment for Alzheimer's disease (one setting in which their use is being evaluated), addition of the
inhibitor induced a side effect characterised by the appearance of goblet cells within the intestine,
mirroring the effects of deliberate genetic disruption of Notch signaling, reported from some animal
studies (Lundkvist and Naslund 2007).
In order to assess whether it was possible to influence the cell fate decisions of progenitor cells within
the IVOC model, the y-secretase inhibitor, Dibenzazepine (DBZ) was added to 1VOC culture media
on a daily basis for 5 days between days 10-15 of culture. Previous reports have suggested that
differentiation of colonic epithelium to a secretory/goblet cell phenotype (muc-2 expression) after y -
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secretase inhibition is most efficacious in those cells that are actively proliferating (Menke et al 2010).
Given that the above results demonstrated that lithium chloride increased proliferation within the
explants, I therefore also assessed the effect of the concurrent addition of these two agents on explant
differentiation.
At day 16, treatment with DBZ alone induced a moderate induction of the secretory cell phenotype,
however the most pronounced effect occurred in those explants that had been concurrently treated
with lithium chloride supplementation. Using immunohistochemistry, there was an increase in the
number of cells that stained positive for Muc-2 expression (figure 4.20a) and following western blot
analysis with antibodies against Muc-2, there was a large increase in the of levels of Muc-2 protein
expression within the tissue extracts after DBZ and lithium chloride treatment (figure 4.20b).
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4.20 Inhibition of Notch signalling induces goblet cell differentiation
Explants were cultured for 16 days in modified Weymouth's media and were either untreated (NT), or
treated daily with 0.5 mM Lithium chloride (Li) supplementation or with daily doses of Dibenzazepine
(DBZ) for 5 days before harvesting a. H&E histology demonstrated the induction of a secretory cell
phenotype in DBZ treated explants . b. Anti-Muc-2 immunocytochemistry demonstrated increased expression
ofMuc-2 in Li- and DBZ-treated explants. DAPI was used as a nuclear marker, c. Anti-Muc-2
western blot analysis of protein extracts from Li/DBZ treated explants. y-tubulin was used as a protein
loading control. Results are representative of 2/3 independent experiements.
4.15 Discussion
This research phase established a number of important findings. Firstly, I made substantial progress in
establishing the optimal conditions for long-term in vitro organ culture of human ex vivo colonic
mucosa. Through this, I observed a biphasic process of apoptosis and proliferation during long-term
culture. Subsequently, proliferation within this model resulted in a diverse, differentiated cell
population organised in epithelial crypt-like structures, thus mimicking the histological features of the
human in vivo colonic mucosa in architectural complexity and population heterogenity. Cells positive
for the putative colonic stem markers, Lgr-5 and BMI-1, were also identified for the first reported time
in a colonic IVOC culture model of this type, suggesting a potential underlying mechanism for the
proliferative and regenerative response observed.
Secondly, I tested a range of agents (lithium chloride, DBZ and aspirin) within an IVOC model of
human ex vivo colonic mucosa. I induced a hyperproliferative effect in the epithelium of explants, by
stimulating Wnt signalling and influenced cell differentiation by Notch inhibition. Importantly, the
experimental outputs following aspirin treatment provide considerable support for the human
biological relevance of findings derived from previous experimentation in CRC cell lines, specifically
in regards to the aspirin-induced c-Src and NF-kB dynamics.
This study is the first to report the detection both Lgr-5- and BMI-1-positively staining cells in human
colonic mucosa within culture. The pattern of staining suggest, in concordance with previous reports,
that these populations of cells are distinct. Focal staining of Lgr-5 cells at the base of crypts was
consistent with their location in previous studies (Barker et al 2007). However, the non-specific
staining pattern of BMI-1 in repopulating crypts, mirroring that of the proliferation markers Ki67 and
PCNA, suggested that whilst BMI-1 is a sensitive marker of proliferating cells, it lacks the specificity
to accurately detect a putative small number of CSC within crypts. Previous studies have suggested an
apparent lack of BMI-1 expression in colon and distal small bowel, which suggest the existence of a
BMI-1-negative intestinal CSC population. It remains to be seen if BMI-1 is expressed in a stem cell
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population only, or provides a non-specific marker for highly proliferative cells, including those
positive for Lgr-5 expression (Haegebarth and Clevers 2009).
There are two main strategies used to identity stem cells. These rely on confirmation of the
characteristics of self-renewal and multi-potency in vitro and in vivo. Stem cells can be identified by
marker expression and then in vitro culture and/or transplantation into animal models is performed.
Alternatively, cells are genetically marked in situ and the cell and its progeny can then be traced over
time. This human mucosal model provides an ideal future platform on which to confirm the
characteristics of multi-potency by potentially allowing the identification of marked stem cell
populations over time or alternatively observation of the dynasty of animal stem cells which are
genetically marked and transplanted into such a model (Bareiss et al 2008). The lack of an immune
response within the model also allows flexibility in avoiding the host/graft responses potentially
present in other more advanced models.
Embryonic cryptal "spheroids"/ residual epithelial formations (Autrup et al 1978a, Autrup 1980) and
cyst-like structures (Bareiss et al 2008) have been described elsewhere in regenerating explants and
may comprise a functional stem cell compartment, augmented by potential stem cells (Autrup et al
1978a). Here, cystic structures contained cells of all lineages but importantly were highly
proliferative, staining heavily for both proliferation markers and BMI-1. The Intestinal Stem Cell
Niche (ISCN) is notable for myofibroblasts adjacent to the crypt base which are believed to secrete
paracrine signals regulating the neighbouring ISCN (Ootani et al 2009, Vermeulen et al 2010).
Previous reports have suggested that these stromal elements can produce inhibitory factors, such as
BMP, which prevent stem-cell proliferation and modulate differentiation within the colonic crypt
(Kosinski et al 2007, Powell et al 2011). There was progressive deterioration and reduction in the
alpha-actin staining smooth muscle layer and muscle fibres surrounding the base of crypts.
Potentially, this degradation could reduce previous inhibitory signals, allowing uninhibited stem cell
activity, and thus the development ofmature architectural structures such as crypts.
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Studies using the drosophila midgut suggest that as intestinal epithelial cells encounter damaging
stress (e.g. bacterial infection) they are able to signal to stem cells to increase proliferation to replace
damaged cells (Jiang et al 2011a, Shaw et al 2010). The simple structure of the fly gut means that
signalling from epithelial cells to stem cells, which are adjacent, is potentially very straightforward.
Whether this type of signalling exists in the human intestine and how the signal may be transduced
from surface epithelial cells to stem cells near the base of crypts, remains to be elucidated. 1VOC of
human colonic tissue is an ideal model to answer this question due to the presence of the diverse cell
populations found in vivo, particularly the stromal cells which may play a role in relaying signals from
the surface epithelium to crypt cells. Such signalling could also explain the selective nature of the
apoptosis seen during short-term culture in RPMI media.
The intestinal epithelium is subject to continuous renewal. This includes progenitor proliferation,
directional migration of epithelial cells from the crypt region and, ultimately, cell death (Gregorieff
and Clevers 2005, Wilson and Radtke 2006). The IVOC model undergoes relatively controlled
regeneration of surface epithelium following a biphasic process of apoptosis and proliferation. The
maintenance of such intestinal homeostasis depends on regulation of various cell processes such as
differentiation, migration and proliferation, which are tightly controlled by a small number of highly
conserved signalling pathways (Kanwar et al 2010).
Extracellular Wnt signals are absolutely required within the stem cell compartment/niche in order to
drive and regulate this cell proliferation (Ootani et al 2009), and studies have observed the rapid
ablation of proliferation and secondary loss of differentiation in the setting ofWnt inhibition (Ootani
et al 2009, Yen and Wright 2006). Here, daily pulses of lithium chloride (for 16 days) stimulated
endogenous Wnt signalling, demonstrated by increased phosphorylation (activation) of p-catenin and
the expression of the Wnt transcriptional targets, cyclin D1 and c-Myc. Lithium-treated explants
demonstrated improved cryptal maturity, proliferation, and an increased differentiated epithelial cell
population. These data are highly significant, as they demonstrate that a hyperproliferative state can be
induced within explants of normal colonic mucosa, mimicking the very early stages of colorectal
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carcinogenesis. This model is therefore relevant for future testing of the efficacy of chemopreventative
agents.
Colonic mucosal epithelium is tightly controlled to ensure maintenance of a monolayer-type
organization and adequate barrier function, however, NSAIDs have been shown to disrupt intestinal
integrity and long-term treatment leads to inflammation of the colonic mucosa (Bjarnason et al 1986).
Specifically, NSAIDs have a deleterious structural effect on the tight junctions that are integral to the
barrier function of the colon (Mima et al 2008). TJs contain the transmembrane proteins occludin and
claudin, which are connected to the cytoskeleton via zonula occludens (Anderson and Van Itallie
1995) (Mima et al 2008). NSAIDs are known to reduce the transcription of claudin (Mima et al 2008)
and previous analysis of the cumulative effects of celecoxib-induced changes in the gene expression
within rectal mucosa from HNPCC patients indicates substantial changes to gene expression of
adhesion-related molecules.
Analysis of the cumulative effects of celecoxib-induced changes in the gene expression within rectal
mucosa indicates substantial changes occur in the expression of proteins associated with cell adhesion.
Forty of these genes encode proteins that are involved in focal contacts and in fact previous authors
have suggested that the pro-apoptotic effect of celecoxib was related to changes in focal adhesion
(Glebov et al 2006). Of interest, both c-Src and FAK play a key role in focal contact turnover,
adhesion and NF-kB signalling (see chapter 3). c-Src localises at the TJ and the tyrosine kinase
activity of c-Src has been found to be involved in the disruption of TJ in human intestinal epithelium
(Basuroy et al 2003). Inhibition of c-Src (by chemical or genetic methods) has been previously
reported to prevent normal tight junction opening in response to selected stimuli (Basuroy et al 2003,
Kevil et al 2001). Given that aspirin induced activation of c-Src, phosphorylation of paxillin Y118 and
the disassembly of membrane aggregates in this model, findings here could suggest that activation of
c-Src in colorectal mucosal tissue occurs concomitantly to junctional disassembly and may be
involved in the pro-apoptotic effects of these agents, but further research focusing on the constituency
of the c-Src-rich membrane aggregates and component proteins of TJ would be required.
207
Surgical procedures on the large intestine are common and offer considerable opportunities for
harvesting surplus fresh tissue from human subjects without ethical problems in principle- provided
the perceived obstacles finding collaborative surgeons can be overcome (Dame et al 2010). Therefore,
this model potentially provides an available, reliable and representative colonic mucosal model in
which to examine molecular mechanisms of relevance to aspirin's chemopreventative effect.
However, further exploration could improve explant quality and survival rates.
Following optimisation, greater than 60% of left sided resection explants were maintained to day 16.
Whilst better, more targeted, antibiotic prophylaxis may have negated some bacterial infections and
improved culture yield, the anatomical site of origin of explant was found to be an important
determinant in culture success. Whilst conflicting reports exist (Wang et al 2005), previous authors
have reported differences in the bacterial species which dominate at different colonic sites, i.e.
lactobacilli spp. favouring the sigmoid/rectum and Eubacterium rectale and faecalibacterium
prausnitzi more dominant in the ascending and descending colon (Ahmed et al 2007). Site-specific
bacterial influences could therefore account for some differences in the success/infection rates
experienced. Additionally, known colonic site-specific gene expression differences, particularly in
developmental gene expression (Noble et al 2008) or stem cell distribution (Sangiorgi and Capecchi
2008) may play an unknown role in the differences observed in tissue damage scores observed in
regenerating right- versus left-sided colonic explants.
As a result of early optimisation and explant survival data, I focused on recruitment of patients who
underwent left-handed resection. Therefore, studies described here are not designed to detect a
differential colonic regional response to aspirin. The wider implications of aspirin-induced side effects
on other areas of the GI tract are, however, of fundamental importance in considering the
viability/design of any future chemopreventative agent and in the interpretation of data derived from
any colonic region-specific study. Of major relevance to this project, recent research has also
demonstrated a divergent response to sulindac in different regions of the colon. Sulindac
administration reduced azoxymethane-induced distal colon tumours in all mice but in the proximal
colon, sulindac induced inflammatory lesions on the mucosal folds, which further developed into
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adenocarcinoma in some mice with a distinct profile of pro- and anti-inflammatory factors including
upregulation of hypoxia inducible factor la and macrophage inflammatory protein 2 (Mladenova et al
2011).
In conclusion, explants of colonic epithelium can be manipulated in culture to represent early stages of
carcinogenesis and may provide an ideal model for studying the molecular mechanisms of CRC
initiation. Furthermore, aspirin-induced effects observed previously within in vitro CRC cell lines,
specifically effects on c-Src/NF-rcB signalling and apoptosis, were also demonstrated to be
biologically relevant in the IVOC model of ex vivo human colonic mucosal. The confirmation of the
molecular mechanisms involved in aspirin's cancer-preventative role has obvious implications for the
design of future, safer, more effective cancer preventative agents. In addition, this process has created
a highly representative human tissue model, which has much value for use in future studies focused on




Collectively, the data presented in this thesis shows aspirin activates c-Src in CRC cells and in human
colonic epithelium. I present evidence that c-Src plays a key role in aspirin-induced activation of the
NF-kB pathway, nucleolar sequestration of RelA and apoptosis. Furthermore, I have optimised an in
vitro organ culture model of human ex vivo colonic mucosa, through which I have identified cells
expressing CSC markers and modified growth and differentiation in colonic explants in long-term
culture. Using this model, I confirmed that aspirin's effects on the c-Src and NF-kB pathways in
previous CRC cell line experiments were relevant in human colonic mucosa. These findings shed
further light on the mechanisms behind aspirin's chemopreventative effects in CRC but also highlight
areas of further research and exploration. The implications of the data presented in this thesis, in terms
of the direction of future research, will be the subject of this discussion.
5.1 Elucidating the molecular mechanisms responsible for linking aspirin-induced c-Src and
NF-kB signalling activation
Whilst data presented in this thesis demonstrate that c-Src was activated following aspirin
administration at a time point prior to NF-kB activation, the precise mechanism underpinning both
aspirin-induced c-Src activation and c-Src-induced stimulation of NF-kB signalling is still not fully
understood.
Previously, in chapter 3, I demonstrated that aspirin effects on the NF-kB pathway and apoptosis in
vitro were dependent upon c-Src and in chapter 4,1 demonstrated the human in vivo relevance of these
data by showing the agent activates c-Src in association with IkBoi degradation and nuclear
translocation of RelA in explants of normal colonic mucosa. The experimental data suggested that the
mechanism behind aspirin induced c-Src mediated activation ofNF-kB involves a) IkBcx degradation,
b) a physical association of c-Src and IkBoi and, c) activation through delayed kinetics.
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Future work is required to further elucidate this mechanisms involved in the activation of these
pathways. Co-immunoprecipitation studies were unable to definitively demonstrate if a physical
interaction of c-Src with NF-kB was modified in CRC cells by aspirin treatment. However,
optimisation of these studies, perhaps in cells which over-express c-Src may help to provide such data.
Direct phosphorylation of IicBa on Y42 by c-Src is one potential mechanism for c-Src mediated NF-
kB pathway activation and is reported in other settings (Abu-Amer et al 1998, Fan et al 2003).
However experimental difficulties prevented the detection of whether aspirin treatment induces IkBci
Y42 phosphorylation. This mechanism is responsible for the liberation of RelA from the cytoplasmic
inhibitor and subsequent RelA nuclear/nucleolar translocation and is therefore critical to the
understanding of the potential kinase pathways involved in the agent-induced response and in
detecting future chemopreventative targets. Using immunoprecipitation to isolate cellular IkBoi, prior
to further western blotting analysis with the phospho-specific Y42 antibody may yield better more
specific results.
Given the delay between the activation of c-Src and IkBcx degradation, it is likely that c-Src may
activate intermediate kinases, such as P13-kinase, (which interacts with c-Src and associates with
tyrosine phosphorylated IkBoi) (Haefner et al 1995, Rang et al 2003) or IKK. The use of IKK/ PI3-
kinase inhibitors, IKK tyrosine residue genetic mutants (c-Src phosphorylates tyrosine residues on the
activation ring of IKK) or IKK:c-Src/ P13-kinase: c-Src immunoprecipitation experiments to dissect
this response could also raise future candidates of future potential pursuit as chemopreventative
targets.
The mechanism of c-Src activation involves phosphorylation of Y418 and occurs some hours after
aspirin administration. Whilst, the regulation of c-Src kinase activity is highly complex, further
dissection of this activation may yet yield information about upstream targets of aspirin. Both Csk and
protein tyrosine phosphatases regulate phosphorylation of c-Src at tyrosine 527 and previous reports
of their modification by other NSAIDs already exist (Kunte et al 2008, Playford and Schaller 2004).
Therefore, the potential for future experimentation utilising assays for the activity of Csk and/or
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protein tyrosine phosphatases may therefore be an intriguing option to identify if these proteins are
implicated in the activation of c-Src by aspirin.
Aspirin-induced activation of c-Src is also associated with other cellular and molecular effects,
including modification of adhesion/membrane dynamics and paxillin Y118 phosphorylation. FAK is
both a known effector of c-Src (Frame 2002), and substrate of c-Src kinase activity. Whether FAK
itself is directly targeted by aspirin, or activates c-Src as a consequence of upstream integrin
signalling, would be of great interest. Exploration of the role of FAK in this response, utilising FAK
chemical inhibitors, or site directed mutagenesis of FAK (such as at the key c-Src substrate site, FAK
Y925) could be undertaken to assess the effect of FAK inhibition on aspirin-induced apoptosis and the
NF-kB signalling response.
Another possible mechanism by which aspirin may translate c-Src activation to induce a NF-kB
signalling response is through MAPK signalling, a known substrate of c-Src activity and involved in
aspirin effects on NF-kB and apoptosis (Thorns et al 2007b). Exploration of the role of the p38 MAPK
in the aspirin-mediated effects of c-Src may shed further light on the intermediate pathways involved
in the transmission of the aspirin-induced pro-apoptotic effect. Evaluating the effect of MAPK
inhibition on the NF-kB and apoptotic response to activated c-Src would be of interest to further
elucidating the role ofMAPK in this response.
Importantly, it is also important to consider if the active agent behind these molecular effects in-vivo
are specific to aspirin or its' metabolite salicylate or NSAlDs generally. As already discussed, the
host lab has previously demonstrated c-Src and NF-kB activation following NSAIDs (Brady et al
2010) and inhibition of the NSAID pro-apoptotic effect with the use of c-Src Inhibitors in CRC cell
lines. Testing the response ofNSAIDs within the ex-vivo model would therefore be of great interest.
There is also the consideration of dosage. In a study of 10 subjects given 40.5 mg aspirin, the mean
peak plasma salicylic acid concentration was 11.8pmol/l, but there was a large inter-individual
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variability in the salicylic acid concentrations after the same dose of aspirin. (Ruffin et al., 1997)
Higher serum concentrations of salicylic acid were present in vegetarians than in non-vegetarians, and
there was overlap in the serum concentrations between vegetarians and those taking aspirin (75 mg
daily). The median serum concentration of salicylic acid in a group of vegetarians not taking salicylate
drugs was 107 nmol/1, with the highest concentration being 2468 nmol/1 (Blacklock et al 2001 )
The study here used supra-pharmacological doses of aspirin, as this has been well characterized before
within the host laboratory, allowing for reasonable logistical analysis of cells (i.e. effects measurable
within realistic time-points). However, further analysis of serum and tissue salicylate levels would be
useful in further evaluation of the ex-vivo model. The host lab have previously demonstrated that
aspirin tumour concentration in xenograted models was of the order of >0.5mM after a dose of
40mg/kg in rats (Stark et al 2005).
Of note, sodium salicylate and aspirin at pharmacological concentrations inhibit Cox-2 transcription in
endothelial cells and fibroblasts. The salicylic acid concentration which inhibited Cox-2 transcription
by 50% is estimated to be 5000 nmol/1, although lower concentrations (100 nmol/1) appear to also
have some effect (Xu et al., 1999). The anti-colon cancer effect of aspirin could therefore be
contributed by suppression of Cox-2 expression by salicylate rather than inhibition of activity. Here,
we focused on non-Cox pathways within this thesis and the host cell line SW480 was Cox negative,
but the relationship of c-Src activity, its' expression and expression of Cox in other cell line models
and within the ex-vivo model, at pharmacological dosages of aspirin, would be of relevance to further
explaining the Cox-dependent and independent nature of the chemopreventative effect of aspirin and
in other settings.
5.2. Utility of IVOC model to future work and exploration of findings derived from
optimisation.
The results of optimisation experiments utilising the IVOC model of colonic mucosa demonstrated
that the strongest predictors of explant survival were a) media-dependent and b) location-dependent.
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Further work is however required to evaluate the effect of individual constituents of media and
additives that were used. Due to time constraints, this could not be performed within the timeframe of
this project, however, evaluating the specific growth factors and chemical constituents of Weymouth'
media which are responsible for the divergent biphasic response may provide some key findings to the
underlying control of cell growth and differentiation within human colonic mucosa. Further variables
such as temperature, patient specific variables (sex, age, co-morbidities; such as diabetes etc.),
anaesthetic time or agents, time delay from harvest to culture, frequency of media changes, pressure
conditions, size of explant and volume of media are areas were further information may assist in
providing further improved conditions to improved explant culture outcomes.
The unpredicted divergent survival patterns that were obtained from explants from right and left colon
harvest sites adds to a compelling weight of evidence that colonic tissue from these two anatomical
locations behave and respond in different ways. As discussed previously, differences in luminal
bacteria, response to NSAIDs, genetic expression patterns, CRC site-specific mortality and morbidity
outcomes, genetic signatures of site-specific CRCs and racial differences in incidence have all been
previously reported. This leads to the suggestion of whether there exists right- and left-sided CRC
disease phenotypes. Exploration of the response to individual chemopreventative or chemotherapeutic
agents with a focus on anatomical location may yield further evidence of this effect. The concept of
tailored therapeutics, geared towards the molecular signatures of cancers, is well described in relation
to chemotherapy and KRAS/BRAF/MMR status, however, whether location-based tailoring for
chemopreventatives/chemotherapeutics is also required, is an area which may benefit from further
evaluation.
The focus of this thesis has been the exploration of the molecular effects of aspirin treatment on c-Src
signalling in colorectal epithelial cells, as a means to further explain aspirin's chemopreventative
effect. However, whilst there are many potential molecular targets, understanding this response is
even more complex when one also considers the other potential factors which putatively effect tumour
growth and metastases. The factors which regulate tumour development and growth are not limited to
the epithelium. This regulation involves key interactions between epithelial cells, activated stromal
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cells, components of the extracellular matrix, platelets and the vascular supply. Of key relevance is
aspirin's widely known property as an anti-platelet agent and the potential effect of aspirin on the
surrounding stroma.
The anti-thrombotic action of aspirin is due to inhibition of platelet cyclooxygenase (COX) causing
irreversible inhibition of platelet-dependent thromboxane formation (Shror et al. 1997). Complex
interactions between tumour cells and circulating platelets play an important role in cancer growth and
dissemination. Platelets facilitate cancer-related coagulation by providing a procoagulant surface,
which can shroud tumor cells from immune responses, and facilitate dissemination of tumour cells
when vascular invasion has occurred. Platelets are also stores of proangiogenic and anti-angiogenic
proteins that can enhance angiogenesis and therefore tumour growth. Platelets also facilitate tumour
cell invasion and induce endothelial cell proliferation. Additional platelet-related proteins and
metabolites which facilitate proteolysis and tissue remodelling also enhance tumor growth and
metastasis. For instance, inhibiting platelet receptors, such as GPlb/IX/V, GPIIbllla and GPVI
attenuates metastases (reviewed in Bambace and Holmes 2011). Aspirin's antiplatelet actions could
therefore have a highly relevant role in the CRC chemopreventative effect.
Aspirin also has mesenchymal targets and has been demonstrated to induce both growth
inhibition/apoptosis of mesenchymal stem cells through a mechanism which involves the WNT/beta-
catenin pathway (Wang Y, Deng L) and also has important effects on the angiogenic response, a key
stromal effect that is required to generate a sufficient blood supply for a solid tumor to grow. For
instance, it is known that tumour cells secrete growth factors such as vascular endothelial growth
factor (VEGF), which stimulates nearby vascular cells to form new blood vessels. Cox-2 inhibitors
modulate angiogenesis indirectly by reducing expression of angiogenic factors, such as VEGF in the
tumour micro-environment (Borthwick 2006). COX-1 and COX-2 over-expression is frequent in large
and high-grade dysplasia adenomas and it it deep stromal but not epithelial expression of COX-2 in
some studies which is a more important predictor of recurrence of such adenomas (Benamouzig et al
2010)
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These non-epithelial targets remain important to explore, as the microenvironment remains the key
incubator of tumour mass and potentially these effects are actually more stable to establish and are
more predictable that the responses of highly disorganized mutating tumour cells (Borthwick G). The
Ex-vivo model therefore provides a useful setting in which to observe mesenchymal effects and, as the
stroma layer is maintained, possibly provides a more attractive and representative model that simple
cell culture or 3d crypt culture models. Observing the aspirin induced stromal effects in such a setting
has obvious interest to this field of future scientific exploration."
Previous reports have documented that Notch inhibition within the setting of clinical trials confers a
differentiation pressure towards a secretory cell lineage within the in vivo patient colonic mucosa.
Given that I also found that Notch signalling antagonists induced colonocytes to differentiate towards
a secretory/Mucin-2 expressing cell lineage in explants of normal colonic mucosa, the replication of
this response in the IVOC setting adds evidence to the representative nature of the model to the in vivo
situation.
Whilst the majority of CRCs are moderately well-differentiated and possess few Mucin-secreting
goblet cells, 10%-20% of CRCs overproduce Mucin, with a characteristic set of clinical/pathologic
features and distinct molecular genetic attributes (Skrzydlewska et al 2005) (Okudaira et al 2010)
(Kim et al 2005). Mucin-related genes {HATH1 and SOX2) are also key components of the Notch
signalling pathway and implicated in the pathogenesis of such cancers (Park et al 2008). Forced
expression of HATH1 in CRC cells results in the up-regulation ofMuc-2 expression (Park et al 2006)
and 80% of this subset of CRCs demonstrate increased expression of Muc-2 (Okudaira et al 2010).
This model therefore provides a potential experimental platform in which to explore molecular
mechanisms responsible for growth and differentiation generally and more specifically, the underlying
mucinous/signet ring cell CRC pathogenesis. Future research could also be extended to assess the cell-
specific response to aspirin in this setting and the implication of chemoprevention in this subset of
CRCs.
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I experienced significant problems with attempting prolonged culture of human polyps. The
difficulties with polyps include variability of the samples, the lack of availability and the small
quantity of tissue available for experimentation and analytical purposes. Here, I observed an inducible
hyperproliferative state within explants by the daily addition of a small molecule Wnt agonist. There
is considerable future merit in evaluating aspirin-induced c-Src and NF-kB pathway responses within
the setting of induced hyper-proliferative mucosa in order to evaluate if the agent induced response
changes within this setting. Importantly, it is perhaps within hyperproliferative mucosa that
exploration and definition of the precise mechanisms underlying the chemopreventative effect of
aspirin is most relevant and as such, this model may provide a means at which to adequately explore
this setting.
The successful optimisation of the ex vivo model therefore provides considerable value beyond the
original aims (to provide a platform for the investigation of chemopreventatives). In just one such
instance, the work undertaken is already being used in the Colon Cancer Genetics Group to study the
function of a number of signalling pathways that have been identified as contributing to colorectal
cancer susceptibility, through ongoing large scale genetic studies. To date the CCGG have identified
14 new genetic loci contributing to colorectal cancer aetiology, many in TGF/BMP signalling
pathways and the model is now being used to explore the mechanisms by which these genetic variants
lead to cancer.
5.3 Conclusion
Taken as a whole, the work presented has explored the mechanism whereby aspirin induces apoptosis
in CRC cells and human mucosa. These data suggest aspirin-induces phosphorylation of c-Src Y418,
activating c-Src kinase function, upstream ofNF-kB signalling. The aspirin-induced NF-kB signalling
response involving IkBcc degradation, RelA nuclear/ nucleolar translocation, and resultant aspirin-
induced apoptosis have demonstrated c-Src-dependency. The upstream mechanisms responsible for
aspirin-induced c-Src activation and the mechanistic link between c-Src activation and the NF-kB
signalling response require further exploration.
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Utilising this model system, exploration of the aspirin induced c-Src and NF-kB signalling response
confirmed that findings derived from in vitro CRC cell lines were relevant in human colonic mucosa.
The findings presented here, in combination with previously published work from the host laboratory,
has progressed the understanding of the signal transduction involved in effecting aspirin-induced
apoptosis in CRC cells and human colonic mucosa. Despite treatments, in view of the high mortality
associated with CRC, it is of vital importance to understand these mechanisms, as this could allow the
rational development of novel therapeutic agents. Hence work aimed at identifying targets for novel
chemopreventative agents, and developing models to expedite the development of such agents, has
much to commend it.
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Long-term aspirin or related non-steroidal anti-inflammatory drugs
(NSAIDs) ingestion can protect against colorectal cancer (CRC).
NSAIDs have a pro-apoptotic activity and we have shown that stim¬
ulation of the nuclear factor-kappaB (NF-kB) pathway is a key
component of this pro-apoptotic effect. However, the upstream path¬
ways have yet to be fully elucidated. Here, we demonstrate that
aspirin activates the c-Src tyrosine kinase pathway in CRC cells.
We show that c-Src activation occurs in a time- and dose-dependent
manner, preceding aspirin-mediated degradation of IkBcx, nuclear/
nucleolar translocation of NF-KB/RelA and induction of apoptosis.
Furthermore, inhibition of c-Src activity, by chemical inhibition or
expression of a kinase dead form of the protein abrogates aspirin-
mediated degradation of IkBol, nuclear translocation of RelA and
apoptosis, suggesting a causal link. Expression of constitutively
active c-Src mimics aspirin-induced stimulation of the NF-kB
pathway. The NSAIDs sulindac, sulindac sulphone and indometha-
cin all similarly activate a c-Src-dependent NF-kB and apoptotic
response. These data provide compelling evidence that c-Src is an
upstream mediator of aspirin/NSAID effects on NF-kB signalling
and apoptosis in CRC cells and have relevance to the development of
future chemotherapeutic/chemopreventative agents.
Introduction
In the developed world, colorectal cancer (CRC) is the third most
common cancer in men after lung and prostate cancer and the second
most common in women after breast cancer (1). Worldwide, it ac¬
counts for 1.2 million new cases each year and 608 000 deaths, rep¬
resenting a major public health concern (2). Despite continuing
research, the overall 5 years survival remains ~50% as patients often
present with advanced or metastatic disease (3). Hence, attention is
focusing on earlier detection and prevention as the most promising
approaches for combating this disease.
Epidemiological, case-control and randomized controlled trials in¬
dicate that aspirin and related non-steroidal anti-inflammatory drugs
(NSAIDs) have considerable potential as chemopreventative agents
against CRC (4-6). We have recently shown protective effects within
a year and at low-dose aspirin (7). However, the chemopreventative
effect imparted by these agents is not complete. Furthermore, even at
low doses, side effect profiles argue against their adoption for CRC
prevention for average risk individuals in the population (5,6). How¬
ever, understanding the molecular mechanisms underlying the ob¬
served chemopreventative properties of NSAIDs could provide the
basis for rational design of safer, more targeted, agents.
Induction of apoptosis through modulation of NF-kB signalling has
been shown to be a key component of the antitumour activity of
NSAIDs against CRC (8,9). NF-kB is an ubiquitously expressed in-
ducible-transcription factor that plays a critical role in inflammatory
and stress responses, proliferation, differentiation and apoptosis (10).
Abbreviations: CRC, colorectal cancer; FCS, fetal calf serum; NSAID, non¬
steroidal anti-inflammatory drug; NF-kB, nuclear factor-kappaB.
It is generally found as a p50/RelA (p65) heterodimer, bound in an
inactive state in the cytoplasm by the inhibitor protein, IkBo( nuclear
factor of kappa light polypeptide gene enhancer in B-cells inhibitor,
alpha. Following cellular stimulation, IkBcx is phosphorylated then
undergoes poly-ubiquitination and proteasomal degradation,
allowing NF-kB to translocate to the nucleus and regulate expres¬
sion of target genes, many of which regulate cell growth and
apoptosis (10,11).
Under normal circumstances, activation of the NF-kB pathway is
transient and tightly controlled. However, several lines of evidence
indicate that in CRC, NF-kB is constitutively activated and that this
activation plays a significant role in the carcinogenic process, regu¬
lating the expression of a number of genes implicated in CRC pro¬
gression (Cyclin Dl, Bcl-xl), angiogenesis (VEGF, IL-8, COX2) and
metastasis (MMP9) (12). A number of chemopreventative agents and
other inhibitors have been shown to induce suppression of NF-kB
signalling, inhibition of proliferation, cell cycle arrest and apoptosis
of CRC cells (12,13).
We have previously reported that aspirin and NSAIDs induce deg¬
radation of IkBcx and nuclear translocation of NF-kB in colorectal
neoplasia both in vitro and in vivo and that the resulting stimulation of
the NF-kB pathway in these conditions is responsible for repression of
NF-kb-driven transcription and critical for the pro-apoptotic effects
of these agents in CRC cells (9,14-16). In more recent studies, atten¬
tion has focused on identifying upstream regulators of this response
and we have identified that activation of p38 is an important upstream
mediator of the NF-kB response to aspirin (17). However, the regu¬
lation of this response is highly complex and there remain aspects of
these upstream mechanisms that require further definition.
One kinase of particular interest is the 60 kDa non-receptor, mem¬
brane-associated proto-oncogene product, c-Src, a protein tyrosine
kinase. c-Src is over-expressed in >80% of colon carcinomas and is
associated with CRC progression, invasion, metastasis and poor sur¬
vival (18-20). Crucially, it is known to modulate NF-kB signalling in
response to a wide variety of stimuli; either directly, through tyrosine
phosphorylation of IkBoi (Y42) (21-24) or indirectly, through stimu¬
lation of intermediate kinase pathways, such as Protein Kinase C Alpha
and IkB kinase (25-31). Furthermore, NSAIDs have been shown to
modulate cellular c-Src tyrosine kinase activity in response to a broad
range of stimulants, in a variety of cellular environments (31-34).
We set out to test the hypothesis that the aspirin/NSAIDs-induced
NF-kB response observed in CRC cells is mediated via c-Src activity




Culture of SW480 CRC cells has been described previously (14). SW480
cells stably transfected with a kinase dead form of c-Src (SW480-
SrcKD) were obtained (kind gift from Prof. M.Frame, Edinburgh Cancer
Research centre) along with control cells stably transfected with the
pBpuro empty vector alone (SW480-pBpuro) and were maintained in
RPMI medium (Gibco BRL, Paisley, UK) supplemented with 10% fetal
calf serum (FCS) and 1% penicillin and streptomycin at 37°C in a hu¬
midified atmosphere containing 5% C02. Cells were plated at a density
of 0.2 x 105/cm2 and treated in 0.5% serum at 6CL80% confluence.
Aspirin (Sigma, St Louis, MO), sulindac (Sigma, Gillingham, UK),
sulindac sulphone (MP Biomedicals, Solon, OH) or indomethacin
(Sigma) were added at the concentrations specified as described
previously (16). Aspirin (Sigma) was dissolved in water using 10 N
NaOH and the pH was then adjusted to 7.0 as described previously
(17). For chemical inhibition of c-Src, the inhibitors PP2 (10 pM)
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amino-5-(-4-chlorophenyl-)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine)
I SU6656 (0.5 pM) (2-oxo-3-(4,5,6,7-tetrahydro-lH-indol-2-
iethylene)-2,3-dihydro-lH-indole-5-sulfonic acid dimethylamide)
ith obtained from Calbiochem, Nottingham, UK), were dissolved in
lethyl sulfoxide and added to the cells in L-15 (Gibco BRL) with
% FCS, 1% penicillin/streptomycin.
stern blot analysis
lowing treatment, whole-cell extracts were prepared using a commer-
lly available lysis buffer according to the manufacturer's instructions
:11 Signaling Technology, Hertfordshire, UK), and western blots were
formed as described previously (35). The membranes were probed
h the following primary antibodies: rabbit phosphorylated c-Src
(Y416) (#2101; Cell-signaling Technology), rabbit phosphorylated pax-
illin (Y118) (Invitrogen, Camarillo, CA), mouse c-Src (Upstate Bio¬
technology, Lake Placid, NY), mouse paxillin (BD Phariningen,
Oxford, UK), sheep polyclonal anti-lKBcx (a gift from Professor Ron
Hay, Dundee) and mouse actin (Clone AC-15; Sigma) was utilized as
a control for protein loading. The horseradish peroxidase-conjugated
secondary antibodies used were anti-rabbit IgG (Cell Signaling Tech¬
nology and Amersham Biosciences, Buckinghamshire, UK), anti-sheep
and anti-mouse IgM (Calbiochem). To examine the levels of non-
phosphorylated proteins, membranes were stripped by heating at
60°C for 45 min in buffer [60 mmol/1 Tris-HCl (pH 6.7), with 2%
sodium dodecyl sulfate and 0.8% P-mercaptoethanol] and blocked
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1. Aspirin-induced activation of the c-Src pathway in CRC precedes NF-kB activation. SW480 cells (A, B, E and F) or those which were transiently
sfected with a wild-type c-Src expression vector (C and D) were cultured and treated with aspirin [0-5 mM; 4 h (A. B, C and F) or 5 mM (D and E)] for the
rifled times.(A-D) Western blot analysis was performed on whole cell extracts using antibodies to phosphorylated Src (Y416), paxillin (Y118) or IkBx Blots
e stripped and reprobed for endogenous c-Src or paxillin. Actin was used as a control for protein loading. (E) Anti-RelA and fibrillarin (a nucleolar marker)
lunocytochemistry was performed on cells treated with aspirin (5 mM) for the specified times. 4',6-Diamidino-2-phenylindole (DAPI) was used as a nuclear
ker. All data is representative of at least three independent experiments. Aspirin (5 mM) induces RelA translocation from the cytoplasm to the nucleus at 8 h,
i further localization within nucleolar bodies at 10 h (fibrillarin-stained bodies). (F) Immunocytochemistry utilizing antibodies against phosphorylated Src
16) was performed on SW480 cells 0-4 h after treatment with 5 mM aspirin. DAPI was used as a nuclear marker.
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Transfeclions
SW480 CRC cells were transiently transfected with empty pUSEamp
vector or a vector that expresses wild-type c-Src, inactive c-Src (pUSE
Src K297R) or constitutively active c-Src (pUSE Src Y529F) (all
obtained from Upstate Biotechnology). Cells were transfected using
a Lipofectamine protocol [as described by manufacturers (Gibco
BRL)] grown for 24 h in low serum (0.5% FCS) medium [as described
previously, Stark et al. (9)] then treated with aspirin at various con¬
centrations. Western blot and immunocytochemistry were subse¬
quently performed to confirm adequate transfection efficacy with
this protocol.
Immunocytochemistry
For fluorescence imaging, the imaging system comprises a Coolsnap
HQ CCD camera (Photometries Ltd, Tucson, AZ) Zeiss Axioplan II
fluorescence microscope with Plan-neofluar objectives, a 100 W Hg
source (Carl Zeiss, Welwyn Garden City, UK) and Chroma #83000
triple band pass filter set (Chroma Technology Corp., Rockingham,
VT) with the excitation filters installed in a motorized filter wheel
(Prior Scientific Instruments, Cambridge, UK). Image capture
and analysis were performed using in-house scripts written for IPLab
Spectrum (Scanalytics Corp, Fairfax, VA). The primary antibodies
used at 1:100 were as follows: NF-kB p65 (RelA; C-20), rabbit
phosphorylated c-Src (Y416) (#2101; Cell Signaling Technology),
c-Src (Upstate Biotechnology), C23 (Santa Cruz Biotechno¬
logy, Santa Cruz, CA) and fibrillarin (AFB01; Cytoskeleton, Denver,
CO). The fluorescein isothiocyanate- and Texas red-conjugated
secondary antibodies (Jackson ImmunoResearch Laboratories, West
Grove, PA) were used at a dilution of 1:200, and the cells were
mounted using Vectashield (Vector Laboratories, Peterborough, UK)
containing 1 pg/ml 4',6-diamidino-2-phenylindole. In order to quan¬
tify the induced nuclear translocation of RelA, individual exposure
channels for each immunocytochemistry image field were captured
and stored using identical exposures throughout image collection and
across treatment arms of the experiment. Later, image analysis created
nuclear outline masks in 4',6-diamidino-2-phenylindole channel
images, which were subsequently transposed onto the matched
fluorescein isothiocyanate channel exposures for that field of view.
The mean intensity of nuclear RelA staining within previously
defined 4',6-diamidino-2-phenylindole masks were then quantified
in at least three separate experiments, in least 15 random fields per
experiment.
Apoptosis assays
Staining for cell surface phosphatidylserine residues was conducted











Fig. 2. Chemical inhibition of c-Src activity blocks aspirin-mediated stimulation of the NF-kB pathway (A-E) SW480 cells were either untreated (-) or
pre-treated with PP2 for 2 h prior to treatment with aspirin [4 h (A), 8 h (B and C) or 16 h (D and E); 0 (—)/5 mM (+)]. (A and B) Western blot analysis using
antibodies to phosphorylated paxillin (Y118), total paxillin or IxBot were performed on cell extracts. Anti-|3-actin was used as a loading control. (C) SW480
nuclear 4',6-diamidino-2-phenylindole exposure image outlines were transposed onto RelA exposure images. Comparative nuclear RelA staining intensity was
then quantified by computer image analysis software. (D-E)The nucleolar localization of RelA was examined using anti-RelA immunocytochemistry as above.
(D) For each experiment, the percentage of cells showing nucleolar RelA (as depicted by areas devoid of DNA/4',6-diamidino-
2-phenylindole staining) in at least 100 cells from a minimum of five fields of view was determined. Data are the average of three independent experiments
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3. Expression of kinase-inactive c-Src inhibits the NF-kB signalling response to aspirin. (A-C) SW480 cells were transiently transfected with an empty
Lamp vector, wild-type c-Src or kinase-inactive c-Src expression vector (pUSE Src K297R). Forty-eight hours after transfection, cells were untreated (—) or
led with 5 mM aspirin (+) for 8 h (A) or 16 h (C). (A) Anti-IicBa western blot analysis was performed on cytoplasmic cell extracts as above. Membranes were
iped and reprobed for c-Src to confirm expression of c-Src plasmids. Actin was used as a loading control. (B) Anti-RelA immunocytochemistry was performed
ransfected cells and the percentage of cells showing nucleolar RelA quantified as above. Data are the mean of three independent experiments ± standard error.
Anti-RelA/anti-c-Src immunocytochemistry was used to examine effects of expression vectors on aspirin-induced nucleolar RelA localization. Aspirin
iced nuclear translocation of RelA in non-transfected cells (white arrows). However, within cells over-expressing Src from transfected plasmids (yellow
ws), those over-expressing pUSE Src K297R demonstrated reduced RelA translocation in response to aspirin, compared to the response in non-expressing
i. However, cells over-expressing wild-type c-Src displayed a similar aspirin-induced RelA nuclear translocation to that observed in non-expressing cells.
cogene Research Products, La Jolla, CA) according to the manu-
urer's instructions. The fraction of apoptotic cells was determined
iuorescent microscopy as described previously (35).
ults
irin induces c-Src activity in CRC cells
initially investigated the effects of aspirin on c-Src activity,
ophosphorylation of c-Src on tyrosine 416 triggers its kinase activ-
by inducing a conformational change that exposes the kinase do-
n to potential substrates (36). Using this phosphorylation event as
arker for activation, we found that aspirin induces a dose-dependent
ease in endogenous c-Src activity in SW480 CRC cells (Figure 1 A),
c activation was further confirmed by demonstration of phosphor-
ion of the c-Src substrate, paxillin at Y118 (Figure IB) (37). SW480
s constitutively express low levels of endogenous c-Src, and so we
:ated these experiments in SW480 cells in which we over-expressed
1-type c-Src. These experiments further confirmed that aspirin
ices c-Src activation in CRC cells through dose-dependent phos¬
phorylation at Y416 of c-Src as a key member of Src Family Kinases
(Figure 1C).
Aspirin effects on c-Src activity precede stimulation of the NF-kB
pathway
Having established that aspirin activates the c-Src kinase pathway, we
next examined the temporal relationship between c-Src activation and
aspirin-induced stimulation of NF-kB signalling, to begin to deter¬
mine whether these two events are causally linked. Using western blot
analysis, we found that aspirin (5 mM)-induced c-Src Y416 phosphor¬
ylation within 6 h of treatment, concurrent with the observed kinetics
of aspirin-induced IkBoi degradation (Figure ID).
Our previous work demonstrated that upon aspirin/NSAID-
mediated degradation of IkBoi, the RelA component of NF-kB
translocates from the cytoplasm to the nucleoplasm and then to the
nucleolus. We also showed that this was required for the agent's pro-
apoptotic effect (9,35). We next used immunocytochemical analysis
to examine the kinetics of nuclear/nucleolar localization of RelA in
response to aspirin. Fibrillarin was used as a nucleolar marker. We
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Fig. 4. Variation in c-Src activity modulates aspirin-induced apoptosis. (A, C and D) SW480 cells were either pre-treated with chemical inhibitors PP2, SU6656
or transiently transfected with c-Src expression plasmids as described in Figure 3, prior to aspirin [0 (—), 5 mM (+); 16 h] treatment. The percentage of cells
in the population undergoing apoptosis was determined using Annexin V-fluorescein isothiocyanate apoptosis assays. Data presented is the minimum of three
independent experiments (± standard error). (B) SW480 cells were either untreated (—) or pre-treated with SU6656 for 2 h prior to treatment with aspirin [0 (—),
5 mM (+); 8 h]. Western blot analysis using antibodies to IkBcx were performed on cell extracts. Anti-[Vactin was used as a loading control.
found that aspirin-induced nucleolar translocation of RelA occurred
subsequent to c-Src Y416 phosphorylation (Figure IE). Immunocy-
tochemistry with antibodies to phosphorylated Y416 c-Src confirmed
that aspirin induced an increase in active form of the protein and that
this preceded effects of the agent on translocation of RelA (Figure
IF). Taken together, these data suggest that c-Src activation may lie
upstream of stimulation of the NF-kB pathway in response to aspirin.
Inhibiting c-Src activity blocks aspirin-mediated stimulation of the
NF-kB pathway
To further investigate the potential for the c-Src dependency of aspirin-
induced NF-kB activation, we used the Src family kinase inhibitor, PP2
(38). As this inhibitor does not block c-Src autophosphorylation at Y416,
we used phosphorylation of paxillin at Y118 as an indicator of c-Src
kinase activity. We found that pretreatment of SW480 cells with PP2-
abrogated aspirin-mediated phosphorylation of paxillin (Figure 2A). This
supports the notion that paxillin phosphorylation in response to aspirin
lies downstream of c-Src.
We next determined whether PP2 influenced the effect of aspirin
on NF-kB signalling. Indeed, we observed that aspirin-induced
degradation of iKBa was prevented in the presence of the inhibitor
(Figure 2B). Furthermore, we observed that both the aspirin-induced
cytoplasmic to nuclear translocation of RelA (Figure 2C) and sub¬
sequent aspirin-induced nucleolar localization of RelA were abro¬
gated in those cells pretreated with the inhibitor (Figure 2D and E).
To further confirm the association between aspirin effects on c-Src
and on the NF-kB pathway, we utilized a kinase dead c-Src mutant, Src
K297R. We initially examined the effects of expressing this mutant on
IkBcx levels. We found that aspirin mediated a reduction in cytoplasmic
IkBo< in those cells expressing vector alone and wild-type Src. How¬
ever, this reduction was completely blocked in cells expressing Src
K927R. We also found that over-expression of WT Src-induced some
degree of degradation of IkBcx, which was further enhanced in the
presence of aspirin, suggesting low level NF-kB stimulation in the
presence of WT Src over-expression alone (Figure 3A). Similarly,
immunocytochemical analysis confirmed that, following aspirin treat¬
ment, the number of cells demonstrating nucleolar RelA accumulation
increased in cells transfected with vector or expressing wild-type Src
but that this response was inhibited in cells expressing mutant protein
(Figure 3B and C).
Inhibiting c-src activity blocks aspirin-mediated apoptosis
Having established a role for c-Src in mediating aspirin effects on the
NF-kB pathway, we next investigated whether c-Src is also involved
in the apoptotic effects of the agent, as might be expected from our
previous studies (35). Using Annexin V apoptosis assays, we found
that blocking c-Src activation, using PP2, abrogated aspirin-mediated
apoptosis of CRC cells (Figure 4A). A further c-Src inhibitor, Su6656
(39) similarly blocked aspirin-induced degradation of IkBoi and ab¬
rogated aspirin-induced apoptosis in CRC cells (Figure 4B and C).
c-Src dependency of aspirin-induced apoptosis was further supported
by demonstration that over-expression of a kinase-dead form of c-Src
also inhibited aspirin-mediated apoptosis of CRC cells (Figure 4D).
c-Src mutant (Y529F) mimics the molecular effects ofaspirin in CRC
cells
To further establish the role of c-Src activation in stimulation of the NF-
kB pathway in CRC cells, we expressed a constitutively active c-Src
mutant (Y529F) in SW480 cells. We found that this mimicked the effects
of aspirin, causing similar degradation of IkBcx (Figure 5A) and nuclear
translocation of RelA (Figure 5B and C). However, expression of c-Src
Y529F did not induce nucleolar translocation of RelA, consistent with
our previous studies, which indicated that nucleoplasmic to nucleolar
translocation of RelA requires an additional aspirin-induced cofactor.
Interestingly, we also found that expression of c-Src (Y529F) increased
baseline levels of apoptosis in SW480 cells and enhanced the apoptotic
effects of aspirin (Figure 5D). This suggests that active Src mutant may
induce apoptosis by a pathway distinct from that utilized by aspirin.
Taken together, these data provide compelling evidence that activation
of c-Src can induce NF-kB signalling and function as a pro-apoptotic




. 5. The active c-Src mutant (Y529F) induces the molecular effects of aspirin in CRC cells. (A-D) SW480 cells were transiently transfected with an empty
SEamp vector, kinase-inactive c-Src expression vector (pUSE Src K297R), wild-type c-Src or constitutively active c-Src (pUSE Src Y529F) and harvested 48 h
r transfection (A-C) or treatment with aspirin [0 (—), 5 mM (+); 16 h] (D). (A) Anti-IxBa western blot analysis was performed as described in Figure 3. (B)
i-RelA/anti-c-Src immunocytochemistry was used to examine effects of expression vectors on RelA localization [yellow arrows = transfected cells, yellow
les = nucleoli (areas devoid of DAPI surrounded by a hyperchromatic ring)]. (C) The nuclear localization of RelA in c-Src-transfected cells was quantified,
lg anti-RelA immunocytochemistry, as described in Figure 2(D). The percentage of cells in the population undergoing apoptosis was determined using Annexin
uorescein isothiocyanate apoptosis assays. Data presented is the minimum of three independent experiments (± standard error).
dence that activation of c-Src and NF-kB signalling is a class
•ct ofNSAIDs
previously reported that non-aspirin NSAIDs induce apoptosis in
C cell lines through stimulation of the NF-kB pathway and nucle-
r translocation of RelA (16). Therefore, we next examined the
uirement for c-Src in the NF-kB response to these related agents,
ng western blot analysis, we found that sulindac, sulindac sul-
>ne and indomethacin-induced c-Src activation (Y418 phosphory-
on) in CRC cells (Figure 6A-C). Activation was transient, in
ping with the transient effects of these agents on degradation of
la. Importantly, c-Src activation was detectable at time points at
ich we previously showed that these agents induce degradation of
la (16).
rhese data suggest an association between activation of c-Src by
i-aspirin NSAIDs and stimulation of the NF-kB pathway was fur-
r examined by immunocytochemical analysis ofRelA in CRC cells
tted with non-aspirin NSAIDs in the presence of the chemical Src
ibitor, PP2. We demonstrate that chemical inhibition of c-SRC
eked cytoplasmic to nuclear/nucleolar translocation of RelA in
ponse to all the NSAIDs (Figure 6D), indicating that c-Src is re-
red for activation of the NF-kB pathway by these agents,
ro determine whether c-Src is required for the apoptotic effect of
i-aspirin NSAIDs, we utilized CRC cells that constitutively express
inase dead form of the protein SW480-SrcKD (kind gift from Prof.
Frame, Edinburgh Cancer Research Centre). Annexin V apoptosis
ays indicated that sulindac, sulindac sulphone and indomethacin
uced a significant increase in apoptosis in cells stably transfected
h the control vector (pBPuro). They also indicated that the apo-
tic effects of these agents were significantly abrogated in cells
iressing the kinase dead c-Src (Figure 6E). Taken together, these
a provide compelling evidence that c-Src is required for the NF-kB
I apoptotic response to NSAIDs as a class (Figure 6F).
Discussion
The present study was undertaken to determine the upstream mecha¬
nisms by which aspirin and NSAIDs stimulate the NF-kB pathway
and pro-apoptotic response and specifically, the role of the c-Src
tyrosine kinase. The work presented provides two important new
insights into the antitumour activity of the agent. Firstly, under the
experimental conditions used here, we show that the apoptotic effects
of aspirin are dependent upon activation of the c-Src tyrosine kinase.
Secondly, we provide compelling evidence that the NF-kB response
to NSAIDs is mediated through c-Src. These findings have important
implications for the development of novel chemopreventative agents
and specifically, those that modulate c-Src kinase activity.
We demonstrate here that aspirin and other NSAIDs (sulindac,
sulindac sulphone and indomethacin) activate c-Src in SW480 CRC
cells, as determined by Y416 phosphorylation of the protein and
phosphorylation of the c-Src target site, paxillin Y118. These data
are in contrast to those of Kunte et al. (40) who recently reported that
sulindac sulfide activates the negative regulator of c-Src, csk, to in¬
hibit c-Src activity in HT29 CRC cells. However, these apparent
differences may be related to both the dose and type of NSAID used
and the time of exposure to the agent, which in their study was
prolonged (72 h). Casanova et al. (41) have also reported that the
NSAID, Celecoxib, inhibits c-Src activity in acute myeloid leukaemia
cell lines. However, interestingly, in four of the five cell lines pre¬
sented within the report, there was an apparent transient increase in
the marker for c-Src Y416 phosphorylation at 4 h following agent
administration. This occurred concurrently with proteolytic cleavage
of Poly (ADP-ribose) polymerase and activation of caspases and mir¬
rored the kinetics of c-Src activation observed here.
In addition, a number of other studies have also demonstrated that
pretreatment with NSAIDs modulates stimulant-induced cellular
c-Src activation (31,34). It is therefore probable that the effects of
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Fig. 6. Activation of c-Src and consequent effects on NF-kB signalling are effects of NSAIDs as a class. SW480 cells were cultured as described previously and
then treated for 0-5 h (A-C) or 16 h (C-D) with sulindac (500 pM), sulindac sulphone (500 pM) or indomethacin (250 pM). (A-C) Western blot analysis was
performed on cytoplasmic extracts using antibodies to phosphorylated Src (Y416). Blots were stripped and reprobed for endogenous c-Src. Actin was used loading
control. (D) Anti-RelA immunocytochemistry was performed on SW480 cells untreated (NT) or pre-treated (2 h) with the c-Src inhibitor PP2 (3.5 pM) and then
treated with sulindac, sulindac sulphone or indomethacin for 16 h. Representative micrographs (x 63) illustrating localization of Rel A and the nucleolar protein,
C23, are shown. Chemical inhibition of c-Src inhibits NSAID-induced targeting of Rel A to the nucleolus. (E) SW480-pBpuro and SW480-SrcKD cells were
treated for 16 h with sulindac, sulindac sulphone and indomethacin. The percentage of cells in the population undergoing apoptosis was determined using Annexin
V-fluorescein isothiocyanate apoptosis assays. Data presented is the minimum of three independent experiments (± standard error). (F) A model for aspirin/
NSAID-induced modulation of NF-kB signalling and apoptosis. In the absence of aspirin/NSAIDs, inducible NF-kB signalling drives the transcription of anti¬
apoptotic genes. Following treatment with aspirin/NSAIDs, c-Src is activated leading to stimulation of intermediate kinase pathways resulting in downstream
degradation of the NF-kB cytoplasmic inhibitor, IkBoc Subsequently, RelA/NF-kb complexes undertake translocation into the nucleus/nucleolus. Nucleolar
localization of RelA is causally involved in the repression of NF-kB driven transcription of anti-apoptotic genes leading to cellular apoptosis.
aspirin and related NSAIDs on c-Src activity are dependent upon the
cellular context, chemical class, timing and concentration of the
NSAID used. These differential effects are consistent with the varia¬
tion in NSAID-induced effects observed on NF-kB pathway signal¬
ling in different cell environment settings and treatment conditions.
For example, following tumor necrosis factor a pretreatment of CRC
cells, certain NSAIDs inhibit activation of NF-kB signalling, how¬
ever, in the absence of tumor necrosis factor a pretreatment, the
converse molecular response is observed (8,9).
We found that blocking c-Src activity, using chemical inhibitors
or a kinase dead mutant, blocked NSAID-mediated degradation of
IkBcx and nuclear translocation of RelA. Previous reports describe
a number of mechanisms by which c-Src can activate the NF-kB
pathway (26-30). In some reports, phosphorylation of IkBcx on
tyrosine 42 (Y42) in response to pervanadate, hypoxia or Vascular
endothelial growth factor stimulation, results in nuclear transloca¬
tion of NF-kB in the absence of IkBcx degradation (23,42-44).
However, these reports contrast with our reported model that
aspirin/NSAID-induced effects on the NF-kB pathway are
associated with degradation of IkBcx (9,16). In keeping with our
observations, it is important to emphasise that c-Src-induced
NF-kB activation has also been shown to occur more indirectly,
through induced stimulation of intermediate kinase pathways, such
as PKCa and IkB kinase. These activation pathways classically
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uce NF-kB signalling by licBa serine 32/36 residue phosphor-
tion and subsequent proteosomal-mediated IkBcx degradation
,28,29). Additionally, have been reported toc-Src has also been
iwn to form part of the IkB kinase complex and contribute to
nal-mediated degradation of IxBa in a manner that does not
uire its kinase domain (25,27).
Molecular mechanisms underlying aspirin/NSAlD-induccd cell
le arrest and apoptosis induction in CRC have been reported to
olve phosphorylation of known downstream substrates of c-Src,
luding p38 and mitogen-activated protein kinase kinase/extracel-
ir signal-regulated kinase pathways (17,45). We have previously
nonstrated that p38 is activated in response to aspirin (17) and that
; effect is upstream of effects on the NF-kB pathway. Since p38 is
nown target of c-Src, it is possible that c-Src effects a response on
NF-kB pathway through p38 signalling. Bernardi et al. (46) re-
tly reported that activation of c-Src is required for the anti-
liferative effects of indomethacin in C6 glioma cells and that
mical inhibition of c-Src-prevented NSAlD-induced ERK activa-
i and the pro-apoptotic response. Determining the pathways that
c c-Src, p38 and NF-kR and specifically, the further dissection of
molecular mechanism by which c-Src activates or interacts with
la, is the focus of our ongoing work.
t is clear that the mechanisms by which NSAIDs act against CRC
Is are complex. While increased c-Src activity is associated with
C progression and metastasis (18-20), here, we show that activat-
endogenous c-Src using aspirin, or expressing a constitutively
ve form of the protein, induces apoptosis in CRC cells. The find-
s presented in this study are in keeping with those ofWelman et al.
) who showed that expression of active c-Src had growth inhibitory
icts against HCT116 and SW480 CRC cells. Using an in situ
iroach in Drosophila, it has also been reported that the cellular
come of altering Src signalling is dependent upon the degree of
vation. Low levels of activation are associated with epithelial cell
vival and proliferation, while high levels of activation mediate
ptosis (48). Importantly, cells which over-express c-Src, such as
plastic colonic cells, can become sensitized to apoptotic stress in
ticular cellular environments (48,49). Indeed, serum starvation and
S/PI3K inhibition favour pro-apoptotic signalling in cells which
r-express activated c-Src (50) and of relevance here, treatment
ditions took place in the setting of a low-serum media culture
ironment. We have also observed, consistent with previous reports,
t cells which express the constitutively active form of c-Src induce
o-apoptotic response and that this effect is further amplified by the
ition of aspirin/NSAIDs (51).
"he work presented here indicates that activation of c-Src is a key
rponent of the pro-apoptotic effects of NSAIDs in CRC cancer and
rkes molecular mechanisms through stimulation of the NF-kB path-
/. These findings have considerable relevance to the future develop-
it of chemopreventative agents by shedding new light on the
rplex nature of the cellular and molecular effects of aspirin on CRC.
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